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ABSTRACT
Two sets of in vitro site-directed mutageneses studies on human dihydropteridine 
reductase (hDHPR) were carried out. The first set involved the mutations, 
T yrl50—>Phe, Tyrl50—>Glu, Tyrl50—>His and Tyrl50—>Ser, and were for obtaining 
information about the amino acid residue(s) that was involved in the chemical 
mechanism of the enzymic reaction. The second set of mutations, Gly23—>Asp, 
G ly l51—>Ser and Thrl23—>ThrThr (threonine insertion), were natural mutations as 
found in children with phenylketonuria due to dihydropteridine reductase deficiency.
A general methodology was required for these site-directed mtageneses studies since 
several were to be done and involved a lot of work. The vector pGEX2T-hDHPR 
which expresses the fused glutathione R-transferase(GST)-human dihydropteridine 
reductase protein in E. coli was used for all the expression work. The site-directed 
mutagenesis work was carried out using the vector pAlter-1 as it gave very high 
mutagjnesis yields. This vector has a gene which confers tetracycline resistance and a 
defective ß-lactamase gene (normally for ampicillin resistance). All the desired
mutations were chosen to be within the Ascl/Sphl restriction sites (481 bp) of the 
DHPR gene in pGEX2T-hDHPR. The hDHPR gene was first engineered into the 
multiple cloning site of the pAlter-1 vector. Oligonucleotides with the desired 
mutations were synthesised and in turn, together with an oligonucleotide with the 
sequence for correcting the ß-lactamase gene, were annealed onto pAlter-1 to produce 
the plasmid pAlter-1— mutated-DHPR after addition of the four dNTPs, T4 DNA 
polymerase and T4 DNA ligase. These plasmids were transformed into E. coli 
(JM109) cells and the clones were selected on ampicillin and tetracycline containing 
agar plates. The plasmids were sequenced to check for the mutations and more than 
80% of the clones had the desired mutations. The DNA flanked by A scl/Sph l 
restriction sites was excised, purified and used to replace the similar cassette of wild- 
type DNA in pGEX2T-hDHPR to produce pGEX2T-mutated-DHPRs which were 
transformed also into E. coli. The pGEX plasmids from the selected clones were
sequenced to confirm that the correct clones were selected and to check that they 
possessed the correct mutations. All the seven mutations presented no serious 
experimental difficulties and were uniformly successful.
All the clones with mutated pGEX plasmids as well as the wild-type were grown in 
culture and the GST-DHPR fusion genes were expressed by addition of isopropylthio- 
ß-D-galactoside (IPTG). The fusion proteins of the Tyrl50 mutants were expressed 
reasonably well whereas those corrsponding to the natural mutations were relatively 
lower except for the Thr 123-insertion mutation which was very low due to extensive 
proteolysis, and the pure product could not be obtained in this case. The fusion 
proteins were purified by virtue of the ability of the transferase to bind strongly and 
selectively to glutathione-bound agarose beads, and woureadily released from the 
beads with buffer containing reduced glutathione. The pure reductases were then 
obtained by thrombin cleavage with removal of uncleaved fusion protein and GST on 
fresh glutathione-agarose beads, or better by thrombin proteolysis of the fusion protein 
bound to the agarose beads. The latter procedure was economical on the expensive 
affinity beads and produced purer reductases.
Detailed kinetic studies were carried out on all the reductases and several of the fusion 
proteins, and the kinetic parameters were compared with those of the wild-type 
enzymes. The Km values for gwmon0/d-6-methyl-7,8(6//)-dihydropterin and natural 
quinonoid-6R-erythro-l,8(6//)-dihydrobiopterin and the respective Km values for 
NADH and the Vmax and kcat values corresponding to them were determined. In each 
study the initial velocities at several concentrations of pterin substrate and several 
concentrations of NADH but one concentration of enzyme (typically 25-36 runs) were 
measured. All the data, i.e. initial velocities and pterin and NADH concentrations, 
were evaluated by a computer program which provided the two Km and two 
Vmax/Km values (pterin and NADH) and one Vmax or kcat value for each set of runs.
The kinetic data imply that the Tyrl50 is most probably the source of the proton for the 
dihydropterin anion form after hydride transfer from NADH. kcat/Km values for the 
pterin substrates were better parameters for comparing the viability of the enzymes and 
showed that replacement of Tyrl50 by Phe reduced the activity considerably. The 
activity was reduced further by replacement with Glu showing that the Glu residue was 
completely in the anion form. Enzyme activity was partly recovered when Tyrl50 was 
replaced by His (a weak acid), and to a lesser extent by Ser which is a weaker acid 
still. The order of activity was ■ Tyr»>His>Ser>Phe>Glu . The reduced enzyme 
activities were more pronounced with ^Mmono/J-6-methyl-7,8(6//)-dihydropterin than 
with the natural substrate but the relative activities of the mutants were unaltered. The 
related kcat/Km values for NADH were not very seriously affected however. The kcat 
value of the wild-type GST-hDHPR fusion protein using quinonoid 6-m ethyl- 
7,8(6//)-dihydropterin and NADH was considerably reduced compared with the value 
of the hDHPR, unlike the kcat values of the mutant fusion proteins which were only 
moderately reduced. The kcat/km values did not show quite the same differences but 
here also the relative values were Tyr»>His>Ser>Phe>Glu . The respective 
kcat/Km values for NADH, on the other hand, showed a different order with enhanced 
activity for the His (3.8 fold) and Ser (7.8 fold) mutants.
The kcat/Km values for gwmö«oni-6-methyl-7,8(6//)-dihydropterin of the DHPRs 
with the natural mutations showed that the Gly23—>Asp was very weakly active (no 
activity was observed before) which was due to an increased Km value and a 
decreased Vmax value. The activity with respect to the natural cofactor, on the other 
hand, was not quite so low due to the relatively larger kcat (compared with the non­
natural cofactor) which is only 35% of the value of the wild-type DHPR. The kcat/Km 
values for NADH with both pterin cofactors showed considerable reduction in activity 
and can be attributed to the effect of the mutation on the NADH binding domain. This 
residual activity would account for the fact that the affected children are bom, albeit 
seriously defective. The activity of the Gly 151—>Ser DHPR mutant with respect to the
Xll
kinetic parameters of the pterin substrates was not so drastically affected although the 
kcat/Km values for NADH were reduced by an order of magnitude or more. The 
moderate activity of this enzyme was consistent with the mild form of this disease in 
the affected child. Attempts to prepare pure DHPR from the T hrl23—>ThrThr 
mutation were unsuccessful and an impure mixture of proteins with DHPR and GST 
activity were oba^j/ned in the preparation of the fusion protein. The 'apparent' kinetic 
parameters for the pterin substrates and NADH were measured for this mixture in 
order to have some idea of the minimum amount of enzyme activity. Considering the 
impure nature of this preparation its enzyme activity was moderate in comparison with 
the kinetic parameters of the fusion proteins of the Gly23-»Asp and the G lyl51—>Ser 
mutants and was also consistent with the fact that the affected child is leading a 
'somewhat normal' life although is mentally retarded.
xm
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CHAPTER 1
GENERAL INTRODUCTION
1.1. OCCURRENCE, NATURE AND FUNCTION OF 
DIHYDROPTERIDINE REDUCTASE (DHPR)
1.1.1. The distribution of dihydropteridine reductase
Dihydropteridine reductase (EC 1.6.99.7; NADH + 7,8(6//)-dihydropteridine =NAD+ 
+ 5,6,7,8-tetrahydropteridine oxide-reductase, abbreviated DHPR) is an enzyme 
whose activity is widely distributed in many human and animal tissues as well as in 
protozoans and some bacteria (Table 1.1., Armarego, Randles and Waring, 1984). It is 
present in most human tissues, e.g. brain, liver, placenta, erythrocytes, skin fibroblasts. 
Table 1.1 lists all the human and animal sources which were found to contain DHPR 
activity. The distribution of the reductase in various tissues was estimated by 
comparing the enzyme activity of certain weights of protein extracts, or extracts from 
certain weights of tissues. The activities in rat tissues specifically were found to be in 
the order of kidney > liver »  brain »  adrenal medulla > heart > muscle = spleen > 
lung (Craine, Hall and Kaufman, 1972). The levels in fetal tissues were lower than in 
cognate adult tissues, and were increased during gestation but the increases were not 
the same for the different tissue (Sanchez-Urretia, Pierce and Greengard, 1978; 
Algeri et al., 1977; Greengard and Herzfeld, 1977).
1.1.2. Nature of dihydropteridine reductase
Dihydropteridine reductase is a soluble cytoplasmic enzyme and has always been 
isolated from the soluble fractions (Armarego, Randles and Waring, 1984). The 
isoelectric point of human liver DHPR is 7.0 (Firgaira, Cotton and Danks, 1981) 
which is higher than that of beef liver DHPR (5.7) (Aksnes et al., 1979) and sheep
2liver (5.4) (Webber et al., 1978 and 1885)). The human liver reductase has optimal 
activity at pH 7.2 (Firgaira, Cotton and Danks, 1981) and the sheep liver reductase has 
maximum enzyme activity in the pH 6.8-7.2 range (Cheema et al., 1973; Webber et 
al., 1978 and 1985). The temperature optimum for human DHPR activity is 37°C 
(Firgaira, Cotton and Danks, 1981). The enzyme consists of two identical subunits, 
although the subunits may differ slightly, e.g. Asp-Asn differences have been reported 
(Webber, Hural and Whiteley, 1986). It appears that the N-terminal amino acids of 
the subunits are protected by acylation of the amino group since attempts to sequence 
the N-terminal end of the natural enzymes were uniformly unsuccessful (Dahl et al., 
1987). The natural substrate is quinonoid(6R)-l,8(6H)-dihydrobioip\.enn which has a 
Km value of 1.3|iM and a kcat value of 23 sec '1 for the human liver reductase 
(Armarego, Randies and Taguchi, 1983).
The crystal structure of the rat liver enzyme was recently determined and showed that 
DHPR is a dimeric protein (Varughese et al., 1992). The molecular weight of this 
dimer is 51,000 Da and consists of two identical monomers whose intimate interaction 
stems from the hydrophobic interplay of a quartet of helices. The two active sites in 
the holoenzyme are structurally identical. They are located some 30 Ä apart, adjacent 
to the distal edges of opposing helices, which form part of the dimer interface.
The crystal structure of the human enzyme has also been determined recently and was 
derived from the rat crystal structure (Su et al., 1993). The work was done by creating 
the human enzyme from a rat DHPR cDNA clone with a single mutagenesis reaction 
using five-oligonucleotide simultaneously. This was possible because the rat and 
human protein sequences differed by only ten amino acids residues. This created 
human DHPR has kinetic data similar to the naturally occurring enzyme, and the 
crystal structure has remarkable structural similarity to that of the rat structure 
described above.
3Table 1.1. Occurrence of DHPR Activity*
SOURCE TISSUES
Human brain, liver, lung, breast, fetal tissues, placenta, 
amniotic cells, periferal blood, platelets 
lymphocytes, erythrocytes, granulocytes, 
leucocytes, continuous lymphoid cells, skin 
fibroblasts
Monkey liver, brain
Bovine brain, pineal gland, liver, kidney, adrenal medulla
Sheep brain, liver, adrenal medulla
Rabbit liver
Cat liver
Rat brain, liver, heart, lung, kidney, adrenal medulla, 
spleen, muscle, uremic, erythrocytes, 
pheochromocytoma
Mouse liver, RAG mouse-man hybrid cells, C-6 
glioblastoma, C-1300 neuroblastoma
Hamster WOR Chinese cells, TG2 Syrian cells
Silkworm Eggs silkworm eggs
Protozoan Tetrahymena, Crithidia fasciculata
Bacteria Pseudomonas sp (ATCC11299a )
*Armarego, Randles and Waring, 1984.
41.1.3. The function of dihydropteridine reductase
Dihydropteridine reductase (DHPR) catalyzes the reduction of quinonoid-1,8(6//)- 
dihydrobiopterin to tetrahydrobiopterin in the presence of the pyridine nucleotides 
cofactors NAD(P)H. However simpler pteridines (eg. quinonoid-6-meihyl-l,8(6//)- 
dihydropterin) are also very good substrates (see Scheme 1.1.).
NAD(P)H NAD(P)
</-7,8(6//)-dihydropterin 5,6,7,8-tetrahydropterin
Scheme 1.1. The DHPR reaction
This reaction is essential in the bio-metabolic system. Dihydropteridine reductase is 
the enzyme that recycles tetrahydrobiopterin in several biosynthetic systems. It 
provides the important cofactor tetrahydrobiopterin for phenylalanine hydroxylase 
(abbreviated PH), to convert phenylalanine to tyrosine (see Scheme 1.2.). When 
phenylalanine levels are high (>4 mg/dl) in humans, they cause serious damage to the 
nervous system (see PKU Section 1.1.4.) (Koch and Friedman, 1981).
Tetrahydrobiopterin is also the cofactor for tyrosine hydroxylase (Kaufman and 
Kaufman, 1985), tryptophan hydroxylase (Kuhn and Lovenberg, 1985), and glyceryl- 
ether monooxygenase (Kosar-Hashemi, Taguchi and Armarego, 1994). The reaction 
of these hydroxylases leads to the synthesis of other amino acids and 
neurotransmitters. Tetrahydrobiopterin is possibly involved in the enzymic
5hydroxylation of steroids (Hagerman, 1964), and in mitochondrial electrons transport 
(Rembold and Buff, 1972a and b). The glyceryl-ether monooxygenase is important 
for glyceryl-ether lipid metabolism and may be associated with the malignant (lethal) 
metabolic disease known as the Zellweger Syndrome (Danks et al., 1975; Borst, 
1983).
Phenylalanine + 0 2 Tyrosine + H20
5,6,7,8-Tetrahydro-
biopterin
Phenylalanine
hydroxylase
r 4-7,8(6//)-dihydro- 
biopterin
NAD(P) NAD(P)H
Scheme 1.2. Tetrahydrobiopterin as cofactor for phenylalanine
hydroxylase
The oxidation of arginine to nitric oxide by macrophages also requires 
tetrahydrobiopterin (Tayeh and Marietta, 1989), and submitochondrial particles show 
strong increases in oxygen consumption in the presence of tetrahydrobiopterin 
implying that DHPR may recycle the oxidised pteridine for electron transport in 
submitochondrial particles from beef hearts (Rembold and Buffer, 1972a and b). It 
has also been reported that the levels of various pteridines in urinary excretion are 
increased in patients with cancer, AIDS and other diseases where the cellular immune 
system is activated (Noronha, 1989).
The above indicate that the function of DHPR is essential in normal growth and 
metabolism. It is a "house-keeping" enzyme, at least in humans, and lack of this 
enzyme results in a lethal form of phenylketonuria (abbreviated PKU, see below).
61.1.4. Phenylketonuria (PKU)
1.1.4.1. D efinition of PK U
Phenylketonuria (PKU) is an inborn error of metabolism and is an inherited genetic 
disease (Foelling, 1934). PKU patients have high concentrations of phenylpyruvic 
acid in the urine, and high levels of phenylalanine in the serum (Koch and Friedman, 
1981). Concentrations of phenylalanine in serum of neonatals of 4 mg/dl or more are 
considered PKU positive (Koch and Friedman, 1981). The highest untreated 
concentrations are found in the range 16-53 mg/dl (Danks et a t 1978). "Classical 
PKU" (see below) can be corrected by restricted diet (phenylalanine-free), but lethal 
forms of PKU (see below) do not respond to this treatment, and children die around 
the ages 6-11 (Danks et at., 1978, Niederwieser, 1979). PKU disease affects 1 in ca 
22,000 new born children (Koch and Friedman, 1981), but varies with geographical 
location. It can be as high as 1 in 5000 of population. Screening for PKU is now a 
routine procedure in developed countries. New bom babies in hospitals are screened 
by the Guthrie inhibition test (Guthrie and Susi, 1963) or the McCaman and Robins 
fluorimetric procedure (McCaman and Robins, 1962) and followed by measurements 
for the levels of DHPR and cofactor.
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The clinical syndrome of PKU|patients is mental retardation and neurological damage 
(Melnick et at., 1981). Children with PKU have difficulty in acquiring language skills 
compared with normal children of the same age even though cognitive abilities are 
within normal limits (Danks et at., 1978). Other manifestations include seizures, 
psychotic behaviour, eczema, dermatographia, "mousy" body odour, and pigment 
dilution (Tourian and Sidbury, 1983).
71.1.4.2. Common PKU (Classical PKU)
Common PKU is due to deficiency in phenylalanine hydroxylase (PH) which oxidises 
phenylalanine to tyrosine (see Scheme 1.2.). This form of PKU is defined as one in 
which the concentration of phenylalanine is consistently higher than 4 mg/dl when 
ingesting a regular diet, but can be lowered to below 4 mg/dl by a phenylalanine-free 
diet which prevents neurological damage (Danks et a i ,  1978, Danks, 1979, 
Giovannini et al.y 1979). The high level of phenylalanine is harmful but its metabolic 
cause is still not clear. It appears to impair mental ability by inhibiting the influx of 
other aromatic amino acids into the developing brain. It also appears to inhibit protein 
synthesis, particularly those proteins which are involved in myelination (Agrawal, 
Bone and Davison, 1970; Takada and Tada, 1970; Lindroos and Oja, 1971) because 
myelination of nerves is seriously inhibited by high levels of phenylalanine. It may 
interfere with microneurone formation and dendritic arborization, thus affecting the 
whole neuronal circuitry (Davison and Dobbing, 1966).
1.1.43. Lethal forms of PKU
Lethal forms of PKU are due to deficiency of DHPR or the cofactor 
tetrahydrobiopterin or enzymes in its biosynthetic pathway (Brown, 1989). The 
functions of phenylalanine, tyrosine and tryptophan hydroxylases are severely 
impaired. Since these enzymes are important for the biosynthesis of neurotransitters, 
the catecholamines, dopamine and serotonin respectively, the function$of the nervous 
system including the brain are compromised. Children with lethal PKU do not 
respond to the restricted diet and usually die by ages of six to eleven (see above). 
Some of these children have been kept alive for extended, but not indefinite, periods 
by treatment with neurotramsitters, eg  Levodopa, as well as cofactor 
(tetrahydrobiopterin) therapy (Blau et al., 1993) This type of PKU has been termed 
malignant hyperphenylalaninemia (abbreviated MHPA) (Danks, 1978) since the term 
lethal has serious implications.
81.1.5. Reaction mechanism of dihydropteridine reductase
1.15.1. The DHPR-NADH binary complex
The reductase can use NADH and NADPH as cofactors but NADH is most probably 
the natural cofactor as it catalyses the reduction reaction between fifteen to forty five 
times faster than NADPH (Nielsen, Simonsen and Lind, 1969). A number of workers 
have reported that NADH binds to DHPR and forms a stable complex (Hasegawa, 
1977; Webber and Whiteley, 1978; Aksnes et al., 1979). The work by Webber and 
Whiteley (1978) demonstrated that one molecule of NADH binds to one molecule of 
the enzyme, while the work reported by Hasegawa (1977) and Aksnes ei al. (1979) 
showed that two molecule of NADH bind to one molecule of the enzyme. It is 
difficult to obtain the reductase free from NADH and the enzyme is unstable in its 
absence. Polyacrylamide gel electrophoresis of purified rat liver DHPR in non­
denaturing conditions gave two bands, the enzyme and enzyme-NADH complex 
(Webber and Whiteley, 1978). The human (Firgaira et al., 1981) and bovine enzymes 
(Hasegawa, 1977) behaved similarly. Addition of two or more equivalents of NADH 
converted the enzyme almost completely to the enzyme-NADH complex. Thus the 
stoichiometry is 1 NADH to 1 enzyme subunit. Recently the published crystal 
structures of rat and human DHPR show that one molecule of NADH binds to one 
DHPR monomer and confirmed the previous electrophoresis work (Varughese et al., 
1992; Su e ta l,  1993).
1.15.2. The chemical mechanism of reduction
Dihydropteridine reductase catalyzes the reaction by direct hydride transfer from the 
reduced nicotinamide ring of NADH and a proton transfer from the enzyme to the 
quinonoid dihydropterin to form tetrahydropterin (Armarego, 1979; Armarego and 
Waring,
9NADH
H2NOC
Figure 1.1. Proposed enzyme mechanism of dihydropteridine reduction
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1982). Hydride transfer was shown to occur from the B face of NADH with transfer 
of the pro-S hydrogen. The N-5 atom of the quinonoid dihydropterin accepts the 
hydride and the electrons migrate so that N-3 becomes negatively charged, and accepts 
the proton from the enzyme (Armarego, 1979) (see Figure 1.1.). From the published 
X-ray structure of the binary complex of rat liver DHPR, the phenolic group from 
tyrosine (146) in rat DHPR (= 150 in human DHPR) appears to be the enzymic source 
of the proton (Varughese et al., 1994; Whiteley, Xuong and Varughese, 1993).
1.2. MUTAGENESIS TECHNIQUES
1.2.1. The mutagenesis
The mutations of genes are very important in the Biological Research. Mutation 
studies can supply the evidence for the relationship between protein structure and its 
activity, and can define the roles of particular proteins and protein assemblies in the 
cell. By using mutations it is possible to determine the logic and order of molecular 
events and which amino acid residues in a protein are responsible for its mode of 
action and function. Several techniques of mutagenesis are listed below.
1.2.2. Classical in vivo mutagenesis
Mutations that happen in biological organisms naturally or spontaneously are termed 
classical in vivo mutagenesis. It was found that organisms exposed to x-rays (Muller, 
1927) or certain chemical compounds (Auerbach and Robson, 1947) yield much 
higher frequencies of mutant progeny, and this led to a revolution in experimental 
genetics. Use of mutations created by these agents increased the chances to study 
biological phenomena systematically (Botstein and Shortle, 1985). Classical in vivo 
mutagenesis was a powerful tool to provide material for genetic and biochemical 
analysis in the past few decays. One of its serious limitations is that specific
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phenotypes could not be produced at will, so that it was not feasible to study more 
than a few mutations in a single gene (Botstein and Shortle, 1985).
1.2.3. Transposon mutagenesis
Transposon mutagenesis, unlike chemical or radiation mutagenesis described above, is 
an insertion mutation caused by inducing in virtually any gene of interest a naturally 
occurring transposable element(s) by the appropriate manipulation. It induces a 
single, unique physical alteration in a gene (Kleckner, Roth and Botstein, 1977). 
Mutagenesis can be carried out to limit the number of transposons inserted to one per 
genome, and insertion can be selected by means of drug resistance or phage immunity 
carried by the transposon (Botstein and Shortle, 1985).
1.2.4. In vitro mutagenesis
Since the development of modem recombinant DNA technology, DNA fragments 
could be isolated from genomes, and cloned into convenient vectors in vitro. This 
development provides a great opportunity to create unlimited numbers of specific 
mutations to any cloned genes in vitro. Now it is possible to alter, efficiently and 
systematically, the sequence of nucleotides in a segment of DNA. In vitro 
mutagenesis can be classified into the following broad categories:
12.4.1. Restructuring o f DNA segments
This method involves the deletion of DNA residues from the 5' and 3' ends of the 
subcloned DNA segment. For example it can be used to identify the regulatory 
sequence at the 5'-end of a gene sequence in a DNA fragment by a set of deletions, 
e.g. with the enzyme Bal31 (Legerski, Hodnett and Gray, 1978) or exonucleaselll plus 
SI (Sakonju, Bogenhagen and Brown, 1980) which remove successive nucleotides at
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the DNA ends. Re-cloning in an expression vector and expressing the gene product 
then allows identification of the regulatory sequence.
1.2 .4 .2. Localized random mutagenesis
This method creates mutations in a small defined DNA segment by chemical 
mutagens. Three strategies can be summarized (Botstein and Shortle, 1985). In the 
first a small restriction fragment is isolated from a larger DNA fragment. The small 
fragment is subjected to chemical mutagenesis, and re-ligated back to the original 
DNA fragment (s). The second strategy is more complicated. It can be applied to a 
piece of DNA sequence which is more sensitive to a chemical mutagen (e.g. C rich) 
than the flanking sequences in a double stranded circular DNA. The sensitive portion 
is converted to a single stranded state (in the double stranded molecule) by the 
appropriate enzymic manipulation (Shortle and Botstein, 1983), then the mutagen e.g. 
sodium bisulfite, induces C to U mutations by catalysing the deamination of cytosine 
to uridine in the single stranded sequence, but not in double stranded flanking 
sequences (Hayatsu, 1976). In the third strategy the single stranded region of a double 
stranded molecule as created by means of appropriated enzymic manipulation like 
above (Shortle and Botstein, 1983), DNA polymerase fills the gap by incorporating 
nucleotide analogues such as a-thiophosphate nucleoside triphosphate (Muller, et al., 
1978) into the DNA molecule.
1.2.4.3. Oligonucleotide-mediated mutagenesis
Oligonucleotide-mediated mutagenesis is the most common method to create 
mutations. It allows a single or several base changes at specific positions without any 
phenotype information. Four known methods are summarised as follows:
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— oligo nucleotide containing 
X desired mutationr  “V
\ single stranded DNA
\y U  U v / template
T4 DNA polymerase 
4 dNTPs
T4 DNA ligase
Y
mutation
in vitro synthesised 
double stranded molecule
transformation to a 
E.coli strain (ung+)
in vivo synthesized double stranded DNA 
(using the strand without AP sites as template)
Figure 1.2. The strategy for oligonucleotide-mediated mutagenesis
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1.2.4.3.1. Oligonucleotide-directed mutagenesis
In the oligonucleotide-directed mutagenesis method the DNA sequence is altered in a 
defined way. This method is extremely useful to determine the effects of particular 
changes in the DNA sequence and to introduce restriction enzyme sites. The work is 
accomplished by synthesising an oligonucleotide whose sequence contains the 
mutation of interest, hybribizing the oligonucleotide to a single-stranded template 
containing the wild-type sequence, and extending the primer with T4 DNA polymerase 
(Smith, 1986). The resulting product is a heteroduplex molecule containing a 
mismatch due to the mutation in the oligonucleotide. The most important step is to 
select the mutated clones against wild type clones. The most common procedure for 
selection is to prepare a uracil-containing single stranded DNA template instead of 
thymine within a strain of E. coli [dur ung'J (Kunkel, 1985; Kunkel, Roberts and 
Zakour, 1987). E. coli dur mutants lack the enzyme dUTPase and therefore contain 
elevated concentrations of dUTP which effectively compete with dTTP for 
incorporation into a newly synthesised DNA strand. Ung~ mutants lack the enzyme 
uracil A-glycosylase which normally removes uracil from DNA. In the combined dur 
ung~ mutant, deoxyuridine is incorporated into DNA in place of thymidine and is not 
removed. After double stranded DNA is synthesised in vitro (the template strand 
contains several uracil residues instead of thymine residues while the newly in vitro 
synthesised strand contains thymine only), the circular DNA is transformed into the 
wild type E. coli strain (ung+ ). The ung+ E. coli cells contain N-glycosylase which 
removes uracil from DNA, producing apyrimidinic (abbreviated AP) sites in the 
template strand, these AP sites are lethal lesions, and the AP containing strand is 
unable to serve as a template for the synthesis of progeny DNA nucleotide (see Figure 
1.2). The frequency to obtain mutated clones, therefore, is increased up to 50% 
(Kunkel, Roberts and Zakour, 1987).
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Figure 1.3. Strategy for linker-scanning mutagenesis of DNA
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1.2.4.3.2. Gene Synthesis: using mutually priming long oligonucleotides
This method is for the synthesis of any kind of mutated gene by using a long 
oligonucleotide (up to 400 bp) in a single step, and further regions can be extended by 
ligation of the products of individual steps (Uhlmann, 1988). The basic strategy is to 
use a oligonucleotide which contains the required mutations and possesses a short 
inverted repeat at its 3' end (containing a restriction enzyme site) to form a hairpin 
structure. The 3' end of this hairpin then serves as a primer to synthesise the second 
strand. After digestion with restriction enzyme, this double stranded oligonucleotide 
can be linked to another synthesised double stranded oligonucleotide, and a custom- 
designed gene is generated. The ability to synthesise long regions of any desired 
sequence is extremely valuable.
1.2.4.3.3. Linker-scanning mutagenesis of DNA
This procedure introduces clusters of point mutations in the required gene sequence 
cloned in a plasmid (Mcknight and Kingsbury, 1982). It is useful in the study of the 
regulatory sequence activity. The whole strategy is summarised in Figure 1.3. A 
nearby unique restriction enzyme site A in plasmid pWT (Figure 1.3.) in the region of 
interest of the gene is used to linearize the plasmid pWT, a nested series of deletion 
mutations are generated by Bal 31 or ExolU digestion. A linker of a unique restriction 
enzyme site such as HindUl is ligated to the deletion endpoints, and DNA is re-ligated 
to form a deletion mutation plasmid (pWT-D). After transformation into bacterial 
cells, several deletion mutation clones are isolated and sequenced to see which 
sequence has been deleted in each clone. The HindUl and another unique restriction 
enzyme, e.g. Xm rl, in the ampicillin gene are used to digest the deletion mutation 
DNA (pWT-D), and the HindlU/Xmnl fragment (portion II in pWT-D) containing part 
of the gene and part of the vector (II, Figure 1.3.) is isolated. A pair of complementary 
oligonucleotides (III, Figure 1.3.) is synthesised to fill in the deleted sequence with the 
linker HindiII site and the nearby unique restriction enzyme site A at each end . This
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Figure 1.4. Strategy for introducing a restriction enzyme site
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synthesised oligonucleotide (HI) contains the clusters of point mutations of interest, 
and are (separately) ligated to fragment I from the plasmid pWT digested with the 
restriction enzymes A and Xmnl , and fragment II digested with HindLTL and Xmnl. 
The final plasmid formed contains the clusters with desired mutations.
1.2.4.3.4. Mutagenesis by the polymerase chain reaction
The polymerase chain reaction (abbreviated PCR) (Saiki et al., 1988) can be used as a 
quick and efficient method for introducing any desired sequence change into the DNA 
of interest. Three related protocols will be described here (Ausubel et al., 1987), their 
general procedures are the same, but the differences are in the design of the synthetic 
oligouncleotide primers and on the subsequent cloning and analysis of the amplified 
fragments.
(i) Introduction of a restriction enzyme site by PCR
In the first protocol a restriction enzyme site is introduced into the desired region of 
the gene (Figure 1.4.). Four of oligonucleotides 1 to 4 are made, which amplify the 
sequence, from the point where a new restriction enzyme site C is required up to the 
polylinker sites. The two oligonucleotides 1 and 2 in the middle have overlapping 
sequences, which between them, contain the restriction enzyme site C. The ends of 
the remaining two oligonucleotides 3 and 4 have sequences complementary with the 
polylinker restriction sites, e.g. A and B. After the PCR reaction, the two amplified 
fragments are digested with the new restriction enzyme C and the two fragments are 
ligated. After the two ends of the ligated fragment are digested with restriction 
enzymes A and B, the fragment can be subcloned back to the original vector after 
digestion with enzymes A and B (Figure 1.4.). Blunt-end ligation can be used to join 
the A and B ends to the original vector (Figure 1.4.).
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Figure 1.5. (a): Strategy for point mutation by PCR
(b): Strategy for a point mutation by sequential PCR steps
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(ii) Introduction of a point mutation by PCR
This protocol, basically, is as same as the above one. The difference is that one of the 
oligonucleotides i.e. 1 or 2 in Figure 1.5.(a) contains the point mutation M. After 
PCR, the two fragments are blunt-end ligated together and then digested with 
restriction enzymes A and B. Finally, this newly synthesised fragment which contains 
the point mutation M is ligated back to the vector after digestion with the restriction 
enzymes A and B.
(iii) Introduction of a point mutation by sequential PCR steps
This protocol uses two steps of PCR amplification to introduce a point mutation, and 
avoids using blunt-end ligation e.g. as in the above protocol [see Figure 1.5.(b)]. 
Fragments 1 and 2 are mixed after the first PCR step, then fragments 1 and 2 are 
annealed to each other in the overlapping sequence which contains the point mutation 
M. The second PCR step is carried out, and the newly synthesised PCR fragment 
contains the mutation M, and is ligated to the original vector after digestion with the 
restriction enzymes A and B.
1.3. EXPRESSION OF PROTEINS IN ESCHERICHIA COLI
Bacteria Escherichia coli (abbreviated E. coli) cells have two characteristics that are 
suited for an ideal expression system for many kinds of foreign proteins. The system 
is easy to manipulate and cells grow quickly in inexpensive media. Normally the 
foreign gene is inserted into a vector (plasmid). After transformation into bacterial 
cells, the gene will be expressed under the control of a regulatory sequence in the 
plasmid as the bacteria grow. Therefore the vector should contain several elements: 
(1) sequences encoding a selectable marker that assures maintenance of the vector in 
the cell such as an antibiotic resistance gene; (2) a controllable transcriptional 
promoter (eg. tac or Ä.PL) which, upon transformation, can produce large amounts of
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mRNA from the cloned gene; (3) translational control sequences, such as an 
appropriately positioned ribosome-binding site and a start codon (e.g. ATG), and a 
stop codon (e.g TAG); and (4) a poly linker for gene cloning in the correct orientation.
1.3.1. T7 RNA polymerase / promoter system
This system uses phage T7 RNA polymerase instead of E. coli RNA polymerase to 
control gene expression (Studier et al., 1990). It uses two kinds of plasmid to 
transform E.coli cells at the same time. One plasmid contains the T7 RNA polymerase 
promoter only and the gene for expression under it. Another one contains T7 RNA 
polymerase gene under the control of a heat-inducible E.coli promoter. Upon heat 
induction, the T7 RNA polymerase is produced and T7 RNA will transcribe the gene 
under the control of the T7 RNA polymerase promoter.
This system has advantages because: (1) T7 RNA polymerase is a very active enzyme, 
it synthesises RNA at a rate several times faster than that of E. coli RNA polymerase; 
(2) T7 RNA polymerase initiates RNA synthesis at its own promoter sequence, not at 
any other sequences in E.coli DNA.
1.3.2. Phage X  regulatory system
This system uses the powerful promoter PL from the phage X to express the gene in a 
plasmid vector (Ausubel et al., 1987). Because the PL promoter can be fully repressed 
by the X  repressor cl gene (supplied by an E. coli host which contains an integrated 
copy of a portion of the X  genome), cells carrying these plasmids can be grown 
initially to high density without expression of the cloned gene and subsequently 
induced to synthesise the gene product upon inactivation of the repressor. A mutated 
cl gene, as the cits 857 gene, has been inserted in the plasmid vector which renders 
the repressor temperature sensitive. The repressor is thus inactivated when the
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temperature of the medium for growth is increased e.g. to 42°C, and induces the 
expression of a foreign or other genes in the vector.
1.3.3. The fusion protein system
This system has been very popular for expressing genes (Ausubel et a i, 1987). It 
involves the fusion of the foreign gene to a carrier gene which is expressed well in E. 
coli. The carrier sequence provides the necessary signals for good expression. The 
carrier gene can be as short as to encode a few amino acids, or encodes an entire 
functional protein. Fusion to the carrier protein can sometimes stabilise eukaryotic 
proteins expressed in E. co li , e.g. by solubilising the foreign protein, allowing it to 
fold correctly. The fusion protein system also provides the opportunity to design a 
way to easily purify the fusion protein from other E. coli proteins, from which the 
desired protein can be recovered in a pure state after cleavage from the carrier protein. 
Several fusion systems are available commercially, but only two are described below:
1.3.3.1. Expression and purification of maltose-binding protein fusions
In this method the desired gene is cloned by ligating its DNA to the 3' end of the malE 
gene of E. coli in the correct reading frame (Kellerman and Ferenci, 1982). The malE 
gene encodes the maltose-binding protein (abbreviated MBP). The malE gene in the 
expression vector is under control of the strong, inducible tac promoter and the malE 
translation initiation signals to give high level expression of the cloned gene. 
Following an affinity purification of the MBP protein with ßAE-Sephadex bead, the 
fusion protein is readily isolated from the bacterial extracts. Protein factor Xa then 
cleaves the fusion protein (on the affinity adsorbent) and provides the intact desired 
protein in pure state.
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7.3.3.2. Expression and purification of glutathione R-transferase fusion protein
This system uses pGEX vectors to express foreign polypeptides as fusions with 
glutathione R-transferase (Enzyme Commission name, but here is abbreviated GST) 
(Smith and Johnson, 1988). Several pGEX plasmids (cloning vectors) are available, 
e.g. pGEX2T and pGEX3X. The structure of the plasmids make it possible to 
engineer a fused gene with the GST gene in the correct reading frame. The GST 
polypeptide can be separated from the desired protein by enzymic digestion, e.g. 
thrombin and factor Xa are used in pGEX2T and pGEX3X plasmids respectively. The 
GST gene is under control of the Ptac promoter and the plasmids contain the LacI 
gene to express a repressor for the Ptac protein. Fusion protein expression is regulated 
by addition of isopropylthio-ß-D-galactoside (IPTG). GST is a 26 KDa cytoplasmic 
protein from Schistosoma japonica. The main advantage of this system for expressing 
and recovering foreign proteins from E. coli is that most fusion proteins remain 
soluble (foreign proteins expressed in E. coli often denature and precipitate). If non­
denaturing conditions are applied at any stage during purification, foreign 
polypeptides may retain their functional activities and antigenicity. The general 
procedure for the purification of GST-fusion proteins is by absorption of cell extracts 
onto glutathione-agarose beads, followed by elution in the presence of reduced 
glutathione. If the GST is to be separated from the fusion protein, the GST-fusion 
proteins adsorbed on glutathione-agarose beads are digested with thrombin (for 
pGEX2T) or blood coagulation factor Xa (for pGEX3X). The supernatant usually 
contains the desired protein in pure form. The fusion protein expression system used 
extensively in this thesis is the pGEX2T system. Details of the procedure for this 
method are reported in Chapter 2.
1.4. DHPR cDNA CLONING
Human DHPR cDNA has been cloned and sequenced by two groups independently in 
1987. The rat DHPR cDNA also has been cloned and sequenced in the same year.
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Mouse DHPR cDNA has been cloned recently, and the three cDNA sequences were 
compared (Yang, Hanssen and Armarego. 1995).
1.4.1. Human DHPR protein purification
Human dihydropteridine reductase was purified from human liver (Firgaira et al., 
1981). The procedure used for purification included three chromatography steps. The 
first step involves passing the liver extract through a 1,2-naphthoquinone-AH- 
Sepharose affinity column to absorb DHPR selectively in the presence of NADH. The 
reductase is then eluted with NADH-free buffer containing DTT. The enzyme is 
usually quite pure at this stage. Traces of impurities, if present, can be removed by 
anion exchange chromatography (DEAE-Sephadex A-50) followed by cation 
exchange chromatography (CM-Sephadex C-50). The purified protein gives a single 
band on non-denaturing PAGE (Mr 52 K) and on SDS-PAGE (Mr ~26 K), and gives 
one spot on two-dimensional gel electrophoresis. The amino acid composition was 
determined and is very similar to that of the sheep and bovine liver DHPR enzymes.
1.4.2. Human DHPR cDNA cloning
Two human DHPR cDNAs were cloned and sequenced by different strategies. The 
two DNA sequences are essentially the same. Dahl et al. (1987) used antibodies 
raised against human DHPR using purified human liver DHPR (Firgaira et al., 1981), 
to screen a Ä.gtll expression library. After a partial cDNA sequence was isolated, the 
cDNA sequence was used to re-screen the library, and the full length of cDNA for 
human DHPR was isolated and sequenced.
Lockyer et al. (1987) used a monocloned antibody against sheep DHPR to screen a 
human liver cDNA library in the expression vector Xgtl 1, followed by re-screening 
the library with a 32P labelled DHPR cDNA fragment isolated from a first screening. 
The isolated cDNA for human DHPR was confirmed by transfection to COS cells
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which had low levels of DHPR activity, but showed higher levels of DHPR activity 
upon transfection.
1.4.3. Rat DHPR cDNA cloning
The rat DHPR cDNA was cloned by Shahbaz et al. (1987). The purified rat DHPR 
protein was cleaved into peptides and sequenced. Oligonucleotides were synthesised 
according to the peptide sequences. These oligonucleotides were used to screen a rat 
liver cDNA library cloned into ^gtlO. The cDNA for rat DHPR was isolated, cloned 
and sequenced.
1.4.4. Mouse DHPR cDNA cloning
Mouse DHPR cDNA was cloned recently by using human DHPR cDNA to screen a 
mouse liver cDNA library in XZAP vector (Yang, Hanssen and Armarego, 1995). The 
mouse DHPR cDNA sequence was then compared with the human and rat sequences. 
Of the 720 nucleotides in the coding region of mouse DHPR only 89 were different 
from those in human DHPR and only 31 nucleotides were different from those in rat 
DHPR. There are 15 amino acid residue differences between those of mouse and 
human DHPR, and 10 residues between those of rat and human, in addition to the 
three extra alanine residues at positions 4,5 and 6 in human DHPR.
1.5. MUTATIONS IN DHPR
1.5.1. Natural mutations in the DHPR gene identified in PKU patients
Several mutations in defective DHPR have been identified in PKU patients. They are 
listed in Table 1.2. (Smooker et al., 1993a).
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Table 1.2. Mutations causing DHPR dificiency identified in PKU patients 
(listed in the order in which mutations appear from the 5'-end of the coding region)
M utation A m ino acid R eference
G93A (Het) Gly23 —» Asp Dianzani e ta l .,  1993; Firgaira et al., 1981; Smooker et 
a l., 1993b
T346G (Horn) Trpl08-> Gly Dianzani e ta l .,  1993; Firgaira et al., 1983
ACT390 Ins. (Horn) Thr 123 ins. Howells et al., 1990
C458T (Het) Prol45-»Leu Firgaira et al., 1983; Smooker et al., 1993b
G475A (Horn) Glyl51-»Ser Blau et al., 1992
C496T (Horn) Hisl58—»Tyr Cotton et al., 1986; Dianzani et al., 1993; Smooker et 
al., 1993b
G532A (Horn) Glyl70—»Thr Smooker et al., 1993b
T638G (Het) Leu205—»Stop Firgaira et al., 1983; Smooker et al., 1993b
T659G (Horn) Phe212-»Cys Blau et al., 1992
C685T (Horn) Arg221-»Stop Smooker et al., 1993b
Het=Heterozygous; Hom=Homozygous
Among all these mutations, Gly23—>Asp is the only one found in more then one 
patient (Smooker, Howells and Cotton, 1993b). The mutation of Leu205—>Stop 
results in a loss of 40 amino acid residues (Firgaira, Cotton and Danks, 1983; 
Smooker, Howells and Cotton, 1993b), while the mutation of Arg221—>Stop results in 
a loss of 24 amino acid residues (Smooker, Howells and Cotton, 1993b).
The Gly23—»Asp, Trpl08-»Gly and Hisl58—>Tyr were extremely susceptible 
to in vitro protease digestion, indicating changes in the three dimensional structure of 
DHPR which allows ready access by proteases (Smooker, Howells and Cotton, 
1993b).
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Three natural mutated DHPR cDNA^have been generated in vitro by oligonucleotide- 
mediated site-directed mutagenesis and cloned to pGEX2T and expressed as GST- 
DHPR fusion proteins (Smooker et a i, 1993a). The DHPR proteins were isolated and 
the kinetics parameters were measured (Table 1.3.)
Table 1.3. Kinetic parameters of three natural mutations in DHPR
Enzyme Vmax Km (DMPH4) Km (NADH)
Wild type 333 ±20 41 ±7.0 11 ±1.8
Trpl08—>Gly 122 ± 9.3 25 ± 6.8 24 ±7.1
Gly23—>Asp 0 NA NA
Hisl58—>Tyr ND ND ND
DMPH4: <7Mmorto^-6,7-dimeLhyl-7,8(6/7)-dihydropterin. NA = not applicable, ND = not determined
From the above data it was suggested that DHPR activity was retained to the extent of 
41% in the TrplOS—>Gly mutant, and the Gly23—>Asp mutant had 0% activity 
(Smooker et a i, 1993a).
1.5.2. Site-directed mutagenesis of DHPR carried out previously
In order to investigate whether one of the four cysteines in DHPR was the proton 
source for the enzymic reduction, Armarego and coworkers replaced four cysteine 
residues in DHPR by serine through oligonucleotide-mediated site-directed 
mutagenesis techniques (Hardy et a i, 1993). They showed that none of these four 
cysteine residues was involved in proton donation, even though the previous evidence 
suggested that one of the cysteine residues was interacting with NADH (Armarego 
and Ohnishi, 1987; Webber and Whiteley 1981).
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Five mutations in rat DHPR have been generated: viz Ala7—»Val, Asp38—»Ile, 
Trpl05—»Phe, Tyrl47—»Phe, and Lysl51-»Gln (Whiteley, Xuong and Varughese, 
1993; Whiteley et al., 1993). The kcat/159 for Ala7—»Val and 150 for Trpl05—»Phe 
did not change in comparison with wild type (156), the kcat of Asp38—»Ile was 
reduced to 43 (wild type 156), the kcat for Tyrl47—>Phe and Lysl51—»Gin decreased 
to 0.89 and nearly zero respectively (wild-type 156). These results showed that 
Tyrl47 (150 in human DHPR ) and Lysl51 (154 in human DHPR) appear to be 
involved in the enzymic reduction.
1.6. AIMS OF THE PRESENT RESEARCH PROJECT
Two main aims are proposed for the present work. The first is to carry out mutations 
in human DHPR such that further information can be obtained requiring the catalytic 
steps of the reduction reaction. Of particular interest is the protonation of the 
quinonoid pteridine substrate after hydride transfer from NADH onto N5 of the pterin. 
All the evidence points to proton transfer onto N3 of the pterin (Armarego, 1979, 
1989). The proton source may be an amino acid residue at the active site or, a water 
molecule in the buffer because the active site is very exposed to the aqueous medium. 
X-ray modelling suggested that the phenolic hydroxy group of tyrosine 150 could be 
the proton source because of its proximity to N3 of quinonoid dihydrobiopterin. By 
using site-directed mutagenesis of DHPR cDNA, it is proposed to in turn replace 
tyrosine 150, by phenylalanine, serine, glutamic acid and histidine. The mutated 
genes will be cloned and the expressed reductases will be isolated in pure form. The 
kinetic parameters, viz the Km values for the cofactor ^6/?5-6-methyl-7,8(6F/)- 
dihydropteridine ( <?-RS-6MeDHP) and natural 6/?-dihydro-ery^rö-biopterin (q-6R- 
BH2) NADH as well as the kcat values for the mutated enzymes will be determined. 
The kinetic data should shed some light on the protonation step of the reduction.
The second aim is to carry out some mutations which have been observed in PKU 
children. The mutations Gly23 —» Asp, Gly 151 —» Ser and Thr insertion at position
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123 were chosen and will be carried out. As above the mutated cDNA will be 
expressed in E. coli and the mutant reductases will be isolated in pure form. The 
activities of the reductases will be evaluated by kinetic measurements. Comparison of 
the kinetic parameters with the wild-type reductase should tell us how the enzymic 
activities correlate with the PKU phenotype.
CHAPTER 2
SITE-DIRECTED MUTAGENESES PROCEDURES
2 . 1 . STRATEGY FOR CLONING AND EXPRESSING
MUTATED DHPR
The aims of the present research program are to carry out several in vitro site-directed 
mutagenesis on the human DHPR cDNA gene in order to express the mutated 
enzymes for kinetic comparison with the wild-type reductase. Four mutations were to 
provide further information regarding the mechanism of the enzymic reaction and three 
further mutations which had been already identified in DHPR deficient children were 
to be investigated (Chapter 1, Section 1.6., page 28). It was therefore necessary to 
devise a strategy in which the same general procedures were used for all the mutation 
experiments.
Human DHPR cDNA was readily available (Armarego et al., 1989) in a pBlueScript 
vector (Figure 2.1.). The vector containing the gene was scanned for restriction 
enzyme sites in order to find two sites which are only present within the DHPR 
section of DNA and which could contain within the sites all the proposed mutations 
for the present work. Two sites were found. The first was an A scI site 
(GGslCGCGCC) very near the ATG start codon and the second site was an Sphl site 
(G C A TG iC ) which was 481 bp downstream along the gene. The whole hDHPR 
cDNA is 732 bp excluding the ATG (start) and TAG (stop) codons.
The available pBlueScript vector could be used for site-directed mutagenesis a»d>
the vector pAlter-1 (Figure 2.2.) because it was designed for site-directed
mutagenesis and was known to give high yields of mutated clones (Promega). For the 
mutagenesis it was first necessary to insert the intact hDHPR cDNA into pAlter-1. 
pBlueScript-hDHPR was digested with BamHl and Hindll and the smaller purified
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DNA fragment (1.02 Kb) was isolated and ligated to pAlter-1 after digestion with the 
same restriction enzymes and purification. This produced the desired template plasmid 
pAlter-1—hDHPR (Scheme 2.1. and Figure 2.10.) which was used for all the site- 
directed mutagenesis experiments. From here on the general strategy is the one 
outlined in Scheme 2.1. Briefly the mutations are then carried out on pAlter-1— 
hDHPR, the Ascl-Sphl segments now have the mutations. These segments are used 
to replace a similar segment from the wild-type hDHPR in another vector pGEX2T- 
hDHPR to form pGEX2T-mutated-DHPRs. The later vectors are then transformed 
into bacteria which should express glutathione R-transferase/mutated DHPR fusion 
proteins from which the mutated DHPRs can be isolated.
2.2 .  PLASMIDS USED IN THIS WORK
2.2 .1 .  The pBlueScript-hDHPR plasmid
pBlueScript (SK or KS) is a phagmid. It contains polylinkers in the £acZ gene which 
allow blue/white colour selection for clones with inserts. Colonies which lack the 
insert produce the galactosidase gene which hydrolyses X-Gal (5-bromo-4-chloro-3- 
indolyl-ß-D-galactoside) and the product is readily oxidised to a blue indigo-type dye 
producing blue plaques on agar plates containing X-Gal. Colonies in which the 
plasmids contain the galactosidase gene interrupted, i.e. non-functional, produce 
colourless plaques. pBlueScript also contains the f l  filamentous phage origin of 
replication which allows production of single-stranded DNA and the ColEl origin of 
replication as well as the ampicillin resistance gene which allows propagation and 
selection of clones containing the plasmid. The difference between SK and KS strains 
is the orientation of the multiple cloning sites (MCS). pBlueScript-hDHPR (Figure
2.1. ) contains the full length of human cDNA flanked with EcoRl sites (subcloned 
from a Xgtl 1 liver library) which were cloned into the EcoRl site of pBlueScript (Dahl 
et al., 1987).
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Reconstruction of pGEX2T-hDHPR
— Asel
DHPR
pGEX2T-hDHPR
AscUSphl
Asel Sphl
l=Z]---------------------------Ezzd
“ n "
— hDHPR
■mutationDHPR N
p Alter-1— hDHPR
AscUSphl
DHPRpGEX2T
ligation
mutated “V 
pGEX2T-hDHPR DHPR
mutation
i
Expression of mutated DHPR protein
I
Measurements of DHPR kinetic parameters
Scheme 2.1. The strategy for cloning and expressing mutated DHPR
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T7 promoter 0.62
BamHl 0.65 
/ \ —  Hindll 0.83
Seal 3.73
fl ori
hDHPRpBlueScript-hDHPR 
4.38 Kb
si— BamHl 1.85 
T3 promoter 1.91
Figure 2.1. The structure of pBlueScript-hDHPR.
2 . 2 . 2 .  The pAIter-1 plasmid
pAlter-1 is a commercially available phagmid designed for site-directed mutagenesis 
(Promega). It contains a multiple cloning site (MCS) inserted into the LacZ gene 
which allows blue/white colour selection for clones with inserts, and a mutated 
(inactivated) ß-lactamase gene (Amps) which confers ampicillin resistance but has a 
normal tetracycline resistance gene (Tetr) (Figure 2.2.). It produces ss-DNA upon 
infection with helper phage R408 or M13K07.
34/ f l ori X
JgT defectiver pALTER-1 5.68 Kb LaciXMCS ■L a c l [ jx ......  TetL-^/
T7 promoter*
EcoRI 5
SacI 15
Kpnl 21
Smal 23
BamHI 26
Xbal 32
Sail 38
PstI 48
SphI 54
Hindlll 56
Sp6 promoter♦
Figure 2.2. The structure of pAlter-1 plasmid.
2.2.3. pGEX2T and pGEX2T-hDHPR plasmids
pGEX2T is a plasmid vector containing the glutathione R-transferase from 
Schistosoma japonica (GST) gene (Smith and Johnson, 1988), and a multiple cloning 
site at the end of the GST gene. Insertion of a gene into this cloning site can be 
engineered such that a fused GST gene is produced which expresses GST-fusion 
protein under the control of a tac promoter. The thrombin protease recognition site 
which is present between the GST gene and the fused gene, allows the desired protein 
to be cleaved from the fusion protein (see Figure 2.3.).
The pGEX2T-hDHPR plasmid kindly provided by Drs R.G.H. Cotton and P. 
Smooker, The Murdoch Institute, Royal Children Hospital, Melbourne, showed 
several restriction enzyme digestion sites which were inconsistent with those expected 
for the pGEX2T portion. This pGEX2T-hDHPR was reconstructed by re-digesting
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with Seal, and the ca 2 Kb fragment which contains the full length of human DHPR 
cDNA (see Figure 2.3.) was isolated from an agarose gel and re-ligated to the purified 
larger fragment of freshly prepared pGEX2T digested with S ea l . The experimental 
procedure is described in Section 2.4.5. (page 61).
Ptac 0
Seal 831
.Thrombin site 933 
^ -P s t l  947
\ \ ------Ascl 949
LacZ
pGEX2T-hDHPR DHPR
i 5905  bp
-----Sphl 1430
-----EcoRl 1542LacN
Seal 2830
Pstl 3340
Figure 2.3. The structure of pGEX2T-hDHPR.
2.3 .  DHPR MUTAGENESIS
2 .3 .1 .  The required DHPR mutations
The desired DHPR mutations are as follows:
1. Tyr(150)—»Glu [Y150-»E], 2. Tyr(150)-»His [Y150-»H], 3. Tyr(150)^Phe 
[Y150—>F], and 4. Tyr(150)—»Ser [Y150—»S]. Also the following mutations 
which have been observed in defective children: 5. Gly(151)—»Ser [G151—»S], 6.
Gly(23)—»Asp [G23—»D], and 7. Thr( 123)—»insert an extra Thr [T123—»TT]. The 
numbers in round brackets are the amino acid positions in the proteins. These 
mutations are for testing that: Tyr (150) (1 to 4) is involved in hydride transfer in
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DHPR, and the three natural mutations (5 to 7) found in PKU patients affecting 
DHPR activity to find the true levels of enzyme activity.
All the mutation sites are within the AscUSphl fragment in human DHPR cDNA and 
are illustrated in Figure 2.4. These mutation positions were indicated by nucleotide
AscI
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Met
ATG
AY-11
(13$-152)
G23—»D 
(58-78)
Sphl
509
T123—>TT 
(353-380)
AY-10
(48^ 5060)
G151—>S 
(437-467)
449
Stop
TAG
68
100
I
200
I
300
367
400
452
500
Y150->E (434-464) 
Y150->H (439-459) 
Y150—»F (439-459) 
Y150—»S (434-464)
600
j 735 
700
Figure 2.4. Human liver DHPR cDNA. The positions of the required 
mutations and the two oligonucleotide sequencing primers 
(AY- 10 and AY-11). The numbers in brackets correspond 
to the site-directed oligonucleotide primers with the desired 
mutations.
numbers. Their amino acid numbers in the protein are also shown. Oligonucleotides 
A Y - 1 0  (5 T G A T G C T A G C G C T G G C C T C T T 3 ') a nd  A Y - 1 1
(5'GCTGTTCTTCCCAGCCAGGC3') were synthesised as sequencing primers for 
all the mutations. Their positions in DHPR cDNA are illustrated in Figure 2.4. AY- 
10 was used to sequence mutations Y150—»E, Y150-»H, Y150—>F, Y150—>S, 
G151->S and T123—>TT, and AY-11 was used to sequence mutation G23—>D.
2 .3 .2 .
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The oligonucleotide sequences containing the desired 
mutations
Following oligonucleotides (1 to 8) containing the mutations were synthesized and 
used as site-directed mutagenesis primers:
1. Oligonucleotide WA10 (434-464): (Tyr->Glu)
G Met I G Y G Met A K
CT GGT ATG ATC GGG TAC GGC ATG GCC AAG GG
II
GAA
E
150
2. Oligonucleotide WA11 (439-459): (Tyr->His)
Met I G Y G Met A
ATG ATC GGG TAC GGC ATG GCC
II
CAC
H
150
3. Oligonucleotide WA9 (439-459): (Tyr—>Phe)
Met I G Y G Met A 
ATG ATC GGG TAC GGC ATG GCC 
II
TTC
F
150
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4. Oligonucleotide WA14 (434-464): (Tyr—>Ser)
G Met I G Y G Met A K 
CT GGT ATG ATC GGG TAC GGC ATG GCC AAG GG
U
TCT
S
150
5. Oligonucleotide WA15 (437-467): (Gly-^Ser)
Met I G Y  G Met A K G
GT ATG ATC GGG TAC GGC ATG GCC AAG GGT GC
u
TCT
S
151
6. Oligonucleotide WA12 (58-78): (Gly->Asp)
G A C  G S R C 
GGC GCT CTG GGT TCT CG A TGC
u
GAT
D
23
7. Oligonucleotide WA12a (58-78): (Gly—»Asp)
G A C G S R C 
GGC GCT CTG GGT TCT CG A TGC
il
GAC
D
23
8. Oligonucleotide WA13 (353-380): (Insert Thr)
S H L A T  K H L
CC AGC CAT CTG GCT ACC AAG CAT CTC AA
u
ACT ACC 
T T 
123
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The numbers in brackets are for the sequence to which the oligonucleotide primers 
(with mutations) anneal to the hDHPR cDNA (see Figure 2.4.), and numbers below 
the stated mutations are the amino acid positions (see Figure 2.4.). Oligonucleotides 1 
to 4 are for mutations of Try 150 —> desired mutations. Oligonucleotides 5 to 8 are 
for mutations found in PKU patients. Two Gly—>Asp oligonucleotides (6 and 7) were 
prepared because codon GAT in oligonucleotide 6 was the one found in patients, and 
GAC in oligonucleotide 7 was a consensus codon present more frequently in E. coli 
cells (Sharp et al., 1988). The latter mutation was made with the hope of obtaining 
better expression of the human gene in bacteria.
2 .4 .  MATERIALS, EQUIPMENT AND METHODS
2.4 .1 .  Materials and equipment
Restriction enzymes and other enzymes, plasmids and reagents were of the best 
quality commercially available materials and the respective sources are stated in the 
text. High strength Analytical Grade Agarose (Ultra Pure DNA Grade Agarose) from 
Bio-Rad was used for making gels. A Model 3000Xi computer controlled 
electrophoresis Power Supply from Bio-Rad was used for running the gels. The 
plasmids pBlueScript-hDHPR (Figure 2.1.) and pGEX2T-hDHPR were kindly 
supplied by Dr. W.L.F. Armarego. Solutions in Eppendorf tubes were centrifuged in 
Eppendorf 5415C or MicroSpin 24 (Sorvall Instruments, Dupont) microfuges. 
Medium speed (4000-15000 rpm, 2000-27000 x g) centrifugation was carried out 
with Sorvall SS-34 rotors in Sorvall RC5C centrifuges thermostated at the desired 
temperatures. The sequencing reactions were performed by the author of this thesis by 
using dye-dideoxy-terminators (Applied Biosystems) in a Corbett Research Thermal 
Cycler FTS4000, and samples were run by the Biomolecular Resources Facility at 
ANU on polycrylamide gels and scanned by the Facility through a DNA 
Autosequencer (Applied Biosystems, Model 373A) which provided the sequence plots 
shown in Figure 2.13. (page 59).
40
2 .4 .2 .  Preparation of pBlueScript-hDHPR DNA
2.4.2.1. Isolation of pBlueScript-hDHPR DNA from bacterial cells
The procedure for preparing phagmid or plasmid DNA is basically the same as the one 
described by Ausubel et al. (1987), and it has been successfully using in this 
laboratory. Swabs of bacterial JM101 glycerol stocks containing pBlueScript- 
hDHPR were streaked onto LB (+Amp, 100 pg/ml) plates (see Appendix 1), and 
incubated overnight at 37°C. One single colony was used to inoculated 3 ml of LB 
(+Amp, 100 pg/ml) medium (see Appendix 1), and incubated at 37°C with shaking 
for 7 hr, then 1 ml of bacterial culture was added to 100 ml of LB (+Amp, 100 fig/ml) 
medium, and incubated overnight at 37°C with shaking. The bacterial cells were 
centrifuged at 3,000 x g for 5 min at 4°C. The cell pellet was re-suspended in 8 ml of 
TGE buffer (see Appendix 2). Lysis buffer (6 ml) (see Appendix 2) was added, 
mixed immediately until the cell lysate was clear and sticky. Neutralising buffer (6 ml) 
(see Appendix 2) was added immediately. The tube was stored on ice for 5 min, then 
centrifuged at 17,500 x g for 10 min at 4°C. The supernatant was transferred to a 
fresh tube, 1 volume of isopropanol was added, and centrifuged immediately at 
17,500 x g for 10 min at 4°C. The supernatant was aspirated, and the pellet was 
dissolved in 1 ml of TE buffer (see Appendix 9). The solution was transferred to 
2x1.5 ml tubes and 10 pi of 10 mg/ml RNase A (DNase free) (see Appendix 9) was 
added to each tube, incubated at 37°C for 20 min. The solution was extracted 3 times 
with chloroform. DNA was precipitated by addition of 1 volume of isopropanol and 
1/10 volume of 3 M sodium acetate (pH 5.2) (see Appendix 9). After it was spun at 
top speed for 10 min in a microfuge and the supernatant was aspirated, the DNA pellet 
was dissolved in 400 p,l of TE buffer, and heated at 70°C for 10 min (the cap was left 
open to allow trace alcohol to evaporate). The pBlueScript-hDHPR DNA 
concentration was determined by running 1 pi of DNA on a 0.7% agarose gel in TBE
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buffer (see Appendix 9) and compared with standard marker. The DNA concentration 
of pBlueScript-hDHPR was 0.37 pg/pl.
2.4.2.2. Isolation o f cDNA fragment ofhDHPRfrom pBlueScript-hDHPR
Digestion with BamHUHindU
BamH\ and Hindi I were used to digest pBlueScript-hDHPR simultaneously and the 
DNA fragment obtained should contain the full length of human DHPR cDNA (Figure 
2.1.). pBlueScript-hDHPR (40 pi of 0.37 pg/pl) was mixed with 4 pi of 8 U/pl 
Hindu (Pharmacia) and 3 pi of 20 U/pl BamHl (Pharmacia) in 7 pi of 10 x One-Phor- 
All Buffer Plus (Pharmacia) and H20  (see Appendix 9) to a total volume of 70 pi. 
The mixture was incubated at 37°C for 2 hr. A small aliquot of digestion mixture was 
run on a 0.7% agarose gel in TBE buffer (see Appendix 9) to confirm digestion, then 
the rest of the solution was run on a 0.7% agarose gel in lxTAE buffer (see Appendix 
9) at 60 V for 1 hr to isolate the 1.02 Kb cDNA fragment of human DHPR 
(BamHUHindU fragment). Results of digestions are shown in Figure 2.5.
Isolation of the hDHPR cDNA fragment from agarose gel
Two methods were used to isolate DNA fragments from agarose gels in this work. 
Procedure 1 was for the isolation of small DNA fragments from agarose gels and 
followed the one described by Mather, Keightley and Fee (1993). The 1.02 Kb 
cDNA fragment of hDHPR (above digest with BamHl and Hindll) was excised from 
the gel (Figure 2.5a.). Sodium iodide solution (2.5 volume of 6 M, see Appendix 3) 
was added, and incubated at 50°C until the gel dissolved, then it was cooled on ice for 
2 min. Silica matrix suspension (see Appendix 3) was vortexed for 1 min and 10 pi 
of this silica was added to each tube for up to 5 pg DNA in gel-DNA solution. After 
vortexing for a few sec, the tube was left on ice for 10 min at level position and then 
mixed by inverting the tube every two min. The tube was centrifuged for 10 sec in a
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23130 bp
■ 9416 bp
■ 6557 bp
■ 4361 bp
■ 2322 bp 
’ 2027 bp
3 2 1
Figure 2.5a. pBlueScript-hDHPR digested with BamHl and HindiI.
Lane 1: XDNA/Hindlll markers (0.5 |LLg). Lane 2: pBlueScript- 
hDHPR digested with BamHl which generated a single band (4380 
bp). Lane 3: pBlueScript-hDHPR digested with BamHl and Hindu. 
This generated two bands, a 1020 bp band containing full length of 
hDHPR cDNA, and a 3360 bp band containing the rest of the 
plasmid.
4380 bp 
3360 bp
1020 bp
23130 bp 
9416 bp 
6557 bp 
4361 bp
2322 bp 
2027 bp
564 bp
2 1
Figure 2.5b. hDHPR cDNA fragment isolated from an agarose gel.
Lane 1: XDNA/HindJll markers (0.5 fig). Lane 2: The 1020 bp 
hDHPR cDNA fragment from digestion of pBlueScript-hDHPR with 
BamHl and Hindi3 (Figure 2.5a), and recovered from the above 
agarose gel.
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microfuge at top speed and room temperature, and the supernatant was removed 
completely. The tube was placed on ice, 30 volumes (with respect to the silica matrix) 
of New Washing solution (see Appendix 3) was added, and the pellet was re­
suspended by pipetting in and out on ice. This was centrifuged as above and the 
supernatant was removed by aspiration, the wash procedure was repeated twice more. 
The last drop of solution from the silica pellet was removed by aspiration , Tris-HCl 
(40 pi of 10 mM, pH 8.0) (for 10 pi silica matrix) was added, and mixed well by 
vortexing. The tube was incubated at 50°C for 5 min, and centrifuged for 30 sec as 
above. The supernatant was transferred to a clean tube, and heated at 70°C for 5 min 
to destroy any potentially contaminating DNase. The concentration of the 1.02 Kb 
fragment was determined by runing 1 pi on a 0.7% agarose gel in IxTBE buffer (see 
Appendix 9) and comparing with standard markers. The DNA concentration of 
recovered DHPR cDNA (BamHUHindü fragment) was 13 ng/pl (see Figure 2.5b.) in 
a total volume of 40 pi. Procedure 2 is described in Section 2.4.3.2.
2 .4 .3 .  Construction of pAlter-1—hDHPR as the site-directed 
mutagenesis template
2.4.3.1. Transformation ofpAlter-1 to JM 109 competent cells to prepare
pAlter-1 DNA
Preparation of JM 109 competent cells
JM 109 bacteria were streaked on an LB agar plate (see Appendix 1), and incubated 
overnight at 37°C. A single colony was used to inoculate 3 ml of LB medium (see 
Appendix 1) and incubated at 37°C with shaking for overnight. The overnight culture 
(1 ml) was added to 100 ml of LB medium and incubated at 37°C with shaking until 
OD600 « 0.45-0.5. The cells were divided to 2 x 50 ml pre-chilled centrifuge tubes 
(SS-34, Sorvall), and stored on ice-H20  for 2 hr, then centrifuged at 2,400 x g for 15 
min at 4°C. The supernatant was discarded, and the cells were re-suspended in 10 ml
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of ice-cold Trituration buffer (see Appendix 4) by shaking gently to mix well, then 
further buffer was added to a final volume of 50 ml in each tube. The cells were 
incubated on ice-H20  for 45 min, and centrifuged at 1.500 x g for 10 min at 4°C. The 
cells were re-suspended with 10 ml of ice-cold Trituration buffer, 2.5 ml of 80 % 
glycerol was added to give a final concentration of 15 %, then mixed gently. The 
JM109 competent cells were aliquoted (1 ml) and were used directly or chilled in 
liquid nitrogen and stored at -70°C for up-to one month.
The transformation procedure
JM109 competent cells (1 ml) were thawed on ice, 15 (il of DMSO was added and 
mixed briefly. The competent cells (3 x 200 ql) were added into 3 x 2 ml Eppendorf 
tubes (pre-chilled on ice) which contained 0.1 ng, 0.5 ng and 1 ng of pAlter-1 DNA 
(Promega) respectively. The cells-DNA mixture in each tube was mixed by tube 
inversion on ice, then incubated for 30 min on ice. The mixtures were heat-shocked at 
42°C for 2 min (the tubes were not shaken during the heat-shock), and then placed 
back on ice immediately for 1 min. LB (+ 20 mM glucose) medium (1.5 ml, see 
Appendix 1) was added and incubated at 37 °C for one hr with shaking. The cells 
were pelleted in a microfuge at room temperature for 1 min, and the medium was 
pipetted out and then 200 |il of LB (+ 20 mM glucose) medium was added to re­
suspend the cells in each tube by briefly vortexing. The cells were spread onto a LB 
(+TC, 12.5qg/ml) plate (see Appendix 1) and incubated at 37°C for overnight. More 
than 300 clones were obtained from each plate. Typically, about 300 clones were 
obtained by transformation of JM109 competent cells with 0.1 ng of pAlter-1 DNA. 
The efficiency of JM109 competent cells was ~ 3xl06 colonies/qg of pAlter-1 DNA 
by this procedure. XLl-Blue cells gave a smaller number of colonies (about l-2xl06 
colonies/qg of DNA), and AN1459 gave less than one million colonies/(ig of DNA. 
The procedure for preparing pAlter-1 DNA is described below.
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Glycerol stocks of pAlter-1 in JM109 were prepared from a single colony from one of 
the above plates which was used to inoculate 3 ml of LB (+TC, 12.5 pg/ml) medium 
(see Appendix 1), and grown for 7 hr with shaking at 37°C. The culture aliquots (0.5 
ml) were mixed with 0.5 ml of 80% (v/v) glycerol (sterilised) and stored at -70°C.
2 A. 3.2. Isolation ofpAlter-1 DNA and digestion with BamHI/Smal
pAlter-1 DNA was digested with BamHl and Smal in order to ligate hDHPR cDNA 
digested with BamHl and Hindll (Figure 2.7.) to it. pAlter-1 in JM109 cells were 
streaked onto an LB (+TC, 12.5 pg/ml) plate (see Appendix 1). One single colony 
from the above plate was used to inoculate 3 ml of LB (+TC, 12.5 pg/ml) medium 
(see Appendix 1), and incubated for 7 hr at 37°C with shaking, then 1 ml of bacterial 
culture was added to 100 ml of LB (+TC, 12.5 pg/ml) medium, and incubated 
overnight at 37°C with shaking. The procedure described in Section 2.4.2.1. (page 
40) was followed to isolate pAlter-1 DNA.
pAlter-1 DNA (100 pi, 190pg) isolated as above was mixed with 10 pi (90 U) Smal 
(Pharmacia) in 15 pi of 10 x One-Phor-All Buffer Plus (Pharmacia) and H20  (see 
Appendix 9) to total volume of 150 pi. The mixture was incubated at 37°C for 2 hr, 
then heated at 70°C for 5 min. One microlitre of mixture was run on a 0.7% agarose 
gel to confirm digestion, then 5 pi (100 U) BamHl (Pharmacia), and 5 pi more of 10 
x One-Phor-All Buffer Plus (Pharmacia) was added to the Smal digestion mixture and 
H20  (see Appendix 9) to total volume of 200 pi. The mixture was incubated at 37°C 
for another 2 hr, and 1 pi of mixture was run on a 0.7% agarose gel in 1 x TBE buffer 
(see Appendix 9) to confirm digestion, and the rest was run on a 0.7% agarose gel in 
1 x TAE buffer (see Appendix 9) at 60 V for 1 hour (see Figure 2.6.) for the isolation 
of the p Alter-1 fragment digested with BamHl and Smal.
The gel slice containing the 5.68 Kb fragment of pAlter-1 digested with BamHl and 
Smal was cut out of the agarose gel with a scalpel. The DNA in the gel slices was
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Figure 2.6. pAlter-1 DNA digested with Smal and BamHl.
Lane 1: IDN A/HindQl markers (0.5mg). Lane 2: pAlter-1 DNA 
digested with Smal and BamHl, which shows the large 5680 bp 
fragment of pAlter-1.
Figure
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2.7. The 5680 bp fragment of pAlter-1 DNA digested with Smal and 
BamHl (Figure 2.6), after recovery from an agarose gel using 
Procedure 1 (Section 2.4.2.1) and Procedure 2 (Section 2.4.3.2). 
Lane 1: IDNAJHindm markers (0.5 mg). Lane 2: IDN A/HindUl 
markers (0.25 mg). Lane 3: IDNAJHindUl markers (0.125 mg). 
Lane 4: pAlter-1 (1 ml, Small BamHl fragment) isolated by 
Procedure 1. Lane 5: pAlter-1 (0.5 ml, SmaUBamHl fragment) 
isolated by Procedure 1. Lane 6: pAlter-1 (0.25 ml, SmaUBamHl 
fragment) isolated by Procedure 1. Lane 7: pAlter-1 (1 ml of 1/10 
dilution, SmaUBamHl fragment) isolated by Procedure 1. Lane 8: 
pAlter-1 (1 ml, SmaUBamHl fragment) isolated by Procedure 2. 
Lane 9: pAlter-1 (0.5 ml, SmaUBamHl fragment) isolated by 
Procedure 2. Lane 10: pAlter-1 (0.25 ml, SmaUBamHl fragment) 
isolated by Procedure 2. Lane 11: pAlter-1 (1 ml of 1/10 dilution, 
SmaUBamHl fragment) isolated by Procedure 2.
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isolated by two methods. Procedure 1 (Silica matrix) was described in Section
2.4.2.2. (page 41). Procedure 2 invpjgved running the desired DNA band onto a NA 
45 filter paper by electrophoresis, and eluting the DNA off from the filter (Armarego et 
ai, 1989). From a 0.7% agarose gel a well was cut out which was slightly larger than 
the size of the DNA gel slice. A piece of NA 45 filter paper was inserted into the well 
down to the bottom, and the DNA gel slice was placed back into the well with the filter 
paper on one side in between, then the gel slice was pushed forward gently to drive 
any air bubbles out. The gel was run at 60 V for 10-15 min, which allowed all DNA 
to move from the slice onto the filter paper (inspected by UV light). The filter paper 
containing all the DNA was removed and placed into an Eppendorf tube, then 400 pi 
of 1M NaCl and 50 mM of arginine was added until the filter paper was covered 
completely. The tube was heated at 70°C for 1 hr, the solution was transferred to a 
fresh tube, then 900 pi of 100 % ethanol was added to precipitate the DNA. The 
mixture was centrifuged for 15 min in a microfuge at top speed at room temperature, 
the supernatant was removed and DNA pellet was dissolved in 40 pi of TE buffer (see 
Appendix 9), then heated at 70°C for 5 min. The DNA concentrations from both 
procedures, were determined by running the DNA on 0.7% agarose gels and 
comparing with standard markers. Similar recovery was obtained from these two 
methods (see Figure 2.7.) and Procedure 1 was easier to use. The concentration of 
the 5.68 Kb fragment of pAlter-1 was found to be ~41 ng/pl (total volume 100 pi) by 
Procedure 1 (Silica matrix) and ~50 ng/pl (total volume 100 pi) by Procedure 2 
(NA41 filter paper).
2.4.3.3. Ligation o f the 5.68 Kb fragment ofpAlter-1 with the 1.02 Kb 
fragment o f DHPR cDNA
The above isolated vector (5.68 Kb fragment of pAlter-X/BamHUSmal, ~41 ng/pl of 
DNA concentration by Procedure 1, and ~50 ng/pl of DNA concentration by
Procedure
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2) and insert (1.02Kb fragment of human DHPR cDNA from pBlueScript-hDHPR 
digested with BamHl and Hindu, 13 ng/'pl, Figure 2.1, Section 2.4.2.2., page 41) 
were adjusted to 1 picomole ends/pl (see Appendix 6 for calculation, i.e. 40 ng/pd for 
vector and 8 ng/pl for insert). Ratios of vectoninsert of 1:1 (1 pi of vector and 1 pi of 
insert); 1:2 ( 1 pi of vector and 2 pi of insert); 1:3 (1 pi of vector and 3 pi of insert); 
and 1:0 (1 pi of vector only) were mixed into 4 Eppendorf tubes, and H2O (see 
Appendix 9) was added to a final volume of 8 pi in each tube, then 12 pi of Master 
Mixture [ 10 pi of 2 x T4 DNA ligase buffer (see Appendix 4); 1 pi of 10 mM ATP 
(see Appendix 4); 1 pi of T4 DNA ligase (3 U/pl, Promega)] were added to each tube 
and mixed on ice. The mixture was incubated at 16°C overnight and left at 4°C for 4 
hr until transformation into competent cells. Each ligation mixture (1 pi) was run on 
an 0.7% agarose gel in 1 x TBE buffer (see Appendix 9) to check the ligation reaction 
(see Figure 2.8.). The ligation reactions in which vector DNA was isolated by 
Procedure 1 and vectoninsert ratios of 1:1; 1:2; 1:3, 1:0, were named A l; A2; A3, A4 
respectively, while vector DNA isolated by Procedure 2 and vectoninsert ratios of 1:1; 
1:2; 1:3, 1:0 were named Bl; B2; B3, B4 respectively. The transformation procedure 
described in Section 2.4.3.1. was followed except that the cells were poured onto LB 
(+TC, 12.5 p.g/ml) plates (see Appendix 1), after the plates were spread with 100 pi 
of 20 mg/ml X-Gal (see Appendix 9) and 100 pi of 100 mM IPTG (see Appendix 9) 
and these chemicals allowed to be absorbed for 30 min. White colonies and blue 
colonies were obtained, and white colonies were the positive ones which contained the 
inserts.
Results from the transformations were as follows: (i) 55 white colonies and 2 blue 
colonies from A l; 46 white colonies and 2 blue colonies from A2; 55 white colonies, 
and 11 blue colonies from A3; 0 colony from A4, (ii) 32 white colonies and 5 blue 
colonies from Bl; 44 white colonies and 2 blue colonies from B2; and 53 white
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Figure 2.8. Ligation mixture from 5680 bp fragment of pAlter-1
(digested with Smal and BamHl, Figure 2.7), and 1020 bp of 
hDHPR cDNA (digested from pBlueScript-hDHPR with BamHl and 
Hindi! , Figure 2.5b). Lane 1: XDNA/Hindlll markers (0.5 (ig). 
Lane 2: A l (1 (il vector, 1 (il insert). Lane 3: A2 (1 pi vector, 2 \x\ 
insert). Lane4: A3 (1 (il vector, 3 (il insert). Lane 5: B 1 (1 (il 
vector, 1 |il insert). Lane 6: B2 (1 (il vector, 2 |il insert). Lane 7: 
B3 (1 ( L i l  vector, 3 (il insert). Vector DNA (5680 bp) used in A1-A3 
was isolated from agarose gel with Procedure 1 (Figure 2.7), and 
vector DNA used in B1-B3 was isolated from agarose gel with 
Procedure 2 (Figure 2.7).
Figure 2.9.
5800 bp
481 bp 
415 bp
3 2 1
pAlter-1—hDHPR DNA with mutations G23—>D and T123—>TT 
digested with Ascl and Sphl. Lane 1: XDN A/Hind markers (0.5 |ig). 
Lane 2: pAlter-1—hDHPR with mutation T123—>TT digested with 
Ascl and Sphl. Lane 3: pAlter-1— hDHPR with mutation G23—>D 
digested with Ascl and Sphl. Both clones generated the 481 bp 
containing the mutations as expected.
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colonies and 3 blue colonies from B3; 6 blue colonies without white colonies from 
B4. These results showed that both methods for isolation of DNA fragments from 
agarose gels recovered about the same quality of DNA, and the ratio between vector 
and insert for successful ligations was not very important.
The white colonies are^p Alter-1 contairf human DHPR cDNA (named pAlter-1— 
hDHPR, see Figure 2.10.) and were confirmed by isolation of plasmid DNA followed 
by digesting with Ascl and Sphl in'following section (see Figure 2.9.).
T7 promoter
EcoRI
SacI
Kpnl
1—  Sma\J H indi
481 bp
415 bp
Figure 2.10. The structure of pAlter-1—hDHPR.
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2.4.3.4. Mini preparation ofpAlter-1—hDHPR DNA fo r  digestion
with AscI and SphI restriction enzymes
Human DHPR cDNA contains a AscI site at bp 28 (from ATG start codon) and an Sphl 
site at bp 509 (from ATG star codon) (see Figure 2.4. page 36) and pAlter-1 only 
contains an Sphl site at the multiple cloning site. When p Alter-1— hDHPR is digested 
with AscI and Sphl and ;s expected first to generate a 5800 bp band (most of the 
vector plus a small part of DHPR with Sphl!Sphl ends), a 481 bp band (part of DHPR 
only with AscUSphl ends) and finally a 415 bp band (part vector plus part DHPR with 
Sphl/Ascl ends).
A white colony from each above plates (Section 2.4.3.3.) was used to inoculate 3 ml of 
LB (TC, +12.5 fig/ml) medium (see Appendix 1), respectively, and was incubated 
overnight at 37°C with shaking. The bacterial cells from each (1.5 ml) were transferred 
into 1.5 ml Eppendorf tubes and centrifuged for 20 sec at top speed in a microfuge. 
Cell pellets were re-suspended in 100 pi of TGE buffer (see Appendix 2). Lysis buffer 
(200 pi, see Appendix 2) was added in, and mixed immediately until the cell lysate was 
clear and sticky. Neutralising buffer (150 pi, see Appendix 2) was added and mixed 
immediately. The tubes were stored on ice for 5 min, then centrifuged for 3 min at top 
speed. The supernatants were transferred to fresh tubes and mixed with 800 jllI of 
100% ethanol, and the mixture was spun for 10 min at top speed. The supernatants 
were aspirated, and the pellets were dissolved in 20 pi of TE buffer (see Appendix 9). 
RNaseA (DN^s-free) (0.5 pi of 10 mg/pi, see Appendix 9) was added to each tube and 
heated at 70°C for 5 min (the tubes were left open to allow trace alcohol to evaporate).
The above DNAs (2 ptl) were each mixed with 1 p,l of 2 U/pi AscI (New England), 1 pi 
of Buffer 4 (New England) and H20  (see Appendix 9) to total volumes of 10 pi. The 
mixtures were incubated at 37°C for 2 hr, then heated at 70°C for 5 min. Then Sphl (1
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pi of 5 U/pl, New England) and 2 pi of Buffer 2 (New England) [because the
concentrations of salts in Buffer 4 (acetate salts) and Buffer 2 (chloride salts) are the
same so that DNA was not precipitated after the first enzyme-AscI digestion] were
added into the Asc\ digestion mixture and H20  (see Appendix 9) was added to total
volumes of 20 pi. The mixtures were incubated at 37°C for another 2 hr, and 10 pi of
each mixture were run on an 0.7% agarose gel in 10 x TBE buffer (see Appendix 9).
The results for the G23 —> D and T123 —> TT mutants are shown in the gel in Figure
S'* »*; feu \ y
2.9. (the other mutations behaved sam«) confirm that these clones contain the 5800 bp 
fragment of vector-DHPR/Sp/zI/5/?M, the 481 bp fragment of DHPR/AscVSphl and the 
415 bp fragment of vector-DHPR/Sp/iI/AscI, as expected from Figure 2.4. (page 36) 
and 2.10. (page 50). These clones containing human DHPR cDNA were named as 
pAlter-1—hDHPR. ss-DNA of pAlter-1—hDHPRs were prepared as follows for site- 
directed mutagenesis reactions.
2.4.3.5. Preparation ofpAlter-1—hDHPR ss-DNA
The protocol described by the manufacturer (Promega) was basically followed. One 
single colony of pAlter-1—hDHPR was used to inoculate 3 ml of 2 x YT (TC, +12.5 
pg/ml) medium (see Appendix 1) and incubated overnight at 37°C with shaking. The 
overnight culture (0.2 ml) was added into 10 ml of 2 x YT (TC, +12.5 pg/ml) medium 
and incubated at 37°C with shaking until an ODöoowas reached to 0.1, then 80 pi of 
R408 help phage (1011 pfu/ml, Promega) was added and the cells were incubated at 
37 °C for another 4.5 hr with vigorous shaking. The bacterial cells were centrifuged at 
3,000 x g for 5 min at 4°C, and the supernatant was collected. DNase I (20 pi of 1 
mg/ml, see Appendix 9) was added to final 2 pg/ml and incubated at 37°C for 30 min, 
then heated at 70°C for 15 min in water bath to destroy residual bacteria and DNase I. 
The mixture was centrifuged at top speed, and the supernatant (1.25 ml) was 
transferred to a fresh microfuge tube, 250 pi of PEG solution (see Appendix 9) was
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added and mixed, set aside for 15 min at room temperature to precipitate phage. The 
mixture was centrifuged at top speed for 5 min as above and the supernatant was 
discarded (the phage pellet should be visible at this stage). The phage pellet was 
centrifuged again for 5 min, all remaining traces of PEG were carefully removed by 
aspiration. TE buffer (200 pi, see Appendix 9) was added to re-suspend the pellet 
completely, then 100 pi of TE-buffered phenol (see Appendix 5) was added. The 
mixture was vortexed for 1 min, set aside for 5 min then vortexed again. Further 
centrifugation for 5 min as above was carried out. The upper aqueous phase (175 pi) 
was transferred to a clean microfuge tube, 20 pi of 3 M sodium acetate (pH 5.2, see 
Appendix 9) and 400 pi of 100% ethanol wa&added and centrifuged for 15 min as 
above. The pAlter-1—hDHPR ss-DNA pellet was dissolved in 20 pi of TE buffer (see 
Appendix 9), 1 pi was run on 0.7% agarose gel in TBE buffer (see Appendix 9) (see 
Figure 2.11.) and the rest was stored at -20°C for the following reactions.
Figure 2.11. shows the results of ss-DNA preparation. In lane 3 (without addition of 
DNasel) the ss-DNA was contaminated with chromosomal DNA, and lanes 4-6 (with 
addition of DNasel) had only ss-DNA. Chromosomal DNA contamination did not
appearjaffect the reaction in the following steps.
2.4 .4 .  Site-directed mutagenesis reactions
2.4.4.1. 5'-Phosphorylation of oligonucleotides
The synthesised and purified oligonucleotides (see Section 2.3.2., page 37) were 
dissolved 1 ml of TE buffer (see Appendix 9), and heated at 70°C for 10 min. The 
solution (5 pi) was used to check the OD260 values in order to calculate the 
concentrations in picomole/pl for each oligonucleotide (see Appendix 6 for formula). 
Oligonucleotides (100 pmole) were mixed with 2.5 pi of 10 x T4 DNA kinase buffer
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Figure 2.11. Single-stranded DNA of pAlter-1— hDHPR.
Lane 1: XDNA/HindBl markers (0.25 |Lig). Lane 2: XDNA/HindlU 
markers (0.125 |ig). Lane 3: ss-DNA (1 |Lil) preparation without addition 
of DNasel. Lane 4: ss-DNA (1 pi of 1/10 diluted) preparation with 
addition of DNasel. Lane 5: ss-DNA (0.5 pi of 1/10 diluted) preparation 
with addition of DNasel. Lane 6: ss-DNA (0.25 pi of 1/10 diluted) 
preparation with addition of DNasel. ss-DNA with addition of DNasel 
shows no contaminating by E.coli chromosome DNA [the concentration 
was determined as 100 ng/pl (total 20 pi)]; and ss-DNA without addition 
of DNasel shows some contaminating by E.coli chromosome DNA [the 
concentration was as 14 ng/pl (total 100 pi)].
Figure 2.12.
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DNA of pAlter-1—hDHPR with a mutation at Tyr (150) —> Glu.
It was isolated after it transformation into BMH71-18 mut S competent 
cells. Lane 1: XDNA/Hindül markers (0.5 pg). Lane 2:XDNAJHindUl 
markers (0.25 pg). Lane 3: XDNA/Hindlll markers (0.125 p,g). Lane 
4: Undiluted sample (1 pi). Lane 5: Diluted sample (5 pi of 1/10). Lane 
6: Diluted sample (2 pi of 1/10). Lane 7: Diluted sample (1 pi of 1/10). 
The pAlter-1—hDHPR DNA concentration was 100 ng/pl by comparison 
to the markers DNA.
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(+ATP) (see Appendix 9), 1 pi of T4 polynucleotide kinase (8 U/pil, Promega), and 
H20  (see Appendix 9) to total volume of 25 p i The mixtures were incubated at 37°C 
for 30 min, then heated at 70°C for 10 min to inactivate the kinase. The mixtures were 
diluted 4 times with H20  (see Appendix 9) to 100 pi, and the final oligonucleotide 
concentrations were ca 1 pmol/pl The mixtures were used directly for the annealing 
reaction.
2.4.4.2. The mutagenesis annealing reaction
ss-DNA of pAlter-1—hDHPR [0.05 pmol (7.9 pi of 14 ng/pl)] was mixed with 0.25 
pmol (1 pi of 2.2 ng/p.1) of ampicillin repaired oligouncleotide (phosphorylated, 
Promega); 1.25 pmol (1.25 pi of kinase reaction mixture from Section 2.4.4.1.) of 
phosphorylated mutated oligonucleotide; 2 pi of 10 x annealing buffer (Promega) and 
7.85 pi of H20  (see Appendix 9) was added to final volume of 20 pi. The annealing 
mixture was heated at 75°C for 5 min in a 200 ml water bath, then it was cooled slowly 
by leaving the tube in the bath until the temperature reached 20°C in a cold room. The 
annealing mixture, then was placed on ice, and 3 pi of 10 x synthesis buffer (Promega); 
1 pi of T4 DNA polymerase (10 U/pl, Promega); 1 pi of T4 DNA ligase (3 U/pl, 
Promega) and 5 pi of H20  (see Appendix 9) were mixed to final volume of 30 pi. The 
reaction was carried out by incubation at 37°C for 90 min to form mutant strand.
2.4.4.3. Transformation to BMH71 -18 mut S and JM109 competent cells
Two bacterial strains BMH71-18 mut S and JM109 were used for the transformation of 
synthesised plasmid DNA in this system (see Promega's protocol). Because BMH71- 
18 mut S is a "mismatch repair minus" strain of bacteria, it is used in the first round of 
transformations to decrease the chance that the ampicillin "repair mismatch" and the
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"mutagenic mismatch" will be successful. The second round of transformations into 
JM109 were carried out to select mutated clones.
The reaction mixture (above) was transformed into BMH71-18 mut S competent cells 
prepared as described in Section 2.4.3.1. (page 43). Then the cells were transferred to 
4 ml of LB (+ Amp, 100 |ig/ml) medium (see Appendix 1) in a 50 ml-flask, instead of 
pouring onto an LB (+ Amp, 100 |ig/ml) plate (see Appendix 1), and incubated at 37°C 
overnight by shaking to select the Ampr positive clones. Normally bacterial cells for all 
transformations with the above synthesised plasmids DNA were successful. This 
means, at least, that the ampicillin resistance gene was repaired. DNA from 4 ml of LB 
(+ Amp, 100 Jig/ml) overnight culture was isolated as follows. pBlueScript (1 ng) was 
transformed into BMH71-18 mut S competent cells and grown on an LB (+ Amp, 100 
P-g/ml) plate at the same time as a positive control to test the efficiency of the BMH71- 
18 mut S competent cells. 2.4 x 106 Colonies/fig of pBlueScript were obtained. The 
efficiency of transformation of BMH71-18 mut S competent cells was therefore good.
The above overnight culture (2 ml) was in a 2 ml microfuge tube was centrifuged as 
above at room temperature for 1 min. The supernatant was removed by aspiration, the 
pellet was re-suspended into 200 ptl of ice-cold TGE buffer (see Appendix 2). Lysis 
buffer (500 |il) (see Appendix 2) was added and mixed immediately by inversion of the 
tube until the cell lysate was clear and sticky. Ice cold Neutralising buffer (350 (il) (see 
Appendix 2) was added and mixed immediately. The tube was stored on ice for 5 min, 
and centrifuged for 5 min at top speed in a microfuge. The supernatant was transferred 
to a fresh tube and 1 volume of TE-buffered phenol/chloroform (1:1) (see Appendix 5) 
was added and was vortexed for 1 min, then centrifuged for 5 min. The upper aqueous 
phase was transferred to a fresh 2 ml tube and the phenol/chloroform washing steps 
were repeated twice more as above. The DNA was precipitated by adding 1 volume of 
isopropanol and centrifuged immediately for 5 min at room temperature. The DNA
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pellet was rinsed by 1 ml of 70% ethanol (pre-chilled) and dried in air, then 50 pi of TE 
buffer (see Appendix 9) was added to dissolve DNA pellet and 1 pi of 10 mg/ml of 
RNase A (DNase free) (see Appendix 9) was added. The tube was heated at 70°C for 
10 min. The DNA concentration was determined by running 1 pi sample on a 0.7% 
agarose gel in 1 x TBE buffer (see Appendix 9) and compared with standard DNA 
markers (see Figure 2.12.). The concentration was found to be 40 ng/pl of DNA. The 
preceding DNA (1 ng, 0.5 ng and 0.1 ng) was transformed into JM109 competent 
cells, as described in Section 2.4.3.1. (page 43). More than 400 clones were obtained 
from each plate. The efficiency of JM109 competent cells were 4 x 106/pg of DNA. 
Five colonies were used to inoculate 5 x 1.5 ml of LB (+ Amp, 100 pg/ml) medium 
(see Appendix 1) in 5 x 10 ml tubes, respectively, then incubated at 37 °C 7 hr with 
shaking. Each culture (0.5 ml) was mixed with 0.5 ml of 80% glycerol and stored at 
-20°C. The rest of the culture was used to inoculate for further growing as below, to 
isolate DNA for sequencing and for identifying mutated clones.
2.4.4.4. Mini preparation of DNA for sequencing
The procedure described in the sequencing protocol manual from the Applied 
Biosystems Equipment was basically followed. Each culture (10 pi) from above was 
added into 10 ml of LB (+ Amp, 100 pg/ml) medium (see Appendix 1) in 50 ml flasks 
and a total 5 samples were prepared at a time, then incubated at 37°C overnight with 
shaking. The cells were centrifuged at 3,000 x g for 10 minutes at 4°C. The cells from 
each tube were re-suspended in 400 pi of TGE buffer (see Appendix 2) and transferred 
to 2 x 1.5ml tubes. Lysis buffer (400 pi) (see Appendix 2) was added into each 1.5 ml 
tube, and mixed immediately by inversion until the cell lysates were clear and sticky. 
Ice cold Neutralising buffer (400 pi) (see Appendix 2) was added into each tube and 
mixed immediately. The tube was stored on ice for 5 min, then centrifuged for 5 min at 
top speed in a microfuge. The supernatants were transferred to fresh tubes and 5 pi of
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10 mg/ml RNaseA (DNase free) (see Appendix 9) was added into each tube. 
Chloroform (400 pi) was added in each tube and shaken by hand for 30 sec, then 
centrifuged for 1 min at top speed in a microfuge. The upper layer was transferred into 
a fresh tube, and the chloroform wash step was repeated two more times. Equal 
volumes of isoproponal were added and centrifuged immediately for 10 min as above. 
The supernatants were aspirated and the DNA pellets were dried in air, then dissolved 
in 32 pi of H20  (see Appendix 9). Sodium chloride (8 pi, 4 M) and 40 pi of 13% PGE 
800 (see Appendix 9) were added, and mixed by vortexing. The tubes were incubated 
on ice for 20 min, then centrifuged at 17,500 for 15 minutes at 4°C. The supernatants 
were aspirated and the pellets were washed with 1 ml of 70% ethanol (pre-chilled) and 
dried in air. H20  (40 pi) (see Appendix 9) was added to dissolve the pellet, then heated 
at 70°C for 5 min (uncapped tubes). The DNA concentrations were determined by the 
OD260 value (see Appendix 6 for the formula) and were about 1 p,g/pl on average. 
These were ready for the sequencing reactions.
2.4.4.5. The sequencing reaction
Double stranded DNA (from Section 2.4.4.4.) was mixed with 9.5 pi of Dye-dideoxy- 
terminator premix (see Appendix 9) and 3.2 pmol of sequencing primers AY-10 or AY-
11 (Section 2.3.1. page 35), then H20  (see Appendix 9) was added to 20 pi final 
volume. The reaction mixture was mixed in a microfuge tube, then transferred into a 
"sequencing reaction tip". The tip was heat-sealed as instructed and then placed into the 
"Corbett Research" Thermal Cycler for the reaction. The reaction cycling was as 
follows: the thermal ramp was rapid heated to 94°C and kept for 30 sec, then rapid 
cooed to 50°C and kept for 15 sec, finally rapid heated to 60°C and kept for 4 min. 
The cycle was repeated for 25 times.
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pAlter-1—hDHPR Sequence pGEX2T-hDHPR(2N) Sequence
ACCCT TG GC CAT G C C T T C CC CG AT CAT AC C A G!
l.T yrwx (GTA) Glu (TTC) (434-464)
'TG GCCATGCCGTGCCCGAT CAT A
2. Tyr WT (GTA)
IT G G C C A T G C C G T G C C C G A T  CAT A
His (GTG) (439-459)
JTGGC CATGCCG AACCCG AT CAT A 
60 ------  70
3. Tyr W t  (GTA) Phe (GAA) (439-459)
4. Tyr wt (GTA) —> Ser (AGA) (434-464)
Figure 2.13. Mutation sequence results. Left hand entries show that the desired 
mutations in the pAlter-1—mutated-DHPR clones were successful. 
Right hand entries show that the desired mutations in the pGEX2T— 
mutated-DHPR clones were successful.
60
(Fig 2.13. continued)
pAIter-l—hDHPR Sequence pGEX2T-hDHPR(2N) Sequence
^ G C A C C C T T G G C C A T A G  A 3 T A C C C G A T  C A T A C C A j  A G C A C C C T T G G C  C A T  AG AG I  ACC CG AT C A T  AC
5. Gly w t  (GCC) -» Ser (AGA) (437-467)
6. Gly w t  (ACC) -> Asp (a) (ATC) (58-78)
[ CG
Al}
C A T  CG AG A G T C C A G A G  CG C C C CG CA T CG AG AGT  C C A G  AG CG C C C
7. Gly wt (ACC) -» Asp (b) (GTC) (58-78)
8. Insert Thr (GGT -> GO TA GT) (353-380)
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The reaction mixture was transferred back to a microfuge tube and 80 pi of H20  (see 
Appendix 9) was added. The free dye-terminators were extracted with 100 pi of 
Phenol:H20:Chloroform (68:18:14) (see Appendix 5) by vortexing for 30 sec then 
centrifuged for 1 min at top speed in a microfuge, the lower organic phase was removed 
and discarded. The flayef\aqueous] was re-extracted with a second 100 p i of 
henol:H20:Chloroform as above. The aqueous upper layer was transferred to a clean 
tube, 10 pi of 3 M sodium acetate (pH 5.2) (see Appendix 9) and 300 pi of 100% 
ethanol was added, then centrifuged for 15 min as above and the DNA pellet was dried 
in air. The samples were run on a gel, and the sequence data were obtained from the 
Autosequencer (Applied Biosystems, Model 373A). All the sequencing data are 
displayed in Figure 2.13. which show that the individual mutations have indeed taken 
place.
2 .4 .5 .  Reconstruction of pGEX2T-hDHPR
The pGEX2T-hDHPR kindly provided by Drs R.G.H. Cotton and M.M. Dahl, The 
Murdoch Institute, Royal Children Hospital, Melbourne, was re-constructed (see 
Section 2.2.3., page 34). pGEX2T-hDHPR DNA (20 pi, 0.6 pg /p l) isolated as 
described for pBlueScript-hDHPR in Section 2.4.2.2. (page 41) was mixed with 3 pi 
of 10 U/pl Seal (Boehringer) and in 3 pi of 10 x Buffer H (Boehringer) and H20  (see 
Appendix 9) was added to total volume of 30 pi. The mixture was incubated at 37 °C 
for 2 hr. A small aliquot of digestion mixture was run on a 0.7% agarose gel in the 10 
x TBE buffer (see Appendix 9) to confirm digestion and the rest was also run on 0.7% 
agarose gel in 1 x TAE buffer (see Appendix 9) at 60 V for 1 hr (see Figure 2.14.). 
The ca 2 Kb cDNA fragment of full length human DHPR was isolated from the agarose 
gel by Procedure 1 as described in Section 2.4.2.2. (page 41), and 75 ng/pl of DNA 
concentration (total volume 40 pi) was obtained.
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I -------2 3 1 3 0  bp
&  1 --------  9416  bp
W L^M ------  65 57  bp
4 K b ~ ^ ^ m — 4361 ^
M ____ 232 2  bp
2 Kb— ---------  202 7  bp
3 2 1
Figure 2.14. pGEX2T-DHPR and pGEX2T DNA digested with Seal.
Lanel: XDNAJHindUl markers (0.5 pig). Lane2: pGEX2T-hDHPR 
digested with Seal. Lane3: pGEX2T digested with Seal. pGEX2T 
digested with Seal generated a ca 4 Kb fragment. pGEX2T-hDHPR 
digested with Seal generated two fragments, a ca 4 Kb and a ca 2 Kb 
fragment. The 2 Kb fragment contains the cDNA of human DHPR 
(Figure 2.3.).
Figure 2.15.
■23130 bp
■ 941 6  bp 
' 655 7  bp
■ 4361 bp
. 232 2  bp
■ 2 0 2 7  bp
4 3 2 1
pGEX2T, pGEX2T-hDHPR and pGEX2T-hDHPR (2N) digested with 
Seal. Lanel: ^DNA/HindIII markers (0.5 p,g). Lane2: pGEX2T- 
hDHPR (2N) digested with Seal. Lane3: pGEX2T-hDHPR digested 
with Seal. Lane4: pGEX2T digested with Seal. This confirm that the
reconstructed pGEX2T-DHPR (2N) contain the 2 Kb Seal fragment.
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pGEX2T (20 pi, 0.35 pg/pl) was isolated as described in Section 2.4.2.2. (page 41), 
and was digested by Seal as above except that 2 pi of 10 U/pil Seal (Boehringer) was 
used. The ca 4 Kb pGEX2T fragment was isolated from an agarose gel as above. The 
concentration of the 4 Kb DNA isolated was 120 ng/pl (tolal volume 40 pi).
The fragment of pGEX2T (about 4 Kb) was used as vector and the 2 Kb cDNA 
fragment containing the full length human DHPR cDNA was used as insert. The 
ligation procedure was as described in Section 2.4.3.3. (page 47). The ligation mixture 
was transformed into AN 1459 competent cells (competent cell preparations and 
transformation procedures were as described in Section 2.4.3.1., page 43). Because 
Seal is a "blunt-end" restriction enzyme, the DHPR insert orientation in newly formed 
pGEX2T-hDHPR hr inserted in two orientations. The orientation was determined by 
Pstl digestion (see Figure 2.3., page 35). If the insert was ligated correctly a 2.4 Kb 
fragment and a 3.9 Kb fragment should be expected by Pstl digestion. If not, a small 
fragment (335 bp) will be seen in addition of the 5570 bp vector fragment. Two 
colonies were picked up for isolation of small amount of DNA from 3 ml of cultures as 
described in Section 2.4.3A (page 51). These two clones were called pGEX2T- 
hDHPRlN and pGEX2T-hDHPR2N, respectively. They were digested with Seal and 
Pstl as follows to determine that they contained the Seal insert and had the correct 
orientation of the insert.
DNA (2 pi) from each of the re-constructed pGEX2T-hDHPR (pGEX2T-hDHPRlN 
and pGEX2T-hDHPR2N) was mixed with 1 pi of 10 U/pl Seal (Boehringer) with 2 pi 
of 10 x Buffer H (Boehringer) and H2O (see Appendix 9) to total volume of 20 pi and 
digested at 37°C for 1 hr. The digestion mixture (10 pi) was run on a 0.7% agarose gel 
in 10 x TBE buffer (see Appendix 9). The gel showed that both clones generated 4 Kb 
and 2 Kb bands (see Figure 2.15.), so that they both contained the inserts in the correct 
orientation.
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399 4  bp 
2 4 0 0  bp
2 3 1 3 0  bp
9 4 1 6  bp 
6 5 5 7  bp 
4361 bp
2 3 2 2  bp 
2 0 2 7  bp
3 2 1
Figure 2.16. DNA of pGEX2T-hDHPR (IN) and pGEX2T-hDHPR (2N) digested 
with Pstl. Lane 1: XDNAJHindlU markers (0.5 Jig/|il). Lane 2: 
pGEX2T-hDHPR (IN) digested with Pstl. Lane 3: pGEX2T-hDHPR 
(2N) digested with Pstl. The both reconstructed pGEX2T-hDHPR 
clones contain 2400 bp fragment as expected (Figure 2.3).
59 05 bp. 
548 7  bp- «■i*
-23130  bp
- 9 4 1 6  bp
- 6 5 5 7  bp
- 4361 bp
- 2 3 2 2  bp 
" 2 0 2 7  bp
41 8 bp —
Figure 2.17.
4 3 2 1
DNA of pGEX2T-hDHPR (2N) digested with Sphl and As cl.
Lane 1 XDNA/HindRl markers (0.5 fig). Lane 2: uncut pGEX2T- 
hDHPR (2N). Lane 3: pGEX2T-hDHPR (2N) digested with Sphl. 
Lane 4: pGEX2T-hDHPR (2N) digested with Sphl and Ascl. The 418 
bp[ expecjjfagmen^ was generated. It confirms that this reconstructed 
pGEX2T-hDHPR (2N) is correct.
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pGEX2T-hDHPRlN and pGEX2T-hDHPR2N (2 pi) were also mixed with 1 pi of 8 
U/pl Pstl (Pharmacia) with 1 pi of 10 x One-Phor-All Buffer Plus (Pharmacia) and 
H20  (see Appendix 9) was added to total volume of 10 pi, and digested at 37°C for 1 
hr. The digestion mixture (10 pil) was run on a 0.7% agarose gel in 10 x TBE buffer 
(see Appendix 9), and the expected 3.9 Kb and 2.4 Kb fragments were produced from 
both clones, which indicated that the orientation of the DNA fragment was correct (see 
Figure 2.16.) in both clones. pGEX2T-hDHPR2N (5 pi) was digested with AscVSphl 
and the expected fragment of DHPR cDNA (481 bp) (see Figure 2.17.) was obtained . 
Further confirmation by expression of DHPR activity by pGEX2T-hDHPR2N was also 
conducted (see methods for expressing fusion protein in Chapter 3). The clone 
pGEX2T-hDHPR2N was chosen for rest of the work.
2.4 .6 .  Preparation of pGEX2T-mutated DHPRs
The 481 bp AscVSphl fragments from all the pAlter-1 mutated-DHPRs were isolated, 
purified and ligated with the common large 5424 bp fragment from AscVSphl fragment 
of pGEX2T-hDHPR to form all the desired pGEX2T-mutated-DHPRs (see Scheme 
2.1., page 32).
2.4.6.1. Digestion reactions
pGEX2T-hDHPR2N DNA and pAlter-1—mutated DHPR DNA were isolated as 
described in Section 2.4.2.1. (page 40). The DNA concentration of pGEX2T- 
hDHPR2N was 1.58 pg/pl, and of pAlter-1—mutated-DHPR was 0.88 pg/pl, after 
comparison with standard markers.
pGEX2T-hDHPR2N DNA (20 pi, 1.58 pg/pl) or 50 pi pAlter-1— mutated DHPR 
DNA (0.88 pg/pl) were each mixed with 30 pi of 2 U/pl Ascl (New England), 10 pi of
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Buffer 4 (New England) and H20  (see Appendix 9) to total volume of 100 pl. The 
mixtures were incubated at 37°C for 2 hr, then heated at 70°C for 10 min. Then 10 pl 
of Sphl (5 U/pl New England) and 20 pl of Buffer 2 (New England) were added into 
the AscI digestion mixture and H20  (see Appendix 9) was added to total volume of 200 
p i The mixtures were incubated at 37°C for another 2 hr, and run on a 0.7% agarose 
gel with TAE buffer (see Appendix 9). The Figure 2.18a. shows the 5424 bp fragment 
of pGEX2T/AscVSphl and the 481 bp fragment of DHPR/AscIAS/?/zI. Figure 2.19a. 
shows the 5800 bp fragment of pAlter-1—DHPR/Sphl/Sphl, and the 481 bp band of 
part of the mutated DHPR/AscI/S/?/zI and a 415 bp fragment of pAlter- USphUAscl 
without the mutated portion of DHPR cDNA (see illustrated in Figure 2.5., page 50).
2.4.6.2. Isolation and ligation of the 5424 bp pGEX2T/Ascl/SphI fragment 
with the 481 bp of mutated DHPRJAscI/Sphl DNA fragments
The 5424 bp fragment of pGEX2T from pGEX2T-hDHPR digested with AscI and 
Sphl and the various 481 bp fragments of mutated DHPRs isolated from pAlter-1— 
mutated-hDHPR were isolated from gels by Procedure 1 described in Section
2.4.2.2. (page 41) (see Figure 2.18b. and Figure 2.19b.). The DNA concentration of 
pGEX2T/AscI/SpM was 40 ng/pl (total volume 40 pl), and the DNA concentration of 
mutated DHPRJAscVSphl (481 bp fragment) averaged 17 ng/pg (40 pi total volume).
The 5824 bp pGEX2T/AscIAS/?M DNA fragment (1 pi 40 ng/pl) was used as vector, 
the mutated DHPR/Ascl/Sphl fragments (481 bp) (each diluted from 17 ng/pl to 5 
ng/pl, and 1 pi, 2 pi and 3 pi) were used as inserts, and were each separately mixed 
with 1 pi of vector. The ligation procedure in Section 2.4.3.3. (page 47) was
followed.
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Figure 2.18a. pGEX2T-hDHPR (2N) DNA digested with As cl and Sphl.
The 5424 bp fragment was cut out and DNA was isolated from the 
gel (Figure 2.18b)
5424 bp— A
■23130 bp
■ 9416 bp
■ 6557 bp
■ 4361 bp
2322 bp 
2027 bp
Figure 2.18b. The 5424 bp fragment from pGEX2T-hDHPR (2N) digested with Ascl 
and Sphl after recovery form an agarose gel (Figure 2.18a.). Lane 1: 
XDNAJHindlll markers (0.5 p,g). Lane 2: XDNAJHindYLl markers (0.25 
fig). Lane 3: 2 pi of sample. Lane 4: 1 |il of sample.
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Figure 2.19a. pAlter-1—hDHPR with the Tyr (150) —> Glu mutation digested 
with Ascl and Sphl. The 481 bp fragment was cut out and DNA 
was isolated (Figure 2.19b.).
2 3 1 3 0  bp
9 4 1 6  bp 
6 5 5 7  bp 
4361 bp
. 2 3 2 2  bp 
2 0 2 7  bp
564  bp
5 4 3 2 1
Figure 2.19b. The 418 bp fragment of cDNA of DHPR with the mutation
Tyr (150)—>Glu after isolation from the above agarose gel slice 
(Figure 2.19a.) and re-run on the gel. Lane 1: XDNAJHindRl 
markers (0.25 jig). Lane 2: XDNAJHindlll markers (0.125 jig). 
Lane 3: 2 pi of sample. Lane 4: 1 pi of sample. Lane 5: 0.5 pi of 
sample. The 418 bp fragment concentration was 17 ng/pl after 
compared with the XDNAJHindUl markers.
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2.4.6.3. Transformation into JM109 competent cells, and confirmation of
mutations by sequencing the pGEX2T-mutated-DHPR plasmids
JM109 competent cells were prepared as described in Section 2.4.3.1. (page 43). The 
above ligation mixture (Section 2.4.6.2.) was transformed into JM109 competent cells 
(see Section 2.4.3.1., page 43). About 600 clones were obtained from 1 ng of 
pGEX2T-mutated DHPR. Five clones were selected from each mutation .
pGEX2T-mutated DHPR DNA was prepared by the same method as described in 
Section 2.4.4.4. (page 57). These DNAs were sequenced using oligo primer AY-10 
for all mutations except for the G23—»D mutatnt for which oligo primer AY-11 was 
used (see Figure 2.4., page 36). The sequencing procedure was the same as before 
(Section 2.4.4.5., page 58). The mutations in all the pGEX2T-mutated-DHPRs were 
confirmed and the sequencing data are in Figure 2.13. (page 59 and 60) [pGEX2T- 
mutated-DHPR (right) and pAlter-1—hDHPR (left)]. At least four of the five clones 
selected in each case contained the required mutations. They were compared with the 
wild-type sequence to show the mutated sequences (markered as yellow in this figure).
2.5. DISCUSSION
A general strategy was used for carrying out all the desired site-directed mutageneses 
(Scheme 2. 1. ,  page 32). General procedures for restriction enzyme digestion, isolation of 
DNA and DNA fragments, ligation and transformation into E. coli cells were used and were 
uniformly successful. The relative amounts of large and small DNA fragments did not 
appear to affect the success of the ligation to form complete plasmids as observed by the 
successful transformations.
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p Alter-1— hDHPR 
ds DNA
oligo with corrected 
ß-lactamase sequence
mut at ion
oligo with 
mutation
Fusion protein 
expression
Scheme 2.2. Sequences for site-directed mutagenesis.
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The plasmid p Alter-1 with the wild type hDHPR cDNA insert, pAlter-1— hDHPR, was 
used for all the site-directed mutagenesis reactions and for confirming that mutagenesis 
was successful. Single stranded pA lter-1— hDHPR was first prepared. An 
oligonucleotide (5'-phosphorylated) containing the desired mutation and an 
oligonucleotide (5'-phosphorylated) containing the correction for the defect in the 
ampicillin resistance gene (Amps) in pAlter-1 were annealed to the same single stranded 
pAlter-1—hDHPR DNA, and the second strand with the DHPR mutation and corrected 
Ampr gene was synthesised. In order to obtain high mutation yields the new pAlter- 
1— hDHPR was first transformed into BMH71-18 mut S bacteria (a "mismatch repair 
minus" strain) for specific plasmid selection followed by transformation into JM109 to 
select for mutated clones. All mutations and transformations were successful as all 
plasmids were sequenced and showed that the mutations had taken place (Figure 2.13., 
page 59). All sequencing-reactions involved the dye-dideoxy-terminator procedure. 
This has the great advantage of not using a radioactive technique and requiring very 
small amounts of template DNA. A thermal recycling procedure was used involving 
DNA synthesis from the template and temination with the four dideoxy nucleotides 
bound to dyes using AmpliTag DNA polymerase. This technique has been found 
outstandingly successful.
The mutated portion of DHPR DNA was excised from pAlter-1— mutated-DHPRs with 
restriction enzymes Ascl and Sphl, and used to replace the Ascl-Sphl DNA segment of 
wild type DHPR in pGEX2T-hDHPR to make pGEX2T-mutated DHPRs (Scheme 
2.2.). After transformation into JM109, five clones were selected in each case. The 
pGEX2T-mutated-DHPR from these clones were sequenced using oligo primer AY-10 
for all mutants except for the G23—>D mutation where oligo primer AY-11 was used. 
At least four of the five clones selected from each preparation contained the desired 
mutations. These showed that the mutations, restriction enzyme digestions, ligations 
and transformations were all uniformly successful.
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CHAPTER 3
EXPRESSION OF MUTANT DIHYDROPTERIDINE REDUCTASES 
3.1 .  INTRODUCTION
The construction of seven mutant plasmids, pGEX2T-mutant-DHPRs, by modification 
of the wild-type plasmid pGEX2T-hDHPR was described in Chapter 2. In this chapter 
is reported the expression of the fusion genes, GST-mutant-DHPRs, and the isolation 
of the seven mutant GST-DHPRs as well as their cleavage and isolation of the 
corresponding mutant DHPRs.
All the plasmids were transformed into E. coli JM109 cells and were induced to 
synthesise the fusion proteins by addition of IPTG at the correct cell growth point in 
time. The cells were then broken and the supernatants were passed through glutathione 
bound agarose beads and washed thoroughly with buffer until almost free from 
proteins. When the fusion proteins were required for kinetic measurements these beads 
were eluted with buffer containing 5 mM of reduced glutathione and the almost pure 
fusion proteins were obtained. The original pGEX2T-hDHPR was engineered such 
that the DNA residues at the amino terminus of DHPR were attached to the DNA of the 
carboxyl end of the glutathione R-transferase DNA sequence. This involved the 
isolation of a 1.2 Kb BamHl and Pstl fragment containing DHPR cDNA (from a 
plasmid vector) and using the oligonucleotide GATCC GCG GCG GCT GCA to 
extend the 5' end of it (A in Figure 3.1.) in order to ligate it into the pGEX2T vector 
digested with BamHl (B in Figure 3.1.) to form pGEX2T-hDHPR (C in Figure 3.1.) 
(Smooker, Howells and Cotton, 1993b.).
Ala Ala Ala Ala Gly Glu Ala 
A GATCC GCG GCG GCT GCA GGC GAG GCG
DHPR
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B
Thrombin
| g iLeu Val Pro Arg yG ly Ser
CTG GTT CCG CGT GGATCC
|______ I
BamHI
Pro Gly 
CCG GGA
pGEX2T
C
Thrombin
---------- G ST----------1 I I-------------------------- DHPR------------------------------
Leu Val Pro Arg iGly Ser Ala Ala Ala Ala Gly Glu Ala
CTG GTT CCG CGT GGATCC GCG GCG GCT GCA GGC GAG GCG
pGEX2T-hDHPR
Figure 3.1. Construction of pGEX2T-hDHPR.
The fusion protein possessed the amino acid sequence shown in Figure 3.LC. at the 
junction between GST and DHPR.
The reductases were obtained by cleavage of the purified fusion protein by digestion 
with human plasma thrombin. This was best done by adsorbing the fusion protein on 
glutathione-agarose beads and then shaking these beads with thrombin. Undigested 
fusion protein and glutathione R-transferase from the digestion remained attached to the 
beads and the DHPR was liberated into medium. The reductases, obtained showed
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only one band at ca Mr 26 KD on SDS-PAGE and, were thus pure. The amino 
terminal sequence of the wild type reductase obtained in this way should read 
SAAAAGEAR and indeed amino acid terminal sequencing showed that this was 
correct. All the mutations in the DHPRs in this work were made within the AscI and 
Sphl cassette (see Chapter 2, Figure 2.4., page 36). The Ascl and Sphl cassette in the 
wild-type pGEX2T-hDHPR was in turn replaced by cassettes containing the desired 
mutations. Therefore all the mutant DHPRs that were prepared have the same 
SAAAAGEAR sequence at the amino terminus.
The kinetics of the mutated reductases and several of the fusion proteins are described 
in Chapter 4.
3.2 .  MATERIALS AND METHODS
Agarose-GS beads, reduced glutathione and human plasma thrombin were from Sigma. 
Peroxidase was from Boehringer or Sigma. Sorvall GSA rotors were used to 
centrifuge 250 ml quantities at low speeds and a 60Ti rotor was used for high speeds in 
an ultracentrifuge (Beckman L8-70). Gel electrophoresis was carried out at 15°C using 
pre-cast gels in a Pharmacia PhastSystem.
3.2 .1 .  Cell extract preparation
After the mutations in pGEX2T-hDHPR were confirmed by sequencing (Chapter 2, 
Section 2.4.6.3., page 69), a single colony of E. coli cells (JM109, see Chapter 2, 
Section 2.4.6.3., page 69) was selected for inoculating 50 ml of 2xYT-G (+Amp, 100 
qg/ml) medium (see Appendix 1), and incubated at 37°C overnight with vigorous 
shaking. The overnight culture was diluted 1:20 into 950 ml of fresh pre-warmed 
2xYT-G (+Amp, 100 |ag/ml) medium and grown at 37°C with shaking until the ODöqo
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reached 1, then 100 mM of IPTG was added to a final concentration of 0.1 mM, and 
incubation continued until the ODöoo reached nearly 2. The culture was transferred into 
250 ml centrifuge bottles and centrifuged at 8,000 x g for 10 min at 4°C to sediment the 
cells. The supernatant was discarded. The cell pellet was washed with 50 ml of ice- 
cold MTPBS buffer (see Appendix 7) and centrifuged as above, then completely re­
suspended in 50 ml of ice-cold MTPBS buffer by stirring with a pipette. The 
suspended cells were disrupted by sonication for 60 x 10 sec on ice-H20  at maximum 
tip power (Ultrasonics Inc Sonicator, model W-220F). The cells were centrifuged at 
17,000 x g for 10 min at 4°C, and kept on ice. Sonication was repeated as above with 
the residue re-suspended in 25 ml of ice-cold MTPBS buffer and centrifuged again. The 
supernatants were combined and centrifuged at 165,000 x g for one hr at 4°C. One ml 
of the supernatants was kept aside for GST and DHPR activity measurements. The rest 
was subjected to GST-DHPR fusion protein purification.
3 .2 .2 . GST and DHPR activity assays and protein concentration 
determination
Enzyme activities as well as protein concentrations were first determined before 
proceeding with the protein purifications. The assay procedures are described in 
Chapter 4 (Section 4.2., page 89). The results of these assays are summarised in Table 
3.1. and are discussed later (Section 3.3.).
3.2 .3 .  Purification of GST-fusion proteins on glutathione-agarose 
beads
The procedures described in the manufacturer's protocol (Pharmacia) were followed. 
Glutathione beaded agarose (500 mg) was washed three times with 30 ml of MTPBS 
buffer (see Appendix 7) by vortexing for 10 sec, centrifuging for 5 sec at 1,000 rpm in
76
52.000 Da-----
26.000 Da-----
8 7 6
94.000
67.000
43.000
30.000
2 0 .0 0 0  
14,400
Da
Da
Da
Da
Da
Da
5 4 3 2 1
Figure 3.2a. SDS-PAGE of purified GST-DHPR.
Lane 1: Protein low molecular weight markers. Lane 2: GST-DHPR 
withW T. Lane 3: GST-DHPR with mutation T123—>TT. Lane 4: 
GST-DHPR with mutation G 151 —»S. Lane 5: GST-DHPR with 
mutation Y 150—>F. Lane 6: GST-DHPR with mutation Y150—>E. Lane 
7: GST-DHPR with mutation Y150—>H. Lane 8: GST-DHPR with 
mutation Y 150—>S. This Figure shows that all samples contain a faint 
26,000 Da band which could be the GST from proteolysis of GST- 
DHPR fusion protein (since all the DHPR mutant proteins were washed 
off the beads), except for Lane 3 (GST-DHPR with mutation T123—>TT) 
where the GST-DHPR fusion protein was largely degraded and showing 
a strong GST band (26,000 Da).
Figure 3.2b.
94.000 Da
67.000 Da
43.000 Da
30.000 Da
20.000 Da 
14,400 Da
SDS-PAGE of purified GST-DHPR with mutation G23-^D.
Lane 1: Protein low molecular weight markers. Lane 2 and Lane 3: 
GST-DHPR with mutation G23—>D. The expected GST-fusion protein 
band was obtained, but another band with 26,000 Da size was revealed. 
This band could be GST from proteolysis of the GST-DHPR fusion 
protein since all the DHPR mutant protein was washed off the beads. 
This also indicates that GST-DHPR fusion protein with the G23—>D 
mutation makes the conjunction site of GST-DHPR readily digested by 
protease.
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a bench-top centrifuge (HERMLE-Z320), and the supernatant was aspirated off. About 
6 ml of bed volume of glutathione beaded agarose was obtained. The washed 
glutathione-agarose (6 ml) was added to 75 ml of cell supernatants (from Section 
3.2.1.), and incubated at room temperature for 1 hr with gentle agitation. The beads 
were then packed into a column and washed with MTPBS buffer (see Appendix 7) until 
no protein was washed out (until a solution made by mixing 600 p,l of distilled H20 , 
200 jil of Bio-Rad Assay Reagent and up to 200 ql of eluate in a 1 ml cuvette had no 
blue colour). All the beads were pushed out of the column (air pressure) into a fresh 
tube. One ml of this bed volume was kept for eluting the GST-DHPR fusion protein, 
and the rest was kept for thrombin digestion to isolate the DHPR.
Glutathione elution buffer (1 ml, see Appendix 7) was added to the above 1 ml of bed 
volume of beads, and incubated at room temperature for 10 min with gentle agitation to 
elute the GST-DHPR fusion protein from the beads. The beads were spun down at 
1,000 rpm as above for 5 min and the supernatant was transferred to a fresh tube. The 
elution steps were repeated two more times. About 1 (il of eluate was run on SDS- 
PAGE (method is described in Section 3.2.5.) to reveal the fusion protein band (see 
Figure 3.2a.), then the first and second eluates were combined and dialyzed against 2 x 
2 L of 50 mM Tris-HCl, 2 mM of DTT, pH 7.5 buffer. The GST-DHPR was 
aliquoted and kept at -70°C for kinetic evaluation.
Figure 3.2a. shows that all GST-DHPR fusion proteins [WT (Lane 2), G151—>S (Lane 
4), Y150—>F (Lane 5), Y150->E (Lane 6), Y150->H (Lane 7), and Y150->S (Lane 
8)] contain a 26,000 Da faint band. This band could be trace GST from GST-DHPR 
fusion protein proteolysis since all the DHPR mutant proteins were washed off the 
beads before the GST-DHPR elution step. The GST-DHPR fusion protein band 
(52,000 Da) form the mutation T123—>TT appeared to be absent in this mutant, but
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Figure 3.3a. The SDS-PAGE of purified hDHPRs. Lane 1: Protein low molecular 
weight markers. Lane 2: hDHPR (WT). Lane 3: hDHPR 
(Tryl50—>Phe). Lane 4: hDHPR (Try 150—»His). Lane 5: hDHPR 
(Tryl50—>Ser). Lane 6: hDHPR (G lyl50—>Ser). Lane 5: hDHPR 
(Gly23—>Asp).
2 6 ,0 0 0 Da
■94,000 Da
■67,000 Da 
•43,000 Da
■30,000 Da
■20,000 Da 
■14,400 Da
5 4 3 2 1
Figure 3.3b. The SDS-PAGE of purified hDHPRs. Lane 1: Protein low molecular 
weight markers. Lane 2: human DHPR protein. Lane 3: hDHPR 
(Tryl50—>Glu). Lane 4: hDHPR (WT). Lane 5: hDHPR 
(Try 150—>Phe). It show** b single band of DHPR after digested from 
GST-fusion protein wuth thrombin.
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bands at 26,000 Da (GST band) and 43,000 Da were present (Figure 3.2a., Lane 3). 
This indicates that the T123—>TT mutant was not stable and readily degraded. The 
GST-DHPR with mutation G23—>D (see Figure 3.2b.) showed a GST-fusion protein 
band (52,000 Da), but another band with 26,000 Da size was also revealed. This band 
could also be GST from proteolysis of GST-DHPR fusion protein since all the DHPR 
mutant protein was washed off the beads. The intensities for the two bands (52,000 Da 
and 26,000 Da) are almost the same. This indicates that GST-DHPR fusion protein 
with mutation G23->D is protease sensitive at the junction between GST and DHPR.
It was not possible to isolate sufficiently pure GST-DHPR fusion protein or DHPR 
protein from the Thr(123)—>ThrThr mutation (see Figure 3.2a., lane 3). The 
preparation was repeated 8 times without improvement in yield or purity (4 times using 
a 1 litre culture, 2 times using a 2 litre cultures, 1 time using 6 litre cultures and 1 time 
using 40 litre cultures). The longer the solutions were allowed to stand the larger the 
extract of degradation.
3.2 .4 .  Digestion with thrombin and isolation of DHPRs
Thrombin solution (200 NIH units) (see Appendix 7) and 5 ml of MTPBS buffer (see 
Appendix 7) were added to 5 ml of bed volume of glutathione-agarose beads (from 
Section 3.2.3.), and incubated for 2 hr at room temperature with gentle agitation. The 
mixture was packed into a column and the DHPR contained in the eluate was collected 
from the column. The digestion steps were repeated for one more time. The eluates 
from the first and second digestion were combined and dialyzed against 2 x 2 L of 50 
mM Tris-HCl, 2 mM of DTT, pH 7.5 buffer, then 1 (il of this DHPR solution was run 
on SDS-PAGE in a PhastSystem (see below) to reveal the DHPR bands (see Figure 
3.3a. and 3.3b.). Note the small amount of proteolysis in the Y150 —» F, Y150 —» H
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and G23 —> D mutant DHPRs. The DHPR solution was aliquoted and kept at -70°C 
for kinetic evaluation.
3.2 .5 .  Wild-type GST-DHPR on non-denaturing PAGE
Although the wild-type fusion protein GST-DHPR gave a strong band at ca 52 K in 
SDS-PAGE (Figure 3.2a., Lane 2), when run on a non-denaturing gel a number of 
bands were obtained (Figure 3.4., lane 3). Several weak bands with Mr values above 
94 K were obtained showing that the fusion protein is a mixture of dimer and higher 
aggregates together with monomer as a fairly strong band at ca 52 K on the gel. The 
band at 27 K cannot be explained unless proteolysis occurred on the non-denaturing 
gel. Pure hDHPR was run on the same gel (Figure 3.4. Lane 2) and showed two main 
bands at 27 K and 50 K due to a mixture of monomer and dimer.
3.2 .6 .  SDS-PAGE and silver staining
Purified GST-DHPR fusion proteins and DHPR proteins obtained from thrombin 
digestion were run on SDS-PAGE in a PhastSystem (Phamacia). The procedures for 
loading the samples, running the gels and staining the gels with Coomassie Blue were 
as described by Pharmacia. This was most convenient as it required only 0.5-0.75 hr 
to run the gels and ca 1 hr for Coomassie Blue staining. The gels were viewed in a 
Novaline Gel Documentation System. The gels were photographed when desired by 
using a Mitsubishi video copy processor and the images were stored on a disk. The 
data were then scanned using an IBM computer and the QGEL-1D program to evaluate 
the relative intensities of bands.
When protein bands were too weak after Coomassie Blue staining in the PhastSystem, 
then further staining with silver was conducted as follows: The gel was washed in
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-04,000 Da 
-67,000 Da
-43,000 Da 
-30,000 Da 
”20,000 Da
Figure 3.4. Non-denaturing PAGE of purified hDHPR (WT) and GST-DHPR 
(WT). Lane 1: Protein low molecular weight markers. Lane 2: 
hDHPR (WT). Lane 3: GST-DHPR (WT).
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8.3% of glutaraldehyde (10 ml of glutaraldehyde mixed with 20 ml of distilled H20 ) for 
6 min at 50°C, then in 10% of ethanol and 5% of acetic acid for 8 min at 50°C and then 
washed at 50°C with distilled H20  for 4 min. This gel was soaked in 0.25% of AgN03 
solution (250 mg of A gN 03 dissolved in 100 ml of distilled H20 ) for 10 min at 40°C 
then washed with distilled H20  for 1 min at 30°C. It was developed in "developer 
solution" (0.04% formaldehyde in 2.5% sodium carbonate, freshly prepared) at room 
temperature until the bands of desired intensity were obtained. The gel was soaked in 
"fixing bath" (5% acetic acid) for 5 min at 50°C and washed in "preserving solution" 
(10 ml of acetic acid and 5 ml of glycerol made up to 100 ml with H20 ) for 5 min at 
room temperature. The gels were left at room temperature to dry.
3.3. DISCUSSION
GST-DHPR fusion proteins were expressed efficiently in most mutated clones. This 
was judged by the specific activity of GST in the supernatants. The activities ranged 
between 0.06 and 0.19 U/mg except for the T 1 23^T T  mutant which was consistently 
low at 0.015 U/mg (Table 3.1.). The DHPR activities in the supernatants varied since 
these depended on the specific mutations. The supernatant from the wild-type DHPR 
was the most active.
The fusion protein from the T123—>TT mutant was not expressed well (about 10 times 
lower than the others), and it was not stable in the supernatant so that the pure reductase 
or pure GST-DHPR was difficult to prepare. Large scale preparations were conducted, 
even using up to 40 litres of culture without success. After the normal purification on 
glutathione-agarose beads to obtain the fusion proteins, SDS-PAGE showed that the 
expected GST-fusion protein band at -52,000 Da was not present but several bands 
were obtained (Figure 3.2a., Lane 3). This material has GST and DHPR activity. This 
indicated that the GST-DHPR with the T123—>TT mutation was not stable and appeared
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to be degraded upon standing and/or purification. It seems that bacterial proteases are 
hydrolysing the fusion protein even through the inhibitor phenyl methyl sulphonyl 
fluoride was added to the supernatant of the cells before sonication. The protein 
solution, however, did have GST activity (0.029U/mg) and DHPR activity 
(0.29U/mg). However, after the usual thrombin treatment no DHPR activity was 
present in the eluate and at least nine bands were obtained. Since the protein before 
thrombin cleavage had some DHPR activity probably due to be the presence of fusion 
protein and some DHPR. DHPR kinetics were carried out with this supernatant in 
order to gain a rough idea of the activity of the T123 —»TT mutant (see Chapter 4).
Table 3.1. Unpurified mutated GST-DHPR assays
Mutant Total Protein Cone 
|Xg/|il
GST activity 
U/mg
DHPR activity 
U/mg
WT 4.65 0.09 1.44
Y150—»E 5.48 0.11 0.20
Y150—>F 5.11 0.07 0.26
Y150—>H 6.16 0.10 1.26
Y150-»S 5.23 0.19 1.28
G151-»S 5.86 0.19 1.34
T123—>TT 6.17 0.015 0.10
G23—>D 6.01 0.060 0.15
G23—>D(a) 5.87 0.15 0.22
WT = wild-type DHPR, Y150—»E = Tyr(150)—»Glu mutation, Y150-»F = Tyr(150)—>Phe mutation, 
Y150—»H = Tyr(150)—»His mutation, Y150-»S = Tyr(150)^Ser mutation, G151-»S = Gly(151)-»Ser 
mutation, T123-»TT = Thr( 123)-» insert an extra Thr added, and G 23-»D = Gly(23)—»Asp(GAT) 
mutation, G23—»D(a) = Gly(23)-»Asp(GAC) mutation
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The G23—>D mutation using the GAT codon identified in DHPR-defective children was 
prepared. Since the expression of the fusion protein was low (GST activity was 0.06 
U/mg, see Table 3.1.), a second mutation experiment was performed using the GAC 
codon which is a more commonly used codon for glycine in bacteria (Sharp et al, 
1988). This produced the same mutant G23—>D(a) in which the expression was better 
(GST activity 0.15 U/mg, Table 3.1.). The overall yields of the defective reductase, 
however, were only marginally better. This is because the fusion protein was slowly 
susceptible to cleavage, by proteases as was previously shown by Smooker, Howells 
and Cotton (1993b).
The fusion proteins and DHPR proteins from the other mutations were readily prepared. 
The fusion proteins did very slowly undergo degradation apparently to GST and the 
respective DHPRs on long standing even at -20°C due presumably to the presence of traces 
of bacterial proteases which were not completely removed. The susceptibility for this 
cleavage appeared to vary with the mutant and could be due to the levels of trace proteases 
or ease of cleavage of the fusion protein. This was not studied further.
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CHAPTER 4
MEASUREMENTS OF DHPR KINETIC PARAMETERS 
4 . 1 .  INTRODUCTION
Enzymes are catalysts which show Michaelis-Menten kinetics. Substrate(s) interact 
with the enzyme in a reversible manner to form an enzyme-substrate(s) complex which 
then decomposes to products. Equation 1 shows the reaction in its simplest form.
S + E ES - >  E +  P Equation 1
This type of kinetics is sometimes called "saturation" kinetics because as the substrate 
concentration increases more and more of the enzyme is complexed until there is 
virtually no free enzyme in solution. At this point a "steady state" is obtained at which 
the velocity of the reaction has reached its maximum and cannot go faster because all 
the enzyme is complexed. This occurs when the substrate has reached a "saturating" 
concentration.
The best way to evaluate the kinetics of an enzymic reaction is by measuring the initial 
rates (initial rates kinetics) at various concentrations of substrate and fixed enzyme 
concentration. The equation for "initial rates kinetics" (Equation 2) allows the kinetic
v
Vmax . S 
Km+S
Equation 2
parameters Km (Michaelis constant, viz concentration of substrate at half maximal 
velocity) and Vmax (maximum velocity) to be determined from the initial rates "v" at 
various substrate concentrations S (Fromm, 1975). The maximum velocity is 
dependent on the amount of enzyme used. The maximum velocity for one mole of
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enzyme (or per enzyme active subunit) is know as the kcat or "turn over number" and 
its units are sec '1. The kcat is therefore the number of moles of substrate which "turn 
over" with one mole of enzyme per second. When the enzyme is impure both the Km 
and Vmax values are "apparent" values. The Km is not usually seriously affected but 
the "apparent Vmax" depends on how pure is the enzyme. Its units are usually 
pmoles of substrate / min. mg protein.
When two "substrates" act on the enzyme as in dihydropteridine reductase, where the 
quinonoid pterin and NADH are essentially substrates, then two equations like 
Equation 2 come into play. One for each substrate, i.e.
Vmax . S ä  Vmax . S B
v =  ----------------- Equation 3a, and  V =  ----------------- Equation 3b
KmA+SA KmB+SB
which combine to give Equation 4.
Vmax* S A  ■ S b
V — ------------------------------------  Equation 4
(KmA+SA) (K uiB+Sb )
Of course, if for example substrate Sb is kept at or above its saturating concentration 
then Equation 4 becomes Equation 3a. Similarly if the concentration of Sa is 
saturating the enzyme then Equation 4 becomes Equation 3b. In many instances it is 
not possible to achieve saturating concentrations of the second substrate, which is 
usually higher than 8 Km values, because very large amounts of material need to be 
used or, more commonly, the second substrate begins to inhibit the enzyme below 
saturating concentration (substrate inhibition). In these cases the kinetic parameters 
Km and Vmax are "apparent" values and the concentration of the second substrate 
must always be stated. In order to obtain the true Vmax and therefore the kcat value 
for an enzyme, a complete kinetic analysis needs to be carried out. This involves the 
measurement of a series of initial velocities at various concentrations of each substrate
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using a known constant weight of enzyme and evaluating the Vmax using Equation 4. 
This requires a large number of calculations and is best done by using a computer 
program. The one used in this work was written by Professor Cleland, W.W. (1979) 
and modified slightly by Dr. Morrison, J. (private communication, 1995). All the 
velocities (typically 25 to 36 runs) and concentrations of both substrates (5 to 6 sets of 
each) are entered and the program fits these data into Equation 4 to provide two Km 
values and one Vmax value. It is therefore possible to obtain these values while 
keeping all concentration below saturating levels, and more important below substrate 
inhibiting concentrations.
If we consider Equation 3a, at saturating levels of substrate B, and decrease the 
concentration of substrate A (decrease Sa) until the value KmA + Sa tends to be equal 
to KmA then Equation 3a becomes Equation 5
Vmax
V ZZ ---------------  S A Equation 5
KmA
which is a first order rate equation since Vmax / KmA is a constant value, i.e. the 
velocity "v" varies only with "Sa", and Vmax / KmA is the first order rate constant for 
substrate A. The Cleland program will also calculate the two first order rate constants 
Vmax / KmA and Vmax / KmB from the data provided. The first order rate constants 
are very important values for comparing the efficiency of an enzyme for various 
substrates, i.e. the viability of substrates, and involve the two important parameters 
(Km and Vmax) that can be measured in enzyme kinetics.
The present chapter describes the kinetic measurements of the wild-type DHPR and 
the mutated DHPRs that were prepared in this work as well some of the GST-DHPR 
fusion proteins for comparison. The kinetic parameters have been evaluated and are 
discussed with respect to the mechanism of action of DHPR and the effect on DHPR 
deficient children.
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4 .1 .1 .  DHPR activity assay methods
Since DHPR was first discovered in conjunction with the phenylalanine hydroxylating 
system, the early assay for DHPR used the coupled enzyme approach where the 
reductase reaction was coupled to the hydroxylase reaction and the rate of tyrosine 
formation was monitored (Craine, Hall and Kaufman, 1972) (Chapter 1, Sceme 1.2, 
page 5). Later when it was found that the reduction of one mole of quinonoid 
dihydropterin required one mole of NAD(P)H, the initial rates of the enzymic reaction, 
using an oxidant instead of phenylalanine hydroxylase, were determined by following 
the rate of oxidation of NAD(P)H at 340 nm and using 6200 M ^cnr1 as its molar 
extinction coefficient.
The unstable nature of the quinonoid-dihydropterin species (e.g. ti/2 of ~20 min for 
gMm0«o/d-6-methyl-7,8(6/7)-dihydropterin; Armarego, 1984) required that the pterin 
substrate for DHPR be produced rapidly and quantitatively in vitro. Several oxidants 
have been reported in the literature but the most commonly used is peroxidase- 
hydrogen peroxide (Nielsen, Simonsen and Lind, 1969) (See Scheme 4 .l.a.). 
Peroxidase alone under aerobic conditions can rapidly oxidise a tetrahydropterin to the 
respective quinonoid dihydropterin (Armarego, Randles and Taguchi, 1983). Another 
commonly used oxidant is potassium ferricyanide (Nielsen, Simonsen and Lind, 
1969; Archer, Vonderschmitt and Scrimgeour, 1972) (See Scheme 4 .l.b.). 
However, bacteria also produce a DHPR-active enzyme which possesses both 
pteridine-dependent and pteridine-independent oxido-reductase activity. The latter 
activity uses ferricyanide as substrate. In addition to this, bacteria also produce at least 
one other pteridine-independent oxido-reductase which uses ferricyanide as oxidant 
and NADH as cofactor (Vasudevan, Shaw and Armarego, 1988) (see Scheme 4.1c.). 
For the present work the peroxidase-hydrogen peroxide-tetrahydropterin assay is used 
because it is particularly specific for DHPR. In this assay the 5,6,7,8-tetrahydropterin 
is oxidised rapidly (< 1 second) and completely to the respective quinonoid-1,8(6//)- 
dihydropteridine (the substrate for DHPR). The reductase then reduces this species to
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the 5,6,7,8-tetrahydropterin at the expense of NADH at the rate which is measured. 
As the tetrahydropterin is formed it is again rapidly oxidised to the quinonoid species 
thus keeping the concentration of these species virtually constant during the initial rate 
measurements, and equal to the concentration of the tetrahydropterin placed in solution 
(Scheme 4.1a.).
4.1 .2 .  The difference between human DHPR and bacterial 
DHPR
Human DHPR reduces quinonoid-dihydropterin to tetrahydropterin at the expense of 
NADH and it has no ferricyanide or ferric ion oxido-reductase activity (see chapter 1, 
Scheme 1.1, page 4; and Scheme 4.1a.). Bacterial DHPR, on the other hand, is a 
trifunctional enzyme that not only has DHPR activity which mediates the reduction of 
quinonoid-dihydropterin to tetrahydropterin, but also has a pterin-independent oxido- 
reductase activity for reducing Fe3+ to Fe2+, or Fe(CN) \  to Fe(CN)*' (the later activity
is 4 times stronger than the former) (see Scheme 4.1b.) as well as dihydrofolate 
reductase activity (Vasudevan, Paal and Armarego 1992). Therefore positive activity 
in the DHPR assays in Scheme 4.1.a. and 4.1.b. cannot be taken as indicative of 
human DHPR unless pteridine-independent oxido-reductase activity is absent in the 
assay (i.e. Scheme 4 .I .C .) .
4.2 .  MATERIALS, EQUIPMENT AND METHODS
4,2 .1 .  Materials and equipment
RiS'-ö-M ethyl-S^J^-tetrahydropterin hydrochloride was kindly supplied by Dr. 
Armarego (Armarego and Schou, 1977) and natural 6R-5,6,1,8-tetrahydro-erythro- 
biopterin hydrochloride was from Schircks Laboratories. Peroxidase was from Sigma 
and other reagents were as stated in Chapter 3, Section 3. A Cary 219 double-beam 
spectrophotometer was used for kinetic measurements, and the cell holders were
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a. DHPR Activity Assay:
n u n  Peroxidase/H20 2 _ Iin g-6MeDHP<:------ --------- 6MeTHP
hDHPR or bDHPR
NADH
b. DHPR Activity Assay:
K4Fe(CN)6 K3Fe(CN)6
6MeTHP
hDHPR or bDHPR
NAD+NADH
c. Oxido-reductase Activity Assay:
K3Fe(CN)6 K4Fe(CN)6
bDHPR
NADH NAD+
Scheme 4.1. The activities of human and bacterial DHPR.
(hDHPR = human DHPR; bDHPR = bacterial DHPR).
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thermostated at 25°C. It was set at 340 nm, 25°C and with 0-0.05 OD range. 
Concentrations of pterin substrates were evaluated from absorbance measurements 
made on a Perkin-Elmer Lambda 1 single beam spectrophotometer at 25°C.
4 .2 .2 . The DHPR assay
To 1 ml masked reference and test cuvettes, 850 pi of ice-cold peroxidase buffer 
mixture [containing 0.1 M Tjj/s-HCl, pH 7.4, 20 p,g/ml of peroxidase and 0.02% w/v 
of H20 2] (see Appendix 8) was added ., followed by 50 pi of ice-cold 2 mM
NADH (see Appendix 8) and 100 pi of ice-cold 1 mM 6MeTHP (see Appendix 8). 
The concentrations of NADH and 6MeTHP with reference and test cuvettes were both 
100 p,M. The cuvette contents were mixed well and allowed to equilibrate at 25°C 
until a steady baseline was obtained on the recorder chart. The reaction was initiated 
by adding 1-20 ptl of enzyme to the test cuvette, mixed immediately, and placed back 
into the cell holder. The absorbance was traced at a recorder speed which produced a 
slope of ca 45°. The reaction extinction coefficient was 6200 M 1 cm 1 at 340 nm.
4 .2 .3 . The oxido-reductase assay
Oxido-reductase activity was assayed to determine if the purified human DHPR is 
contaminated with bacterial DHPR (Scheme 4.1.). Spectrophotometer settings were 
as in Section 4.2.2. To the test and reference cuvettes were added 950 pi of 
ferricyanide buffer mixture [0.1 M Tris-HCl (pH 7.4) and 300 pM of K3Fe(CN)6 (see 
Appendix 8)] followed by addition of 50 pi of ice-cold 2 mM NADH (see Appendix 
8). After equilibration at 25 °C, the assay was started by adding 0.5-5 pi of enzyme 
to the test cuvette and recording the rate. The reaction extinction coefficient was 
6200 M 1 cm 1 at 340 nm.
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4 . 2 .4 .  The GST activity assay
GST activity was measured in the cell extracts to check the expression level of the
fusion protein. The reaction in the GST assay is illustrated in Scheme 4.2. (Habig,
and Jakoby, 1981). Spectrophotometer settings were as in Section 4.2.2. To the
reference and test cuvettes, 900 pil of buffer mixture [0.32 M of K2HPO4 , 0.68 M of
KH2PO4 and 0.1 mM of EDTA (see Appendix 8 )] were added followed by addition of
50 p,l of ice-cold 20 mM reduced glutathione (GSH) (see Appendix 8 ). The enzyme
(5-10 pi) was added into the test cuvette, mixed well and kept in the cell holders until a
steady baseline was obtained on the recorder. Ice-cold 20 mM of chloro-2,4-
dinitrobenzene (CDNB) (50 pi) (see Appendix 8 ) was first added into the reference
cuvette and mixed well, then another 50 pi of ice-cold 20 mM CDNB was added into
the test cuvette to initiate the reaction. The final concentrations of GSH and of CDNB 
Hw
in'cuvette were 1 mM. The reaction extinction coefficient was 9,615 M ' 1 c m 1 at 340 
nm.
CDNB
+  HC1
no absorbance at 340 nm absorbance at 340 nm
Scheme 4.2. The reaction between glutathione and chloro-2,4- 
dinitrobenzene in the for GST assay.
4 .2 .5 .  The Bio-Rad protein concentration assay
A single beam spectrophotometer (Perkin-Elmer, Lambda 1 UV/VIS) was set at 595 
nm. Distilled H2O (800 pi) was mixed with 200 pi of Bio-Rad Protein Assay reagent 
in a disposable cuvette, placed in the spectrophotometer and the OD reading was set to 
zero. The sample solution (1-5 pi) was added to the cuvette and the amount added
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was measured gravimetrically on a Sartorius analytical balance. The weight of protein 
solution (~ equal to its volume) was noted. After mixing well, the OD595 value was 
recorded. The protein concentration was then deduced from a calibration curve made 
from the absorbance versus the various concentrations of Bovine Serum Albumin 
(Bio-Rad).
4 .2 .6 .  Procedures for measuring the kinetic parameters
The above procedure for assaying DHPR activity (Section 4.2.2.) has been extended 
for measuring the kinetic parameters. The stock peroxidase buffer used was prepared 
by mixing 1 M of Tris-HCl pH7.5 (16 ml) and peroxidase (3.2 mg, Sigma, 
Horseradish Type 1), distilled H20  (104 ml) and 10% aqueous H20 2 (268 pi, w / v) 
and keeping on ice. RS-6-Methyl-5,6,7,8-tetrahydropterin hydrochloride or 6R- 
5,6,7,8-tetrahydrobiopterin hydrochloride stock solutions with concentrations of 
about 1 mM were prepared by dissolving the salts in 4 mM HC1 and kept on ice. The 
solutions were diluted to 6.6, 5.0, 3.3, 2.5, 0.125 and 0.06 mM in aliquots and all the 
concentrations were checked using the extinction coefficients 12,023 (at 268 nm in 4 
mM HC1) and 10,000 (at 265 nm in 4 mM HC1) M 1 cm-1 respectively. In the kinetic 
runs the final concentrations of pterin substrates were ca. 100, 66, 50, 33, 25, 12.5 
and 6.0 pM because of the 1/10 dilution in the cuvettes. Similarly a 2 mM NADH 
stock solution was made in 0.1 M of Tris-HCl pH 7.5 buffer and diluted to 1.32, 1.0, 
0.66, 0.50, 0.25, and 0.125 mM aliquots and the concentrations were checked using 
the extinction coefficient 6200 M"1 cm-1 (at 340 nm). Since the final dilution in the 
cuvettes was 1/20 then the NADH concentrations were ca. 100, 66, 50, 33, 25, 12.5, 
and 6.0 pM respectively. All ingredients were kept on ice during the runs.
The kinetic runs were as follows: the spectrophotometer was set at 340 nm, and the 
maximum deflection of the recorder was set at 0.05 absorbance units. The chart 
speeds were 120, 60, 30 and 12 cm / mm, but were adjusted such that all, or about all 
rate measurements have performed at one chart speed. The chart speeds were checked
94
and found to be correct. To the reaction and reference masked cuvettes (1 cm) were 
added 850 fil of peroxidase buffer, 100 |il of tetrahydropterin solution, and 50 |il of 
NADH solution and equilibrated at 25°C in the thermostated cell holders. This was 
evidenced by observing a steady baseline on the recorder. The enzyme solution (1-5 
fil) was added to the reaction cuvette using a 5 |il Hamilton syringe. The cell was 
mixed by rapid inversion, placed in the cuvette holder and the recorder was 
immediately started. Initial rates were evaluated for each concentration, and together 
with the respective concentrations of pterin and NADH, were entered into a computer 
program (Unix System; Cleland, 1979). The Km values for NADH and pterin and 
the maximum velocities were computed. When the Km values did not fall within the 
concentrations used, the errors in the Km and Vmax tended to be too large. In such 
cases the concentrations were then altered such that the Km values fell within the 
tentative Km concentrations determined from the first set of runs. A second set of 
runs then gave parameters with acceptable standard errors. Generally one set of runs 
was sufficient to give acceptable values. All the kinetic parameters that were measured 
are in Tables 4.1.— 4.6.
4.3. DISCUSSION
It was suspected for some time that the chemical mechanism in the enzymic reduction 
of DHPR involved transfer of hydride from NADH to N5 of the quinonoid-1,8(6#)- 
dihydropterin followed by protonation from an amino acid residue at the active site 
(Armarego, Randles and Waring, 1984; Chapter 1, Figure 1.1., page 9). N5 is the 
least electronegative heteroatom and accepts only the 4-pro-S hydrogen from NADH 
(Armarego, 1979). Since the non-enzymic reduction of quinonoid-dihydropterins by 
NADH is slow in aqueous buffer at ca pH 7, and because hydride reductions are fast 
at acidic pH, then some acidic amino acid residue at the active site must provide the 
proton in order to accelerate the reduction at near-neutral pH. The enzyme was first 
titrated with thiol reagents as hDHPR has four cysteine residues. The titration results 
indicated that one thiol group was at or near the active site since only three thiol groups
j Glyl51
Tyr 150 / /
Lys15 4
NADH
Figure 4.1. Molecular model of the active site of hDHPR
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were titrated when NADH was present in solution (Armarego and Ohnishi, 1987). 
Site-directed mutagenesis studies were then carried out in which the cysteine residues 
were in turn replaced by serine residues. The mutated enzymes were expressed in E. 
coli and purified, but their kinetic parameters, although different from the wild-type 
enzyme, showed that none of the mutated DHPRs had significantly decreased the 
wild-type enzyme activity (Hardy et al., 1993).
In 1992 rat DHPR was crystallized and the complete X-ray structure of the binary 
complex, i.e. DHPR-NADH complex, was reported by Whiteley and Matthews and 
their coworkers (Varughese et al., 1992). Later the rat DHPR cDNA was converted
by site-directed mutagenesis to human DHPR cDNA (only 10 amino acid residues
t
difference) and the later was expressed in E. coli, crystallized and its X-ray structure 
was determined (Varughese et al., 1994). Very minor differences were found 
between the structures of the human and rat DHPRs. This has helped considerably in 
understanding how the enzyme behaves. The authors had at first stated “there are no 
amino acid side-chains in the vicinity of the DHPR active site that could serve a similar 
function (i.e. protonating function), suggesting that proton delivery to q- 
dihydropteridines is mediated directly by solvent”. They were comparing DHPR with 
dihydrofolate reductase and must have been referring to glutamic or aspartic acid 
side-chains. At that stage Dr. Armarego began to look for an acidic side-chain at the 
active site which would be likely to protonate N3 of the pterin substrate. By using the 
coordinates of natural tetrahydrobiopterin hydrochloride by Matsuura et al. (1985) and 
molecular modelling, the cofactor was “docked” into the DHPR active site such that 
C4 and the pro-5 hydride from NADH were along the same line as N5 of the pterin 
cofactor (i.e. for facile hydride transfer the orbitals should be well aligned). This is 
shown in Figure 4.1. which was taken direcly from the computer figure on the screen.
Dr. Armarego argued that after hydride transfer to N5 (in 1) (Scheme 4.3.) electron 
movement should place a negative charge on N3 (2) (Scheme 4.3.) which would be
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( 1 )
Schem e 4.3. Electron movements in the reduction o f quinonoid- 
dihydropterins by hydride ions
partly delocalised onto the oxygen atom as in species (3) (Scheme 4.3.)* Protonation 
to complete the reduction should occur on N3 or 04 ' (these are tautomeric positions). 
The pKa of species (3) should be about 10.6 (Bobst and Viscontini, 1966) and it 
appeared from the model that the phenolic OH group of tyrosine 146 in rat DHPR 
(=150 in hDHPR) could be acidic enough under the circumstances to supply the 
proton, since the pKa of tyrosine amide is about 9.9 (Perrin, 1965). This group is 
close enough to 0 4 ’ or N3 of the pterin to complete the reduction. The first proposal 
for the present research program was to replace Tyrl50 (in hDHPR) by phenylalanine 
to see if e^nzyme activity was affected.
Since the present work was started several mutations were carried out in rat DHPR 
(Whiteley et al., 1993) and human DHPR (Smooker el al., 1993a and b) and have 
been summarised in Chapter 1 (Tables 1.2. and 1.3., page 26 and 27). Unfortunately 
all the kinetic data reported on the mutant enzymes produced were “apparent” values 
because relative rates were compared and full kinetic analyses were not done and the 
second substrate was assumed to be at saturating concentrations. Particularly when 
the second substrate was a pterin it was not possible to attain saturating concentrations 
since inhibition starts to occur when the concentrations were ca > 4 Km values.
\AlCre
However, the data was of qualitative value. For example it was shown that mutations 
T yrl46-^P he in rat DHPR caused a decrease in “apparent” kcat from 156 to 0.89
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sec*1 (Whiteley et d l., 1993), and the mutation G23-»D in hDHPR abolished enzyme 
activity (Smooker, Howells and Cotton, 1993b). Substantial quantities of mutant and 
wild-type enzymes have been prepared in the present work because reliable values of 
the kinetic parameters are required. The parameters for ^-6-m ethyl-7 ,8(6//)- 
dihydropterin and natural <7-6^7,8(6//)-dihydropterin, and for their respective NADH 
cofactor have now been measured and are reported here (Tables 4.1. to 4.6.).
Mutations at Tyrl50 for understanding proton transfer
The reasons for the choice of these Tyrl50 mutations are as follows: Tyrl50—»Phe 
was carried out in order to remove the acidic phenolic group (acidic pKa ~ 9.8). It 
was thought that a stronger proton source as in Tyrl50—»Glu could produce a “super” 
DHPR (Glu acidic pKa « 3) if it is protonated at the active site, or a very poor enzyme 
if the P-CO2H is completely ionized. The third mutation Tyr-*His would introduce a 
slightly stronger acidic group than a phenolic OH (His acidic pKa * 7) at the active 
site. The fourth mutation Tyr—»Ser would insert a very weakly acidic group (alcoholic 
OH, acidic pKa > 12) in place of the tyrosine OH group.
The kinetic parameters for the four mutated DHPR are in Table 4.1 together with the 
values for the wild-type enzyme. A quick look at all the values reveals that the Km 
values for NADH are not very significantly different for the mutations, whereas those 
for pterins vary more significantly. The kcat values with ^-6-MeDHP vary from one 
mutant to another more than the kcat values with natural ^-BH2. Note that generally 
the synthetic pterins behave more ideally as substrates with DHPR than the natural 
substrate (Armarego, 1989b). Perhaps this is necessary with #BH 2  for unknown 
"regulatory" function(s).
if
There is a considerably amount of data in Table 4.1. In order to simp^ comparisons 
the kcat / Km (V/K) values will be considered and these are in Table 4.2. The rule of
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thumb is that the larger the kcat / Km the more active the substrate or enzyme. The 
values for <?-RS-6MeDHP for the mutatnts are all smaller than those for the wild- 
type— the activity for the mutant DHPR was decreased by more than two orders of 
magnitude compared to the wild-type. Replacement of Phe by Glu did not improve 
matters, but replacement by His caused some recovery of activity and as did 
replacement by Ser but not quite as much, i.e. the activities were in the order: wild- 
type (100) » »  Phe (0.24) = Glu (0.16) < His (4.9) > Ser (1.4). The kcat /Km 
values for the natural substrate <?-6R-BH2 show the same order of activity for the 
mutants except that they are generally more active than with g-RS-6-MeDHP as 
substrate, i.e. wild-type (100) » »  Phe (1.8) > Glu (0.14) «  His (21) » S e r  (3.3). 
For the natural substrate, replacement of Phe or Glu by His results in 21% recovery of 
wild-type activity. This clearly shows that the free CO2H of Glu is completely ionised 
and cannot act as a proton source. The kcat /  Km values with the mutant DHPRs for 
NADH with q-RS-6-McDHP as second substrate show a similar order of activity with 
respect to the wild-type enzyme except that the activities are now considerably higher 
i.e. the activities o f the mutants are reduced by about only half to one order of 
magnitute. The values with the mutant DHPRs for NADH and the natural substrate q- 
6R-BH2 are not seriously decreased by the mutations, in fact two mutants (Phe and 
Ser) exhibit higher activities relative to the wild-type enzyme and the other two 
mutants (Glu and His) have marginally weaker activities.
These extensive data show that the overall order of activities of the mutant enzymes 
with respect to the non-natural substrate, ^-/?5-6-MeDHP, are similar to those for the 
natural substrate ^-6/?-BH2 but that the natural substrate is more efficient {i.e. kcat / 
Km values are generally larger). It is clear that considerable reduction activity is 
observed in the Phe and Glu mutants which is partly recovered in the His mutant with 
slight recovery in the Ser mutant. The effect of these mutations on the parameters for 
NADH are not affected anywhere as seriously as those for the pterin substrates. The 
data demonstrated that the tyrosine OH group is acting as the proton source but that in 
its absence the substrate may be protonated by a more weakly acidic group replacing it
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or at some other “acidic” side-chain at or near the active site. Whiteley and coworkers 
have identified the sequence Tyrl46 X X X  Lysl50 or Tyrl50 X X X  Lysl54 in 
rDHPR or hDHPR respectively which is common in short chain dehydrogenases 
(Varughese et al., 1994), and proposed that Tyr and Lys act co-operatively to 
protonate the pterin (Varughese etal., 1994). The protonated e-amino group of lysine 
could act as an acid (pKa « 10). Their evidence was that replacement of Lys 150 (in
rat DHPR) with a glutamine residue decreased the relative velocity from 300 U/mg to 
50 U/mg (only relative activities were measured under similar conditions). The 
protonated e-amino group of this lysine could not in itself be the proton source 
because it is more than 6 Ä away from 04' or N3 of the pterin and could only act by 
relaying its proton via another side-chain on the protein or one or two water molecules 
at the active site (see Figure 4.1.). In the absence of tyrosine 150 (in hDHPR) 
protonated lysine 154 may well be the proton source. It does, however, appear that 
the proton source is not a water molecule from the buffer since 04' and N3 of the 
pterin molecule are well enbedded in the active site compared with sustituents at C6 
and C7 (Waring and Armarego, 1987), and to a more limited extent on the 2-NH2 
group (Armarego, Ohnishi and Taguchi, 1986).
Clearly mutations at Tyrl50 do perturb the kinetic parameters in a way which may 
indicate that Tyr 150 would be the proton source which accelerates the reduction 
process. However it should be noted that stop-flow, temperature and other kinetic 
studies by Poddar, S. and Henkin, J. (1984) and Randles, D. (1986) have shown that 
in DHPR the protonation step is fast and not rate-limiting. Like in many other 
enzymes the slow steps of the reaction are "product release". This means that any 
mutations that are made affecting the proton source could have effects on substrate 
binding due to the altered residue and then if the proton source is removed there may 
be some other proton source at the active site that will take its place.
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Three natural mutations
The three natural mutations Gly23—»Asp, G lyl51—>Ser, and Thrl23—»ThrThr were 
chosen partly because they were within the Ascl-Sphl restriction sites and partly 
because some data about them was already available in the literature. The kinetic data 
for the first two mutations were determined and are compared with those for the wild- 
type in Tables 4.3. and 4.4. The first mutation (Gly23—»Asp) had already been 
studied previously but the DHPR produced was found to be inactive (Smooker, 
Howell and Cotton, 1993b). Larger quantities of the protein for this mutant were 
prepared in this work and detailed kinetic studies were possible. This mutation caused 
a severe drop in enzyme activity (kcat /  Km) for the two pterin substrates. The drop in 
activity with respect to NADH, however, was even more marked (compare with the 
wild-type Tyrl50 mutant above) indicating that this mutation is affecting the NADH  
binding domain. Examination of molecular models shows that Gly23 is quite a 
distance away from NADH. However the glycine is on the a  portion o f the ß aß  
sequence which affects the NADH domain, and the mutation would be affecting the 
active site groove. It should be noted that with the natural substrate, #-6R-BH2, the 
kcat for this mutant is 35% of the value of the wild-type enzyme. The mutant enzyme 
has therefore some reasonable activity and would account for the fact that children 
with this mutation are alive, albeit defective. This mutation is the more common of the 
mutations discovered (Smooker et a l, 1993a).
The child found with the G ly l5 1 —»Ser mutation was diagnosed as having a “mild” 
atypical form of DHPR deficiency (Blau et a l ,  1992). This is reflected in the kinetic 
parameters of the mutant enzyme (Tables 4.3. and 4.4.). The kcat for <?-RS-6MeDHP 
is 50% of that of the wild-type whereas the turnover for the natural cofactor #-6R-BH2 
is ca 15% larger than the wild-type. The kcat / Km for the pterins are more favourable 
than those for NADH implying that NADH binding may be affected as shown by
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relatively larger Km values (one order of magnitute) compared with the wild-type 
enzyme. It should be noted that Gly 151 is one residue removed from Tyrl50 (c f  
above) and changing Gly for Ser would affect the hinging effect of the glycine-residue 
and may well alter the freedom of movement around the active site groove.
All attempts to prepare the Thrl23—>ThrThr mutant DHPR where an extra amino acid 
residue is inserted, failed resulting in considerably degradation by proteases. This 
mutation was attempted because molecular modelling showed that this threonine 
insertion affects the portion of the enzyme which stabilizes the formation of a dimer. 
DHPR is a dimeric enzyme and is active as a dimer. It had been suggested that 
inability to form a dimer allowed the now “naked” back of the molecule to be open to 
the action of proteases (Varughese et a l, 1992). The present work confirmed this 
(Chapter 3, Section 3.2.3., page 75). The fusion protein with T123—»TT insertion 
was expressed and attemps to isolate i t , even in a large preparation, resulted in a 
mixture of proteins which, although appeared to contain a small amount of the fusion 
protein may also contain some free mutant DHPR. Since the pure preparation 
possessed hDHPR activity the kinetic parameters for it using the crude mixture were 
determined. This was done because some very rough idea of the activity was required 
since the child with this defect is now almost a teenager and her general metabolic 
functions are quite satisfactory although she is mentally retarted. As the DHPR 
activity in this mutant was suspected to be due to the fusion protein (or partly due to it) 
the determination of the kinetic parameters of several mutant fusion proteins were 
determined for comparison.
Kinetic parameters ofGST-DHPR fusion proteins
The kinetic parameters for the fusion proteins with Tyrl50 mutations were determined 
for #-RS-6MeDHP and NADH and are in Table 4.5. The kcat value for the wild-type
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enzyme was reduced by close to one order of magnitude when compared with the 
corresponding DHPR (see Table 4.1.). The kcat values for the mutant fusion 
proteins, on the other hand, differed slightly from the corresponding mutant DHPRs 
but the relative order of values between them were not different from those of the 
respective DHPRs, i.e. His > Ser > Phe > Glu. The higher kcat for the His mutant 
(60 sec-1) and Ser mutant (42 sec-1) compared with the wild-type (31 sec-1) is a 
reflection of the decreased activity of the wild-type fusion protein. On non-denaturing 
PAGE the wild-type fusion protein showed bands for the monomer, dimer and several 
multimers compared to the SDS-PAGE gel which showed only one band for the 
monomer at Mr ca 52 K. The differences between the kcat values of these mutants 
and the wild-type protein could well be due to the relative ratios of aggregate species 
which may have different enzyme activities. The kcat / Km values for the fusion 
proteins (Table 4.5.), unlike the kcat values (above), reveal a different view, i.e. the 
relative values for q-RS-6-MeDUP are W T » >  Phe > Glu «  His > Ser (as for the 
respective DHPRs in Table 4.1) and is due to the contributions from the Km values. 
The kcat / Km values for NADH, on the other hand, show that the turnover of this 
cofactor is much more efficient, with an over seven fold increase in the Tyrl50—>Ser 
mutant.
The kinetic parameters for the fusion proteins of the natural DHPR mutants have been 
measured and are compared with the wild-type GST-hDHPR enzyme (Table 4.6.). 
Here the kcat/Km  values for both pterin substrates of the Gly23—>Asp, Glyl51->Ser 
and Thrl 23—»ThrThr fusion proteins are lower than those of the wild-type fusion 
protein, similarly with the kcat values for NADH. It should be noted that the values 
for the Thrl 23-> ThrThr mutant were for an impure mixture of several proteins 
(Chapter 3, Figure 3.2a., page 76) and are therefore "apparent" values but do reflect 
the minimum possible activity that can be obtained for this mutant and demonstrates 
that this mutant does exhibit enzyme activity. The extensive proteolysis observed with 
this mutant DHPR and GST-DHPR fusion protein is most probably due to the high
110
susceptibility of proteolysis by traces of bacterial proteases compared to all the other 
mutant enzymes prepared in this work. The Gly23—>Asp fusion protein preparations 
used in the kinetics also were not completely pure. Two bands of about equal 
intensity on SDS-PAGE were revealed for Gly23—>Asp, a band at ca 52 KDa of the 
fusion protein and a band at 26 KDa which must be GST (since all the DHPR mutant 
protein was washed off the beads, see Chapter 3, Figure 3.2b., page 76). Thus the 
concentration of fusion protein in the mixture was 0.06 mg/ml and the kinetic 
parameters in Table 4.6.have been corrected but are "apparent" values. The none- 
fused Gly23—>Asp DHPR used to obtain the data in Table 4.3., on the other hand, 
was pure.
I l l
CHAPTER 5
GENERAL SUMMARY AND FUTURE WORK 
5 .1 . GENERAL SUMMARY
Seven in vitro site-directed mutagenesis experiments on human dihydropteridine 
reductase were carried out using a general procedure. This involved two plasmids: 
pAlter-1—hDHPR for the mutageneses experiments and pGEX2T-hDHPR for 
expressing the proteins. All the mutations were chosen within the AscI/SphI 
restriction sites of hDHPR. The mutations included Tyrl50—»Phe, Tyrl50—»Glu, 
Tyrl50—»His and Tyrl50—»Ser for studies of the chemical mechanism of reduction, 
and Gly23—»Asp, Glyl51—»Ser and Thrl23—»ThrThr (threonine insertion) which 
were to provide defective DHPRs produced in PKU children.
pAlter-1—hDHPR was first engineered by inserting the hDHPR gene taken from 
pBluescript-hDHPR into pAlter-1. The latter plasmid contains a gene for tetracycline 
resistance and a defective ß-lactamase gene (the normal gene confers ampicillin 
resistance). Mutagenesis was performed by annealing two oligonucleotides to pAlter- 
1—hDHPR: an oligonucleotide containing the DNA sequence for correcting the ß-
lactamase gene and 20-mer oligonucleotides (taken in turn) containing the desired 
mutations. The four deoxynucleoside triphosphates together with T4 DNA ligase were 
used to complete the mutated plasmid which was selected by its ampicillin resistance 
and by using a bacterial strain (BMH71-18 mut S) which was a "mismatch repair 
minus" strain. The yields of the desired mutated clones obtained using these 
procedures were uniformly better than 80%. The pAlter-1—mutated-DHPR clones 
were checked by sequencing the mutated portion of the DNA. The dye-dideoxy
nucleotide procedure was used for all DNA sequencing and was found to be very 
reliable, and obviated to use of radioactive isotopes. The latter is very desirable when 
a lot of sequencing is to be carried out.
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The Ascl/Sphl DNA cassette was excised from pAlter-1— mutated-DHPR, purified 
and used to replace the similar DNA cassette in wild-type pGEX2T-hDHPR to form 
the respective pGEX2T-mutated-DHPR which were then transformed into E.coli 
(JM109) cells. Five clones were selected, the plasmids were sequenced and at least 
four out of the five clones gave the desired DNA sequences.
Cultures of E. coli containing pGEX2T-mutated-DHPR were grown to absorbances of 
0.8-1.0 OD units (1 cm cuvettes) and the GST-DHPR fusion proteins were induced by 
addition of IPTG. The pure fusion proteins were selectively bound to GS-agarose 
beads and either released by buffer containing 5 mM reduced glutathione or shaken 
with thrombin to provide the respective pure DHPRs. The yields of fusion proteins 
for the four Tyrl50 mutants were better than those for the Gly23—>Asp and 
Glyl51—»Ser mutants. The fusion protein from the Thrl23—»ThrThr mutant could not 
be obtained pure due to extensive proteolysis by bacterial proteases even though the 
protease inhibitor-phenyl methyl sulphonyl fluoride was present in the medium.
The kinetic parameters for quinonoid 6-methyl-7,8(6//)-dihydropterin (q-6Me-DHP) 
and natural quinonoid 6/?-eryf/zrö-7,8(6//)-dihydrobiopterin (#-BH 2) and the 
respective values for NADH were determined from a complete kinetic analysis 
whereby the Km values for the pterin and NADH and one Vmax value were 
determined from each set of measurements. The kcat/Km values were best for 
comparing the relative activities of the mutant enzymes with the wild-type (WT) 
enzyme. The following results were obtained for the Tyrl50 mutants: with q- 
6MeDHP: WT (100%) » >  Phe (0.24) > Glu (0.16) < His (4.9) > Ser (1.4) and for
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NADH: WT (100%) > Phe (51.5) »  Glu (8.6) «  His (87) > Ser (55.4); whereas 
with q-BH2: WT (100%) »  Phe (1.8) > Glu (0.14) «  His (21) > Ser (3.3) and for 
NADH: WT (100%) < Phe (343) »  Glu (76) * His (73) < Ser (143) [see Table 4.2, 
Chapter 4, page 100]. The data are consistent with the suggestion that Tyrl50 is the 
proton source for the hydride reduction since replacement of Tyr by Phe reduced the 
activity with repect to pterin substrates considerably; replacement by Glu reduced it 
further since the Glu residue is completely in the anionic form at pH ca 7; repl^ement
CO
by a His residue restores the activity to some extent and repjbement by the very weakly 
acidic Ser residue restores activity to a still smaller extent. If water from the buffer 
(pH 7.2-7.4) were the proton source then the effects on the kinetic parameters of the 
Phe, Glu and Ser mutants would have been similar to each other as they are virtually 
neutral at the neutral pH of the buffer.
The effects of mutating DHPR on the respective GST-DHPR fusion proteins were also 
studied by mesuring the kinetic parameters using <?-6Me-DHP and NADH. The 
Kcat/Km were in the following order: <?-6Me-DHP: WT (100%) » »  Phe (0.8) > 
Glu (0.24) «  His (11) > Ser (1.6); and NADH: WT (100%) > Phe (56) « <  His 
(377) «  Ser (778). The order of activities were almost similar to those observed 
above for the DHPRs except that the kcat/Km for the NADH with the His and Ser 
mutants were significantly higher than for the wild-type [see Table 4.5, Chapter 4, 
page 106].
The kinetic data for the Gly23—>Asp and Glyl51—>Ser mutants were evaluated and the 
kcat/Km values for ?-6M e-DHP were : WT (100%), G ly23->A sp (0.024), 
G lyl51—>Ser (138) and for NADH: WT (100%), Gly23->Asp (0.008), G lyl51->Ser 
(2.9) showing that the parameters for NADH are more seriously affected. The 
kcat/Km values with <7-BH2 were of the same relative order as for <?-6Me-DHP above 
and were : WT (100%), Gly23->Asp (0.22), G lyl51->Ser (13.8) and for NADH:
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WT (100%), Gly23—»Asp (0.5), G lyl51—»Ser (11.8) [see Table 4.3, Chapter 4, page 
102]. These data are consistent with the severity of the Gly23—»Asp mutation in 
children with this mutation and on the mild nature of the G lyl51—»Ser mutation on the 
afflicted child. The Thrl23->ThrThr mutant was completely degraded on attempted 
isolation from thrombin cleavage of the respective GST-DHPR fusion protein. In 
order to show that this mutation did lead to an active DHPR, since the child affected 
with this mutation is now in her teens and alive although mentally retarded, the impure 
fusion protein obtained from this mutation was evaluated kinetically. The data [see 
Table 4.6, Chapter 4, page 108] show that the DHPR is active in the fusion protein 
compared with the WT and the Gly23—»Asp and G lyl51—»Ser fusion proteins and 
show the DHPR of the affected child must be reasonably active although in our 
bacterial system is degraded considerably more rapidly than any of the other mutated 
DHPRs studied.
5. 2 .  FUTURE WORK
Time did not permit further extensive studies on the above proteins that were readily 
obtained in pure state. For example temperature stability studies and the effects of 
proteases on the DHPRs and their fusion proteins with GST would reveal interesting 
information. The dimeric and polymeric nature of the proteins should be investigated 
by non-denaturing gel electrophoresis and by cross-linking reagents and their effects 
on enzyme activity should be evaluated.
Detailed studies of the kinetics of all the DHPRs in deuterium oxide should also reveal 
some interesting features since the protonation aspects of the NADH reduction are 
under investigation.
All the Tyrl50 mutants studied here resulted in decreased activity with respect to the 
pterin cofactors. It should be very interesting to include studies of the Tyrl50—>Lys 
mutant since the protonated e-NH2 group of lysine would be almost as acidic as the 
phenolic OH group of tyrosine and may well restore enzyme activity completely.
Further investigations to obtain the Thrl23—»ThrThr mutant DHPR in pure form may 
prove more rewarding if a bacterial strain in which eukaryotic proteins are stabilised 
and the activity of proteases responsible for degrading abarrent proteins is abolished, 
e.g. Ion strains such as E.coli SG4119 [F~Agal i— m+ Ion 100], were used to 
express the fusion protein. These bacterial strains should also be used to express other 
mutants which showed sensitivity to proteases, e.g. the Gly23—>Asp mutant.
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APPENDIX
APPENDIX 1 Media
LB medium Bacto-tryptone (10 g), yeast extract (5 g), NaCl (5 g) were
dissolved up to 1 L of distilled H20  and adjusted to pH 7.5 with 5 N NaOH. 
Autoclaved and stored at room temperature.
LB (+Amp, 100 pg/ml) medium Amp (1 ml, 100 mg/ml) was added into 1 
L of autoclaved and cooled LB medium. [100 fig/ml of Amp: Amp (100 mg) was 
dissolved in 1 ml of distilled H20  and filtered through a 0.25 pM filter, then stored at 
-20°C].
LB agar plates Agar (15 g) was added to 1 litre of LB medium, autoclaved and 
poured onto 20 petri dishes when the medium was cooled to about 60°C.
LB (+Amp, 100 pg/ml) plates Amp (1 ml, 100 mg/ml) was added to 1 L
of LB + agar medium when the medium was cooled to about 60°C, then poured onto 
20 petri dishes. [100 pg/ml of Amp: Amp (100 mg) was dissolved in 1 ml of 
distilled H20  and filtered through a 0.25 pM filter, then stored at -20°C].
LB (+TC, 12.5 pg/ml) medium TC (1 ml, 12.5 mg/ml) was added to 1 L 
of autoclaved and cooled LB medium. (12.5 mg/ml of TC: TC (12.5 mg) was 
dissolved in 1 ml of 70% ethanol and filtered through a 0.25 pM filter, then stored at 
-20°C).
LB (+TC, 12.5|ig/ml) plates TC (1 ml, 12.5 mg/ml) was added to 1 L
of LB + agar medium, when the medium was cooled to about 60°C it was poured into 
20 petri dishes. (12.5 mg/ml of TC: TC (12.5 mg) was dissolved in 1 ml of 70%
117
ethanol and filtered through a 0.25 |iM filter, then stored at -20°C).
LB (+ 20 mM glucose) medium G lucose (100 pi 1, 2 M, and filtered
through a 0.25 (iM filter) was added to 10 ml of LB meduim.
2xYT (+TC, 12.5 (ig/ml) medium Tryptone (16 g), Yeast extract (10
g) and NaCl (5 g) were dissolved in 900 ml of distilled H20  and the volume adjusted to 
1 liter. The medium was autoclaved for 20 min. TC (1 ml of 12.5 mg/ml, filtered) 
was added after the medium was cooled to room temperature.
2xYT-G (+Amp, 100 |ag/ml) medium Try ptone (16 g), Yeast extract (10
g) and NaCl (5 g) were dissolved in 800 ml of distilled H20  and the volume adjusted to 
900 ml. The medium was autoclaved for 20 min. Once the medium was cooled, 
filtered glucose solution (100 ml, 20%) and Amp (1 ml of 100 mg/ml, filtered) were 
added into the medium.
APPENDIX 2 Solutions for DNA preparation
TGE buffer was Tris-HCl (25 mM, pH 8.0), glucose (50 mM) and EDTA (10 mM). 
It was autoclaved and stored at 4°C.
Lysis buffer was 0.2 N of NaOH and 1% of SDS. It was prepared freshly from 10 
N NaOH and 10% SDS.
Neutralising buffer was 5 M potassium acetate (pH 4.8). It was prepared by 
adding KOH pellets to 29.5 ml of glacial acetic acid and 50 ml of H20  to give pH 4.8, 
then H2 O was added to 100 ml, and stored at 4°C.
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APPENDIX 3 ISOLATION OF DNA FRAGMENTS FROM AGAROSE
GEL
6 M Sodium iodide solution Nal (90.3 g, Sigma) was dissolved in 80
ml of H20 . Na2 SC>3 (1.5 g) was added (it might be not dissolved completely). H20  
was added to make 100 ml. The solution was filtered through a 0.45 or 0.2 pM filter 
and further 0.5 g of Na2 SC>3 was added, and stored in a dark bottle at 4°.
New Washing solution was prepared by mixing 45 parts (volume) of Tris-HCl (20 
mM, pH 7.5), EDTA (2 mM) and NaCl (0.4 M) with 55 parts (volume) of absolute 
ethanol. This was filtered through a 0.45 or 0.2 pM filter and stored at 4°C.
Silica matrix Silica powder (250 ml, 325 mesh; kindly prepared by Dr 
Armarego) was suspended in a total volume of 500 ml of distilled H20 . It was stirred 
for 1 hr, and heavier particles were allowed to settle for 1 hr. The fines in the 
supernatant were pelleted by centrifugation in an SS-34 rotor at 4,000 rpm for 5 min. 
The pellet was re-suspended in 150 ml of distilled H20  and 150 ml of nitric acid was 
added. This was heated just below the boiling point in a fume hood and allowed to cool 
to room temperature. It was washed 4 times by centrifugation at 3,000 rpm (SS-34 
rotor) for 5 min, discarding the supernatant (including any ultrafine particles that did not 
pellet down), and the pellet was re-suspended in 150 ml of H20 . It was transferred to a 
glass bottle and autoclaved for 30 min. This was transferred to a tube with valume 
scale. The fine was allowed to settle for 48 hr. The supernatant was removed
carefully, and equal volume of TE buffer was mixed in. The silica matrix was aliquoted 
1 ml, and stored at 4C.
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APPENDIX 4 Solutions for competent cells preparation
AND LIGATION
10 mM ATP ATP (5.5 mg, Sigma, MW 551.1) was dissolved in 1 ml of 50
mM of Tris-HCl (pH 7.0), and stored in 50 pi aliquots at -20°C.
2xT4 DNA ligase buffer (10 ml) was prepared by mixing 0.031 g of DTT 
(Sigma) with 200 pi of 1 M of MgCl2 , Tris-HCl (5 ml, 200 mM, pH 7.5) and distilled 
H20  to 10 ml. The solution was filtered through a 0.2 p,M filter and stored in 1 ml 
aliquots at -20°C.
Trituration buffer (200 ml) was prepared by mixing distilled H20  (140 ml, 
autoclaved), CaCl2 (20 ml, 1 M, autoclaved), M gC^ (20 ml, 700 mM, autoclaved) and 
NaOAc (pH 5.5). NaOAc (20 ml, 400 mM, pH 5.5) was prepared by dissolving 
NaOAc in distilled H2 O and adjusted pH to 5.5 with HC1.
A p p e n d ix  5 phenol/chloroform solution
Phenol: H2O: Chloroform (68: 18: 14) R edistilled phenol [68 parts 
(volume)]was mixed with 18 parts (volume) of H20  and 14 parts (volume) of 
chloroform.
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TE-buffered phenol was made by mixing one volume of re-distilled phenol and one 
volume of TE buffer (pH 8).
TE-buffered phenol/chloroform (1:1) One volume of TE-Buffered phenol was 
mixed with one volume of chloroform.
APPENDIX 6 Formulae for calculation of DNA
CONCENTRATION
Formula for calculating oligonucleotide concentration (picomole/|il)
e = (nA X 15.4) + (nC X 7.3) + (nG X 11.7) + (nT X 8.8) (ml/pmoles)
C = OD26o/£ X 1000 (pmoles/pl)
Formula for calculating picomole ends (|il) of DNA fragment:
Picomole ends/pl = 3030.303 x micrograms / number of bp
Formula for determining DNA concentration by value of OD260
c = OÖ260 X 50 / 1000 (ng/pl)
A p p e n d ix  7 Solutions for purification of fusion proteins
Glutathione elution buffer was 5 mM reduced glutathione in 50 mM Tris-HCl (pH 
8.0). It was dispensed in 1-10 ml aliquots and stored at -20°C until needed.
MTPBS buffer NaCl (4.38 g), Na2H P 0 4 (1.135 g), and NaH2P 0 4 (0.312 g) 
were dissolved in 500 ml of distilled H20.
Thrombin solution Thrombin (1,000 NIH units) was dissolved in 1 ml of
distilled H20  and dispensed in 100 ql aliquots and stored at -20°C until needed. 0.2 
NIH units digest 100 qg of a test fusion protein in 16 hours at 22°C in Glutathione 
elution buffer.
A p p e n d ix  8 solutions for enzyme assay
1 mM 6MeTHP Stock solution (10 mM) was prepared by dissolving 0.015 g of 
6MeTHP in 5 ml of 4 mM HC1 and dispensed in 1 ml aliquots and stored at -20°C. It 
was diluted 10 times with 4 mM of HC1 before use.
2 mM NADH NADH (16 mg) was dissolved in 10 ml of 0.1 M Tris-HCl (pH 
7.5) (it was prepared before use).
20 mM CDNB. Chloro-2,4-dinitrobenzene (40.6 mg) was dissolved in 10 ml of 
100% ethanol (it was prepared before use).
20 mM GSH. Reduced glutathione (30.7 mg) was dissolved in 5 ml of distilled 
H20  and was prepared before use.
Reaction mixture for DHPR assay Peroxidase (4 ml, 0.2 mg/ml) was
mixed with Tris-HCl (4 ml, 1 M, pH 7.4) , H20 2 (67 ql, 10% v/v) and 26 ml of 
distilled H20 , stored on ice until required.
Reaction mixture for GST activity assay 1 M KH2P 0 4 (34 ml) was
mixed with 16 ml of 1 M K2H P04 and 100 ql of 0.5 M EDTA.
Reaction mixture for oxido-reductase assay 3 mM K3Fe(CN )6  (4 ml)
was mixed with 4 ml of 1 M Tris-HCl (pH 7.5) and 30 ml of distilled H20 , and stored 
at room temperature (it was prepared freshly).
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APPENDIX 9 OTHERS
1 mg/ml of DNasel DNase I (2 mg) was dissolved in 1 ml of 10 mM of Tris- 
HCl (pH 7.5) and mixed with 1 ml of 50% of glycerol. It was stored in 0.5 ml aliquots 
at -20°C.
3 M Sodium acetate (pH 5.2) was made by dissolving 40.8 g of sodium 
acetate.3 H2O in 80 ml of H2O. The pH was adjusted to 5.2 with glacial acetic acid. 
Water was added to 100 ml, and autoclaved, then stored at room temperature.
10xT4 DNA kinase buffer (+ATP) was Tris-HCl (0.5 M, pH 7.5), MgCl2(0.1 
M), DTT (50 mM), spermidine (1 mM) and ATP (10 mM).
13% PGE 8000 (100 ml) was prepared by dissolving 100 g of PEG 8000 in 
distilled H2O, then autoclaved and stored at room temperature.
20 mg/ml X-Gal X-Gal (20 mg) was dissolved in 1 ml of dimethyl
formamide, and was wrapped with a piece of foil and stored at -20°C.
100 mM IPTG Isopropylthio-ß-D-galactoside (IPTG, 500 mg) was
dissolved in 20 ml of distilled water, then filtered through a 0.25 pM filter and stored in 
small aliquots at -20°C.
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Dye-dideoxy-terminator premix was A-DyeDeoxy (1.58 pM), T-DyeDeoxy 
(94.74 pM), G-DyeDeoxy (0.42 pM), C-DyeDeoxy (47.37 pM), dITP (78.95 pM), 
dATP (15.79 pM), dCTP (15.79 pM), dTTP (15.79 pM), Tris-HCl (168.42 mM, pH 
9.0), (NH4)2S04 (4.21 mM), MgCl2 ( 42.1 mM), AmpliTaq DNA polymerase (0.42 
U/pl).
H20  Milli Q H20  was filtered through a 0.25 pM filter, then stored in 1 ml
aliquots at -20°C.
PEG solution was 3.75 mM ammonium acetate (pH 7.5) and 20% PEG.
RNase A (DNase free) RNase A (10 mg) was dissolved in 1 ml of 10
mM Tris-HCl (pH 7.5) and 15 mM of NaCl. The solution was boiled in H20  for 15 
min and allowed to cool to room temperature slowly.
TAE buffer 50 x TAE buffer (1 litre) was made from Tris base (242 g, 2 M),
glacial acetic acid (57.1 ml), Na2EDTA.2H20  (37.2 g, 0.1 M), adjusted to pH 8.5 with 
HC1, not autoclaved, but stored at room temperature. It was diluted to lx TAE buffer 
freshly before using.
TBE buffer 10 x TBE buffer (1 litre) was made from Tris base (108 g, 0.89
M), boric acid (55 g, 0.89 M), EDTA (40 ml, 0.5 M, pH 8.0) and distilled H20  to 1 L. 
The pH was not adjusted. It was autoclaved and stored at room temperature. It was 
diluted to 1 x TBE buffer freshly before using.
TE buffer was made from 10 mM Tris-HCl (pH 8) and 1 mM EDTA (pH 8).
124
REFERENCES
Agrawal, H., Bone, A. and Davison, A. (1970). Effect of Phenylalanine on Protein 
Synthesis in The Developing Rat Brain. Biochem. J. 117,325-331.
Aksnes, A., Skotland, T., Fiatmark, T., and Ljones, T. (1979). Bovine 
Dihydropteridine Reductase Purification by Affinity Chromatography and 
Comparison of Enzymes From Liver and Adrenal Medulla. Neurochem. Res. 4, 385- 
398.
Algeri, S., Bonati, M., Brunello, N., and Ponzio, F. (1977). Dihydropteridine 
Reductase and Tyrosine Hydroxylase Activities in Rat Brain During Development and 
Senescence: A Comparative Study. Brain Res. 132, 569-574.
Archer, M., Vonderschmitt, D. and Scrimgeour, K. (1972). Mechanism of Oxidation 
of Tetrahydropterins. Canad. J. Biochem. 50,1174-1182.
Armarego, W. (1979). Hydrogen Transfer from 4R and 4-S (4-3H) NADH in the 
Reduction of d,l-cis-6,7-(8//)-Dihydropterin with Dihydropteridine Raductase from 
Human Liver and Sheep Liver. Biochem. Biophys. Res. Commun. 89, 246-249.
Armarego, W. (1984). Chemical and Biological Reactions of Reduced Pterins. 
Lectures in Heterocyclic Chemistry. J. Heterocycl. Chem. 7: 121-130.
Armarego, W. (1989a). The Structure of <7-BH2-Chemistry and Biochemistry. 
Chemistry and Biology of Pteridines. Eds., Curtius, H., Ghisla, S., and Blau, N. 213- 
218. Walter de Gruyter. Berlin, New York.
Armarego, W. (1989b). Structure-Activity Studies of Pteridine Cofactors with 
Dihydropteridine Reductase. Pteridines 1, 179-188.
125
Armarego, W. and Ohnishi A. (1987). Inactivation of Dihydropteridine Reductase 
(Human Brain) by Platinum (II) Complexes. Eur. J. Biochem. 164, 403-409.
Armarego, W. and Schou, H. (1977). Stereochemistry of Catalytic Reduction of 6- 
Methyl- and 6,7-Dimethyl-pterin and of 2,4-diamino-6-Methylpteridine. JCS Perkin 
Transactions 1. 2529-2536.
Armarego, W. and Waring, P. (1982). Pterin. Part 9. The Structure of Quinonoid 
Dihydropterins [2-Amino-7,8-dihydropteridin-4-(6//)-ones]. J. Chem. Soc. Perkin 
Transactions 2. 1227-1233.
Armarego, W., Randles, D. and Taguchi, H. (1983). Peroxidase Catalysed Aerobic 
Degradation of 5,6,7,8-Tetrahydrobiopterin at Physiological pH. Eur. J. Biochem. 
135, 393-403.
Armarego, W., Randles, D. and Waring, P. (1984). Dihydropteridine Reductase 
(DHPR). Its cofactors and its Mode of Action. Med. Res. Rev. 4, 267-321.
Armarego, W., Cotton, R., Dahl, H. and Dixon, N. (1989). High-Level Expression of 
Human Dihydropteridine Reductase (EC 1.6.99.7), Without N-terminal Amino Acid 
Protection, in Escherichia Coli. Biochem. J. 261, 265-268.
Armarego, W., Ohnishi, A. and Taguchi, H. (1986). Reduced 2-Methyl-4-oxo, 2- 
Methylamino-4-oxo, 2-Methylthio-4-oxo and 2-Amino-4-thioxo 6,7- 
Dimethylpteridines, and 6,8-Dimethylpterin as Substrates for Dihydropteridine 
Reductase. Aust. J. Chem. 39,31-41.
Auerbach, C. and Robson, J. (1947). XXXII.-The Production of Mutation by 
Chemical Substances. Proc. Royal. Soc. Edinburgh B. 62, 271-283.
126
Ausubel, F., Brent, R., Kingston, R., Moore, D., Seidman, J., Smith, J., and Struhl, K. 
(1987). Current Protocols in Molecular Biology. John Wiley & Sons. New York.
Blau, N., Heizmann, C., Sperl, W., Korenke, G., Hoffmann, G., Smooker, P. and 
Cotton, R. (1992). Atypical (Mild) Forms of Dihydropteridine Reductase Deficiency: 
Neurochemical Evaluation and Mutation Detection. Pediatrics Res. 32, 726-730.
Blau, N., Thöny, B., Heizmann, C. and Dhondt, J. (1983). Tetrahydrobiopterin 
Deficiency: From Phenotype to Genotype. Pteridines. 4,1-10.
Bobst, A. and Viscontini, M. (1966). Neues Verfahren Zur Darstellung und 
Stabilisierung von Tetrahydrofolsäure und Tetrahydropteridine. 49, 875-884.
Borst, P. (1983). Animal Peroxisomes (Micorbodies) Lipid Biosynthesis and the 
Zellweger Syndrome. Trends in Biochem. Science 8, 269-272.
Botstein, D. and Shortle, D. (1985). Strategies and Applications of in Vitro 
Mutagenesis. Science 229,1193-1201.
Brown, G. (1989). Biosynthesis of H4 Biopterin and Related Compounds. 
Chemistry and Biology of Pteridines. Eds., Curtius, H., Ghisla, S., and Blau; N. 199- 
212. Walter de Gruyter. Berlin, New York.
Cheema, S., Soldin, S., Knapp, A., Hofmann, T., and Scrimgeour, K. (1973). 
Properties of Purified Quinonoid Dihydropteridine Reductase. Canad. J. Biochem. 
51, 1229-1239.
Cleland, W. (1979). Statistical Analysis of Enzyme Kinetic data. Meth. Enzymology 
63, 103-138.
127
Craine, J., Hall, E. and Kaufman, S. (1972). The Isolation and Characterization of 
Dihydropteridine Reductase From Sheep Lver. J. Biol. Chem. 247, 6082-6091.
Dahl, H., Hutchison, W., McAdam, W., Wake, S., Morgan, F. and Cotton, R. (1987). 
Human Dihydropteridine Reductase Characterization of a cDNA Clone and Its Use in 
Analysis of Patients with Dihydropteridine Reductase Deficiency. Nucl. Acids Res. 
15, 1921-1936.
Danks, D. (1978). Pteridine and Phenylketonuria: Report of a Workshop: 
Introductory Comments. J. Inher. Metab. Dis. 1, 47-48.
Danks, D. (1979). Current Practice: Current Status of PKU Diagnosis and Treatment. 
Aust. Paediatrics J. 15, 227-228.
Danks, D., Bartholome, K., Clayton, B., Curtius, H., Groebe, H., Kaufman, S., 
Leeming, R., Pfleiderer, W., Rembold, H. and Rey, F. (1978). Malignant 
Hyperphenylalaninaemia—Current Status (June 1977). J. Inher. Metab. Dis. 1, 49- 
53.
Danks, M., Tippett, P. Adams, C. and Campbell, P. (1975). Cerebro-Hepato-Renal 
Syndrome of Zellweger. J. Pediatrics 86,382-387.
Davison, A. and Dobbing, J. (1966). The Developing Brain. Applied 
Neurochemistry. Eds., Davison, A. and Dobbing, J. 253-286. Blackwell, Oxford.
Firgaira, F., Cotton, R. and Danks, D. (1981). Isolation and Characterization of 
Dihydropteridine Reductase from Human Liver. Biochem. J. 197, 31-43.
Firgaira, F., Choo, K., Cotton, R. and Danks, D. (1981). Heterogeneity of The 
Molecular Defect in Human Dihydropteridine Reductase Deficiency. Biochem. J.
128
198, 677-682.
Firgaira, F., Cotton, R. and Danks, D. (1983). Human Dihydropteridine Reductase 
(DHPR) Deficiency. Chemistry and Biology of Pteridines. Ed., Blair, J. 771-775. 
Walter de Gruyter. Berlin, New York.
Foelling, A. (1934). Ueber Ausscheidung von Phenylbrenztraubensaeure in den Ham 
als Stoffwechselanomalie in Verbindung mit Imbezillitaet. Hoppe-Seyler's Z. Physiol. 
Chem. 227, 169-177.
Fromm, H. (1975). "Initial Rate Enzyme Kinetics" in "Molecular Biology, 
Biochemistry and Biophysics 22". Springer-Verlag, Berlin, page 7.
Giovannini, M., Riva, E.,Segre, A. and Episcopi, M. (1979). A Practical Approach to 
the Dietary Management of Phenylketonuria. Advances in Inborn Errors of 
Metabolism. Eds., Berra, B. and Durand, page 117-131. Edi., Ermes, Milan, Italy.
Greengard, O., and Herzfeld, A. (1977). The Undifferentiated Enzymic Composition 
of Human Fetal Lung and Pulmonary Tumors. Cancer Res. 37, 884-891.
Guthrie, R., and Susi, A. (1963). A Simple Phenylalanine Method for Detecting 
Phenylketonuria in large Populations of Newborn Infants. Pediatrics 32, 338-343.
Habig, W. and Jakoby, W. (1981). Assay for Differentiation of Glutathione S- 
Transferases. Meth. Enzymology 77, 398-405.
Hagerman, D. (1964). Pteridine Cofactors in Enzymatic Hydroxylation of Steroids. 
Fed. Proc. 23,480-480.
Hardy, C., Averdunk, H., Paal, B., Cotton, R. and Armarego, W. (1993). CYS—>SER
129
Mutation in ch-Human Dihydropteridine Reductase. Chemistry and Biology of 
Pteridines and Folic acid, Eds., Ayling, J., Nair, M. and Baugh, C. 131-134. Plenum 
Press. New York and London.
Hasegawa, H. (1977). Dihydropteridine Reductase from Bovine Liver. J. Biochem. 
(Tokyo) 81, 169-177.
Hayatsu, H. (1976). Bisulfite Modification of Nucleic Acids and Their Constituents. 
Prog Nucleic Acids Res. Mol. Biol. 16, 75-120.
Kaufman, S. and Kaufman, E. (1985). Tyrosine Hydroxylase. Folates and Pterins. 
Ed., Blakley, R. and Benkovic, S. 2, 251-352. J. Wiley and Sons, New York.
Kellerman, O. and Ferenci, T. (1982). Maltose Binding Protein From E.coli. Meth. 
Enzymology. 90, 459-463.
Kleckner, N., Roth, J. and Botstein, D. (1977). Genetic Engineering in Vivo using 
Translocatable Drug-Resistance Elements. J. Mol. Biol. 116, 125-159.
Koch, R. and Friedman, E. (1981). Accuracy of Newborn Screening Programs for 
Phenylketonuria. J. Pediatrics 98, 267-269.
Kosar-Hashemi, B., Taguchi, H. and Armarego, W. (1994). Glyceryl-ether 
Monooxygenase [EC 1.14.16.5] Part V: Some Aspects of the Stoichiometry. 
Pteridines 5 , 1-7.
Kuhn, D. and Lovenberg, W. (1985). Tryptophan Hydroxylase. Folates and Pterins. 
Ed., Blakley, R. and Benkovic, S. 2, 353-399. J. Wiley and Sons, New York.
Kunkel, T. (1985). Rapid and Efficient Site-Specific Mutagenesis without
130
Phenotypic Selection. Proc. Natl. Acad. Sei. U.S.A. 82, 488-492.
Kunkel, T., Roberts, J., and Zakour, R. (1987). Rapid and Efficient Site-Specific 
Mutagenesis Without Phenotypic Selection. Meth. Enzymol. 154, 367-382.
Legerski, R., Hodnett, J. and Gray, H. (1978). Extracellular Nucleases of 
Pseudomonas BAL 31.III. Use of the Double-Strand Deoxyriboexonuclease Activity 
as the basis of a Convenient Method for the Mapping of Fragments of DNA Produced 
by Cleavage with Restriction Enzymes. Nucleic Acids Res. 5, 1445-1464.
Lindroos, O. and Oja, S. (1971). Hyperphenylalaninaemia and the Exchange of 
Tyrosine in Adult Rat Brain. Exp. Brain Res. 14, 48-60.
Lockyer, J., Cook, R., Milstien, S., Kaufman, S., Woo, S., and Ledley, F. (1987). 
Structure and Expression of Human Dihydropteridine Reductase. Proc. Natl. Acad. 
Sei. U.S.A. 84, 3329-3333.
Matsuura, S., Sugimoto, T., Murata, S., Sugawara, Y. and Iwasaki, H. (1985). 
Stereochemistry of Biopterin Cofactor and Facile Methods for the Determination of 
the Stereochemistry of a Biologically Active 5,6,7,8-Tetrahydrobiopterin. J. 
Biochem. (Tokyo). 98. 1341-1348.
Matther, M., Keightley, J. and Fee, J. (1993). Recovery and Cloning of genomic 
DNA Fragments from dried Agarose Gel. Meth. Enzymol. 218, 695-704.
McCaman, M. and Robins, E. (1962). A Fluorimetric Method for the Determination 
of Phenylalanine in Serum. J. Lab. Clin. Med. 59, 885-890.
McKnight, S. and Kingsbury, R. (1982). Transcriptional Control Signals of a 
Eukaryodc Protein Coding Gene. Science 217, 316-324.
131
Melnick, C., Kimberlee, K., Michals, R., and Matalon, R. (1981). Linguistic 
Development of Children with Phenylketonuria and Normal Intelligence. J. Pediatrics 
98, 269-272.
Muller, H. (1927). Artificial Transmutation of the Gene. Science 66,84-87.
Muller, W., Weber, H., Meyer, F. and Weissmann. C. (1978). Site-directed 
Mutagenesis in DNA: Generation of Point Mutation in Cloned ß Globin 
Complementary DNA at the Position Correponding to Amino Acids 121 and 123. J. 
Mol. Biol. 124,343-358.
Niederwieser, A. (1979). Inborn Errors of Pterin Metabolism. Folic Acid in 
Neurology, Psychiatry and Internal Medicine. Eds., Botez, M. and Reynolds, E. 349- 
384. Raven Press. New York.
Nielsen, K., Simonsen, V. and Lind, K. (1969). Dihydropteridine Reductase—A 
Method for the Measurement of Activity, and Investigations of the Specificity for 
NADH and NADPH. Eur. J. Biochem. 9, 497-502.
Noronha, J. (1989). Urinary Excretion of Total Pteridines in Cancer. Chemistry and 
Biology of Pteridines. Eds., Curtius, H., Ghisla, S. and Blau, N. 515-518. Walter de 
Gruyter. Berlin, New York.
Perrin, D. (1965). Dissociation Constants of Organic Bases in Aqueous Solution. 
Butterworths , London. 403-404.
Rembold, H. and Buff, K. (1972a). Tetrahydrobiopterin, a Cofactor in Mitochondrial 
Electron Transfer: A Soluble Transfer System. Eur. J. Biochem. 28, 586-591.
Rembold, H. and Buff, K. (1972b). Tetrahydrobiopterin, a Cofactor in Mitochondrial
132
Electron Transfer: Effect of Tetrahydropterin on Intact Rat-Liver Mitochondria. Eur. 
J. Biochem. 28, 579-585.
Saiki, R., Gelfand, D., Stoffel, S., Scharf, S., Higuchi, R., Horn, G., Mullis, K. and 
Erlich, H. (1988). Primer-directed Enzymatic Amplification of DNA With a 
Thermostable DNA Polymerase. Science 239,487-491.
Sakonju, S., Bogenhagen, D. and Brown., D. (1980). A Control Region in the Center 
of thr 5S RNA Gene Directs Specific Initiation of Transcription: I. The 5' Border of 
the Region. Cell 19, 13-25.
Sanchez-Urretia, L., Pierce, C., and Greengard, O. (1978). Dihydropteridine 
Reductase Activity of Adult, Fetal and Neoplastic Tissues. Enzyme 23, 346-352.
Shahbaz, M., Hoch, J., Trach, K., Hural, J., Webber, S., and Whiteley, J. (1987). 
Structural Studies and Isolation of cDNA Clones Providing the Complete Sequence of 
Rat Liver Dihydropteridine Reductase. J. Biol. Chem. 262, 16412-16416.
Sharp, P., Cowe, E., Higgins, D., Shields, D., Wolfe, K. and Wright, F. (1988). 
Codon Usage Patterns in Escherichia Coli, Bacillus Suhtilis, Saccharomyces 
cerevisiae, Schizosaccharomyces Pombe, Drosophila Melanogaster and Ho mo  
sapiens; A Review of the Considerable Within-Species Diversity. Nucl. Acids Res. 
16, 8207-8211.
Shortle, D. and Botstein, D. (1983). Directed Mutagenesis with Sodium Bisulfite. 
Meth. Enzymol. 100, 457-468.
Smith, D. and Johnson, K. (1988). Single-step Purification of Polypeptides 
Expressed in Escherichia coli as Fusions with Glutathione-S-Transferase. Gene 67,
31-40.
133
Smith, M. (1986). In vitro mutagenesis. Ann. Rev. Genet. 19, 423-463.
Smooker, P., Howells, D., Dianzani, I. and Cotton, R. (1993a). The Spectrum of 
Mutations in Dihydropteridine Reductase Deficiency. Chemistry and Biologyof 
Pteridines and Folic Acid, Ed., Ayling, J., Nair, M. and Baugh, C. 135-138. Plenum 
Press. New York, London.
Smooker, P., Howells, D. and Cotton, R. (1993b). Identification and in vitro 
Expression of Mutation causing Dihydropteridine Reductase Deficiency. Biochmistry 
32, 6443-6449.
Studier, F., Rosenberg, A., Dunn, J. and Dubendorff, J. (1990). Use of T7 RNA 
Polymerase to Direct the Expression of Cloned Genes. Meth. Enzymol. 185, 60-89.
Su, Y., Varughese, K., Xuong, N., Bray, T., Roche, D. and Whiteley, J. (1993). The 
Crystallographic Structure of a Human Dihydropteridine Reductase NADH Binary 
Complex Expressed in Escherichia coli by a cDNA Constructed from its Rat 
Homologue. J. Biol. Chem. 268, 26836-26841.
Takada, G. and Tada, K. (1970). Incorporation of 14C-Leucine into Brain Protein in 
Rats with Hyperaminoacidemia. Tohoku J. Exp. Med. 102, 103-111.
Tayeh, M. and Marietta, M. (1989). Tetrahydrobiopterin is required for Oxidation of 
Arginine to Nitric Oxide by Macrophages. Chemistry and Biology of Pteridines. 
Eds., Curtius, H., Ghisla, S. and Blau; N. 300-305. Walter de Gruyter. Berlin, New 
York.
Tourian, A. and Sidbury, J. (1983). Phenylketonuria and Hyperphenylalaninemia. 
The Metabolic Basis of Inherited Disease (Fifth Edition). Eds., Stanbury, J., 
Wyngaarden, J., Fredrickson, D., Goldstein, J. and Brown, M. 270-286.
134
Uhlmann, E. (1988). An Alternative Approach in Gene Synthesis: Use of Long Self­
priming Oligodeoxynucleotides for the Construction of Double-Stranded DNA. Gene 
71, 29-40.
Varughese, K., Skinner, M., Whiteley, J., Matthews, D. and Xuong, N. (1992). 
Crystal Structure of Rat Liver Dihydropteridine Reductase. Proc. Natl. Acad.Sei. 
U.S.A. 89,6080-6084.
Varughese, K., Xuong, N., Kiefer, P., Matthews, D., and Whiteley, J. (1994). 
Structural and Mechanistic Characteristics of Dihydropteridine Reductase: A Member 
of the Tyr-(Xaa)3-Lys-containing Family of Reductases and Dehydrogenases. Proc. 
Natl. Acad. Sei. U.S.A. 91, 5582-5586.
Vasudevan, S., Shaw, D. and Armarego, W. (1988). Dihydropteridine Reductase 
from Escherichia coli. Biochem. J. 255,581-588.
Vasudevan, S., Paal, B and Armarego, W. (1992). Dihydropteridine Reductase from 
Escherichia coli Exhibits Dihydrofolate Reductase Activity. Biol. Chem. Hoppe- 
Seyler 373, 1067-1073.
Waring, P. and Armarego, W. (1987). The Dihydropteridine Reductase (Human 
Brain) Activity of Some Lipophilic Quinonoid Dihydropterins. Eur. J. Med. Chem. 
22, 83-90.
Webber, S., and Whiteley, J. (1978). Pyridine Nucleotide Interaction with Rat Liver 
Dihydropteridine Reductase. J. Biol. Chem.. 253, 6724-6729.
Webber, S. and Whiteley, J. (1981). The Effect of Specific Amino Acid Modification 
on the Catalytic Properties of Rat Liver Dihydropteridine Reductase. Arch. Biochem. 
Biophys. 206, 145-152.
135
Webber,S., Hural, J. and Whiteley, J. (1986). Multiple forms of Rat-Liver 
Dihydropteridine Reductase identified by their differing Isoelectric Points. Archives 
of Biochem. Biophys. 248,358-367.
Webber, S., Deits, T., Snyder, W. and Whiteley, J. (1985). The Purification of Rat 
and Sheep Liver Dihydropteridine Reductase by Affinity Chromatography on 
Mothotrexate-Sepharose. Anal. Biochem. 84, 491-503, (1978). Ed. You, K. (1985). 
CRC Crit. Rev. Biochem. 17,313-415.
Whiteley, J., Xuong, N. and Varughese, K. (1993). Is Dihydropteridine Reductase an 
Anomalous Dihydrofolate Reductase, A Flavin-Like Enzyme, or a Short-Chain 
Dehydrogenase? Chemistry and Biology of Pteridines and Folates. Eds., Ayling, J., 
Nair, M. and Baugh, C. 115-121. Plenum Press, New York and London.
Whiteley, J., Varughese, K., Xuong, N., Matthews, D. and Grimshaw, C. (1993). 
Dihydropteridine Reductase. Pteridines 4,159-173.
Yang, N., Hanssen, K. and Armarego, W. (1995). The Sequence of Mouse 
Dihydropteridine Reductase cDNA, and Comparison with Human and Rat Sequences. 
In preperation.
